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O câncer é a segunda causa de mortes no mundo, com mais de 18 milhões de novos casos registrados 
em 2018, com cerca de 9,5 milhões de mortes. A quimioterapia antineoplásica é o tipo de tratamento em 
que fármacos são utilizados para retardar ou impedir o crescimento de células cancerígenas, ou até 
mesmo matá-las. O uso de metalofármacos em quimioterapia começou com a descoberta das 
propriedades citotóxicas da cisplatina, que foi aprovada para uso em 1978. Desde então, a busca por 
outros metalofármacos tem sido um importante campo de investigação em Química Bioinorgânica e 
Medicinal. 
Nesta Tese, complexos metálicos com ligantes bioativos foram sintetizados, caracterizados e 
investigados quanto às suas atividades antiproliferativas sobre um painel de células tumorais. Na 
primeira parte da Tese são apresentados cinco complexos metálicos de Ag(I), Au(I), Pd(II) e Pt(II) com 
derivados de uracila como ligantes: os complexos de prata, paládio e platina com 5-fluorouracil (Ag-
5fu, Pd-5fu e Pt-5fu, respectivamente), o complexo de ouro com 2-tiouracil (Ph3P-Au-tuH) e o complexo 
de prata com 2,4-ditiouracil ([Ag2(dtu)]). O complexo Ag-5fu apresentou o melhor perfil 
antiproliferativo entre os complexos com 5-fluorouracil enquanto o complexo Ph3P-Au-tuH foi o que 
apresentou os melhores resultados dentre os complexos metálicos com tiouracilas. Os complexos Ag-
5fu e Ph3P-Au-tuH tiveram seus mecanismos de morte celular investigados em linhagens celulares 
específicas, sendo capazes de promover a parada do ciclo celular na fase G1, inibir a formação de 
colônias e promover a morte celular programada. 
A segunda parte desta Tese trata de tiossemicarbazonas, que são uma classe importante de agentes 
quelantes de metais também investigados como potenciais fármacos com ação sobre células tumorais. 
A COTI-2 é uma nova tiossemicarbazona desenvolvida pela Cotinga Pharmaceuticals, que está em 
ensaios clínicos de fase I. A COTI-2 e derivados da COTI-2, bem como os primeiros complexos 
metálicos de Fe(III), Cu(II) e Zn(II) com COTI-2 foram sintetizados e caracterizados por análises 
químicas e espectroscópicas. Todos os compostos tiveram suas atividades citotóxicas avaliadas in vitro 
sobre a linhagem tumoral SW480 (colorretal) e linhagens quimiorresistentes derivadas da SW480 (por 
exemplo a SW480/COTI que é resistente a COTI-2). A linhagem SW480/COTI foi sensível ao derivado 
N4-terminal dimetilado (COTI-NMe2) e o complexo de cobre(II) (Cu-COTI-2) apresentou os melhores 
resultados dentre os complexos metálicos, sendo mais ativo do que o ligante livre sobre as linhagens 








Cancer is the second leading cause of deaths worldwide, with over 18 million new cases reported in 
2018, with about 9.5 million deaths. Antineoplastic chemotherapy is the type of treatment in which drugs 
are used to slow or stop the growth of cancer cells, or even kill them. The use of metallodrugs in cancer 
chemotherapy began with the discovery of the cytotoxic properties of cisplatin, which was approved for 
use in 1978. Since then, the search for other metallodrugs has been an important field of investigation 
in Bioinorganic and Medicinal Chemistry. 
In this Thesis, metal complexes with bioactive ligands were synthesized, characterized, and investigated 
concerning their antiproliferative activities over a panel of tumor cells. The first part of the Thesis 
presents five metal complexes of Ag(I), Au(I), Pd(II) and Pt(II) with uracil derivatives as ligands: the 
silver, palladium and platinum complexes with 5-fluorouracil (named Ag-5fu, Pd-5fu and Pt-5fu, 
respectively), the gold complex with 2-thiouracil (Ph3P-Au-tuH) and the silver complex with 2,4-
dithiouracil ([Ag2(dtu)]). The Ag-5fu complex presented the best antiproliferative profile among the 
complexes with 5-fluorouracil, and the Ph3P-Au-tuH complex presented the best results for the metal 
complexes with thiouracils. The Ag-5fu and Ph3P-Au-tuH complexes had their cell death mechanisms 
investigated in specific cell lines, being able to promote G1 phase arrest of the cell cycle, to inhibit 
colony formation, and promoted regulated cell death. 
The second part of this Thesis deals with thiosemicarbazones, which are an important class of metal 
chelating agents also investigated as potential drugs that can act on tumor cells. COTI-2 is a novel 
thiosemicarbazone developed by Cotinga Pharmaceuticals, which is currently in phase-I clinical trials. 
COTI-2 and COTI-derivatives, as well as the first metal complexes of Fe(III), Cu(II), and Zn(II) with 
COTI-2 were synthesized and characterized by chemical and spectroscopic techniques. All compounds 
had their cytotoxic activities evaluated in vitro over the SW480 (colorectal) tumor cell line, and SW480 
chemoresistant lines (for example SW480/COTI, which is resistant to COTI-2). The SW480/COTI line 
was sensitive to the dimethylated N4-terminal COTI-derivative (COTI-NMe2), and the copper(II) 
complex presented the best results among the metal complexes, being more active than the free ligand 











[Ag2(dtu)] – Silver(I) complex with 2,4-dithiouracil 
5fu or fuH2 – 5-Fluorouracil 
7-AAD – 7-Aminoactinomycin 
ACN - Acetonitrile 
Ag-5fu – Silver(I) complex with 5-fluorouracil 





COTI-NH2 – 2-(6,7-dihydroquinolin-8(5H)-ylidene)hydrazine-1-carbothioamide 
COTI-NMe2 – 2-(6,7-dihydroquinolin-8(5H)-ylidene)-N,N-dimethylhydrazine-1-carbothioamide 
CP/MAS – Cross-polarization magic angle spinning 
Cu-COTI-2 – Copper(II) complex with COTI-2 
DCFH-DA – 2′,7′-Dichlorofluorescein diacetate 
DMF – Dimethylformamide 
DMSO - Dimethyl sulfoxide 
DPBS – Dulbecco’s phosphate buffered saline 
dtu – 2,4-Dithiouracil with two deprotonated sites 
dtuH2 – 2,4-Dithiouracil 
ESI-QTOF-MS – electrospray ionization quadrupole time-of-flight mass spectrometry 
FBS – Fetal bovine serum 
FDA – U.S. Food and Drug Administration 
Fe-COTI-2 – Iron(III) complex with COTI-2 
 
 
fu – 5-Fluorouracil with two deprotonated sites 
fuH – Deprotonated 5-fluourouracil 
GI50 – Concentration that inhibits 50% cell growth 
GSH – Glutathione 
HMG – High mobility group (protein) 
IC50 – Half minimal inhibitory concentration (inhibition of a biological process or component by 50%) 
IR – Infrared spectroscopy 
MRP – Mismatch repair proteins 
MS – Mass spectrometry 
MTT – 3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium 
NMR – Nuclear magnetic spectroscopy 
Pd-5fu – Palladium(II) complex with 5-fluorouracil 
PE – Platting efficiency 
P-gp – P-glycoprotein 
Ph3P or PPh3 – Triphenylphosphine 
Ph3P-Au-Cl – Chlorido(triphenylphosphine)gold(I) complex 
Ph3P-Au-tuH – Thiouracilato(triphenylphosphine)gold(I) or gold(I) complex with 2-thiouracil 
pIRES – Internal ribosome entry site plasmid 
PS – Phosphatidylserine 
Pt-5fu – Platinum(II) complex with 5-fluorouracil 
RA – Rheumatoid arthritis 
Rh123 – Rhodamine-123 
ROS – Reactive oxygen species 
RPMI – Roswell Park Memorial Institute; medium for cell culture 
RR – Ribonucleotide reductase 
SD – Standard deviation 
 
 
SI – Selectivity index 
SYBR Green – Nucleic acid electrophoresis stain: N',N'-dimethyl-N-[4-[(E)-(3-methyl-1,3-
benzothiazol-2-ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine.  
TGI – Total growth inhibition; concentration that inhibits 100% cell growth 
TrxR – Thioredoxin reductase 
TSC – α-(N)-Heterocyclic thiosemicarbazone 
tuH – Deprotonated 2-thiouracil 
tuH2 – 2-Thiouracil 
WHO – World Health Organization 
Zn-COTI-2 – Zinc(II) complex with COTI-2 
 
Human tumor cell lines: 
U251 (glioma); MCF-7 (breast); NCI-ADR/RES (multidrug resistant ovarian); 786-0 (kidney); NCI-
H460 (lung, non-small cells); PC-3 (prostate); OVCAR-3 (ovarian); OVCAR-8 (ovarian); HT29 (colon 
adenocarcinoma); K562 (chronic myeloid leukemia); SW480 (colorectal adenocarcinoma); SW480/tria 
(colorectal, Triapine resistant); SW480/COTI (colorectal, COTI-2 resistant) 
 
Non-tumor human line: 





























Thiouracilato(triphenylphosphine)gold(I) or gold(I) 
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What is cancer? 
 Cancer is the name given to a series of diseases which have in common the rapid, abnormal, and 
uncontrolled growth of cells at any part of the body, which can spread into surrounding tissues [1]. 
Normally, cells grow and divide to form new cells in a controlled way, and when cells get old or 
damaged, they die, giving place to new cells. However, it can happen that cells become abnormal or 
damaged, and survive. Consequently, if these cells survive, they divide and create more abnormal or 
damaged cells that are not needed. This is the developing of cancer, and if these cells continue to 
multiplicate without stopping they form what is called a cancerous tumor [2]. Also, the different types 
of cancer can be differentiated by the tissue of origin of the cancerous cell, the multiplication speed of 
the cell, the capacity to invade surrounding tissues or to spread throughout the body (as known as 
metastasis), and the formation of solid tumors (which are masses of tissue) or not. For example, cancers 
of the blood (as leukemia) do not form solid tumors [1,2]. 
 
Causes of cancer and risk factors 
 Cancer is a genetic disease; it is caused by alterations in the genes (sequences of the DNA). 
More specifically, it is caused by the mutation (activation) of proto-oncogenes or by the mutation 
(inactivation) of tumor suppressor genes [3]. The development of the disease can have a hereditary factor 
involved or not, normally occurring due to ageing (because ageing means that cells have had more cell 
cycles, so the probability of a mutation is higher). However, there are many environmental exposures 
which can lead to cancer, which are called risk factors [2,4]. In fact, 80% to 90% of cancer cases are 
related to external causes rather than to heredity [5]. For example, tobacco smoke (even secondhand) 
[6], alcohol consumption, obesity, exposure to radiation (as ultra-violet radiation from sunlight [7]), and 
infectious agents (hepatitis, papillomaviruses, HIV [8,9]) are common risk factors. 
Usually it is not possible to know the reason why some people develop cancer and others do not, 
however risk factors increase the chances of developing the disease [10], because the exposure to risk 
factors increases the chances of acquiring mutations in the genes. In this way, protective factors, that is, 
factors that are linked to a lower risk of cancer, as a healthy diet, being physically active, avoid smoking, 
among others, are ways of preventing cancer. However, it does not mean that one will not develop the 
disease, it just diminishes the risks. As an example, quitting smoking can avoid more than 60% of the 




Cancer statistics worldwide and in Brazil 
In 2018 more than 18 million new cases were reported worldwide, with about 9.5 million deaths, 
according to the International Agency for Research on Cancer, from World Health Organization (WHO). 
Lung and breast cancers are the most diagnosed (about 2 million cases each), followed by colorectal 
(1.8 million cases), prostate (1.2 million cases), stomach (1 million cases) and liver (841 thousand cases). 
Lung cancer takes first place in mortality (1.7 million deaths), followed by colorectal (880 thousand 
deaths), stomach (762 thousand deaths), liver (781 thousand deaths) and breast (626 thousand deaths) 
cancers. Incidence and mortalities are higher in Asia and Europe, followed by North America, Latin 
America, Africa and Oceania [11]. 
In Brazil 559 thousand cancer cases were reported in 2018, with 243.5 thousand deaths 
(International Agency for Research on Cancer, WHO). Breast and prostate cancer represent 30% of new 
cases (about 85 thousand cases each), followed by colorectal, lung and thyroid cancers. In males, 
prostate cancer leads the number of new cases in 30.5%, followed by colorectal (8.9%), lung (6.9%), 
stomach (4.4%) and bladder (3.3%) cancers. For females breast cancer is in first place, representing 
30.5% of new cases, followed by colorectal (9.6%), thyroid (6%), cervix uteri (5.8%) and lung (5.5%) 
cancers [12]. Considering mortality, for both genders lung cancer leads with 14.6% of deaths, followed 
by breast (8.4%) and prostate (7.7%) cancers. Data from Brazil’s National Cancer Institute (2015) state 
that in males lung cancer is in first place of deaths (14.0%), followed by prostate (13.4%), colorectal 
(8.0%) and stomach (8.0%) cancers. For females breast cancer is in first place of deaths (16.1%), 
followed by lung (11.4%), colorectal (9.3%) and cervix uteri (6.2%) cancers [13]. 
 
History of cancer 
The oldest description of what could be considered as cancer was discovered in Egypt, dating 
back to 3000 BC. It is part of an ancient Egyptian textbook, which describes tumors or ulcers of the 
breast that were removed by cauterization. The writing says that the disease had no treatment. 
Nevertheless, the origin of the word “cancer” was coined much latter, being credited to the Greek 
physician Hippocrates (460-370 BC). In Greek, the word carcinos and carcinoma refers to a crab, which 
was applied to describe the disease, because the finger-like spreading projections from the tumor 
reminded the shape of a crab. Afterwards, the Greek expressions were translated to cancer, the Latin 
word for crab [14]. 
There are many old theories about cancer. Hippocrates himself believed that the body contained 
different body fluids, and an imbalance of these fluids would result in disease. The excess of one of the 
fluids in a particular organ site was thought to cause cancer. This theory was standard through the Middle 
Ages for over 1300 years. As autopsies were forbidden for religious reasons, not much was known about 
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cancer by that time. Also, until the 18th century scientists believed that cancer was contagious [15]. By 
that time the first autopsies relating patient’s illness to pathologic findings after death were done, what 
led to the foundation of scientific oncology, the study of cancer [16]. Also, with the development of 
anesthesia a century later, surgery was applied to “cure” cancer, and it was possible to correlate 
microscopic pathology (with the use of modern microscope) to illness [17]. It was only by the middle of 
the 20th century that scientists began to solve the complex problems of chemistry and biology behind 
cancer, and surgeons developed new methods for cancer treatment by combining surgery with 
chemotherapy and/or radiation [15]. The publication of Hanahan and Weinberg “The Hallmarks of 
Cancer” in the year 2000 was the breakthrough for a better understanding of the mechanisms of the 
disease [18,19].  
 
Cancer treatment and chemotherapy 
 There are many kinds of cancer treatment, and each treatment depends on the type of cancer and 
on how advanced it is. In general, most ill people receive a combination of treatments. Common 
treatments are surgery, radiation therapy, chemotherapy, targeted-therapy and immunotherapy [20]. In 
this Thesis the focus will be on chemotherapy. 
 The term “chemotherapy” was coined by Paul Ehrlich by the 1900s and is defined as “the use 
of chemicals to treat diseases” [21]. Chemotherapy is the type of cancer treatment that uses drugs to 
slow or stop the growth of cancer cells, or even kill them. It is interesting that until the middle of the 
20th century there was a lot of skepticism surrounding the clinical usefulness of chemotherapy for cancer 
treatment, because no one knew whether drugs caused more harm than good. It was only with 
combination therapy, that is, using more than one drug in treatment, that the concept of cure using 
chemotherapy in earlier stages of cancer was accepted [21]. 
Chemotherapeutic drugs can be administered orally, intravenously or topically. The first two 
delivery methods are systemic, that is, the drug goes through the bloodstream and throughout the body, 
while for the last method the drug is directed to a specific area of the body [22]. The first cures were 
obtained with systemic chemotherapy to treat leukemia, the cancer of the blood, by the 1960s [21,23]. 
 
Different types of chemotherapeutic agents 
 The idea of using toxic drugs for cancer therapy was inspired by the usage of nitrogen mustard 
during the World Wars [21,23]. Various DNA alkylating agents were then developed based on nitrogen 
mustard, however difficulty in administration and acute side effects such as nausea, vomiting and bone 
marrow suppression delayed the use of these drugs [24]. Folic acid antagonists were also synthesized by 
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the same time, based on experiments which showed that the administration of folic acid would accelerate 
tumor growth. Methrotrexate, a folate antagonist which is an anticancer drug used until nowadays in 
clinics was discovered by the 1950s [21,24]. After the first consistent successes of chemotherapy in the 
1960s, several efforts were made to identify new treatments for cancer from 1970s onwards. In this way, 
several new classes of drugs were identified, such as anthracyclines, vinca alkaloids, and platinum drugs 
(which will be further explored in this Thesis) [24]. 
 All cytotoxic chemotherapeutic agents exert their effect by disrupting the cell cycle by one or 
more processes. They cause cell death by apoptosis, either by directly interfering with DNA, or by 
targeting key proteins required for cell division. Unfortunately, they are also cytotoxic for normal cells, 
particularly to those with a high turnover, such as bone marrow and mucous membranes (mouth and 
intestine). Thus, chemotherapeutic drugs can be classified by their cell cycle effects, or by their 
biochemical properties. The ones which belong to the same biochemical class present a similar 
mechanism of action [25]. Table 1 shows the biochemical classification of chemotherapeutic drugs. 
 
Table 1. Biochemical classification of chemotherapeutic drugs (adapted from the reference [25]). 
Drug class Mechanism of action Examples 
Alkylating agents Impair cell function by forming 












Anti-metabolites Structural analogues of 
metabolites involved in DNA 
and RNA synthesis. May 
substitute a metabolite that is 
normally incorporated into DNA 
or RNA, or compete for the 







Anti-tumour antibiotics Intercalate DNA at specific 
sequences, creating free radicals 






Drug class Mechanism of action Examples 
Topoisomerase inhibitors Topoisomerase I and II are 
enzymes responsible for the 
uncoiling of DNA during 
replication. These enzymes are 
required for DNA synthesis to 
occur. 
Irinotecan, topotecan 
(topoisomerase I inhibitors); 
 
Etoposide, teniposide 
(topoisomerase II inhibitor). 
Tubulin-binding drugs Prevent the formation of 
microtubule, which is important 
during mitosis, but also 








Growth factor antagonists Block signal transduction 
pathways implicated in 
proliferation and survival of 
tumor cells. 
Gefitinib (tyrosine kinase 
inhibitor, targets the 
intracellular domain of the 
epidermal growth factor 
receptor - EGFR). 
Monoclonal antibodies Target specific proteins from 
tumors (targeted therapy). 
Herceptin (targets Her-2/neu 





*Anthracyclines also have mechanism of action of topoisomerase I and II. 
**Taxanes also prevent the disassembly of microtubules, inhibiting its normal functioning. 
*** VEGF: Vascular Endothelial Growth Factor 
 
Resistance to chemotherapeutic agents  
Unfortunately, resistance to chemotherapy is one of the main reasons for treatment failure. After 
some chemotherapy sessions, the tumor cells can become resistant to drugs by a combination of different 
mechanisms, such as: (adapted from the reference [25]) 
1. Reduced delivery to the cell: as tumors grow they do not need much blood supply, so being 




2. Decreased drug uptake: tumor cells can modify the structure or function of proteins involved 
in drug transport, affecting the amount of drug reaching the target. For example, a defective 
reduced folate carrier system confers resistance to methotrexate; 
 
3. Decreased drug activation: many chemotherapeutic drugs require metabolic activation. For 
example, carboxylesterase is responsible for the conversion of irinotecan to its active 
metabolite SN-38, and reduced enzyme expression may cause resistance (the drug is not 
converted to its active form); 
 
4. Increased drug efflux: presence of transport proteins that actively pump drugs out of cells. 
For example, MDR-1 (multi-drug resistance) gene, which codes for a trans-membrane P-
glycoprotein that correlates with resistance when it is overexpressed; 
 
5. Alteration in target protein: when a compound is designed to target a specific enzyme 
resistance can occur when the cell mutates the enzyme. It continues functioning; however, 
the drug has no affinity to the target; 
 
6. Increased DNA repair: overexpression of genes involved in DNA repair can inactivate the 
effects of DNA binders, such as platinum compounds; 
 
7. Inhibition of apoptosis, reducing cell kill; 
 
8. Increased drug metabolism and detoxification. 
 
Even though combination therapy reduces the chances of resistance by using compounds with 
different mechanisms of action, allowing additive of synergistic effects, toxicity plays a key role, and 
the absence of alternative results in the cessation of the therapy [25]. In this way, the search for new and 
improved chemotherapeutic compounds is of high interest. One recent example are targeted therapies, 
which can inhibit specific molecular targets implicated in cancer or single oncogenic drivers, rather than 
affecting cell division or DNA synthesis. Examples are small molecule inhibitors (as kinase inhibitors), 
monoclonal antibodies, and immunotherapeutics [26].  The last ones will not be discussed in detail here. 
This work has its focus on anticancer compounds in Medicinal Inorganic Chemistry, which can 
be divided into two categories: (1) drugs that target metal ions in some form, and (2) metal-based drugs 
where the central metal ion is essential to the clinical application [27]. The first part of this Thesis will 
deal with the development of anticancer metal-based drugs, while the second part will be on novel 
anticancer drugs that target metal ions. Data from the first part of the Thesis was published in the 
following journals: Journal of Fluorine Chemistry 195 (2017) 93-101, Journal of Molecular Structure 
1178 (2019) 169-178, and Toxicology In Vitro 60 (2019) 359-368. 
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PART 1: Metal complexes with uracil derivatives 
 
Introduction 
Metal compounds in cancer treatment 
 The vast majority of drugs in the market are organic (non-metal containing) substances, but there 
has been a great interest in the development of metal complexes as drugs or diagnostic agents. Based on 
the wide spectrum of coordination numbers and geometries, as well as kinetics properties, metal 
compounds offer mechanisms of drug action which cannot be achieved by organic compounds [28]. 
Also, therapeutic potentials of metal-based compounds date to ancient times. For example, arsenic 
trioxide was used as an antiseptic, in the treatment of rheumatoid diseases, syphilis and psoriasis by the 
Chinese, and was among the first compounds suggested for use in the treatment of leukemia during 18th 
and 19th centuries. Considering other therapeutic uses of metals, gold and copper were used by ancient 
Egyptians and Chinese in the treatment of syphilis [29], and copper was also used to sterilize water 
[30,31]. Silver was used by ancient Greeks and Romans to keep beverages pure for long periods [1], 
while in the middle ages it was applied in the treatment of skin wounds and burns [32]. 
 
Platinum compounds  
Platinum complexes are widely used as anticancer compounds in the clinics. As a matter of fact, 
50-70% of all chemotherapeutic treatments use a platinum compound [33,34], showing the importance 
of these metallodrugs in cancer chemotherapy. The discovery of the antiproliferative activities of 
cisplatin (cis-diamminedichloridoplatinum(II), [PtCl2(NH3)2], Figure 1a) by Rosenberg and co-workers 
can be considered the starting point of the use of metal complexes in cancer treatment [35]. Cisplatin 
was synthesized by Peyrone in 1844 and had its structure elucidated by Werner in 1893, however only 
in the 1960s its biological properties were observed [36]. While studying the effects of an electric field 
over Escherichia coli bacterial strain it was observed that the bacteria stopped to replicate. After 
investigating the reason of the replication cease it was found that platinum compounds were being 
generated by the platinum electrode and the ions in solution, and cisplatin was the main compound 
responsible for ceasing bacterial growth [37]. This led to the investigation of cisplatin in tumors (animal 
models) [38], which showed a great anticancer potential, and cisplatin was approved for clinical use by 
the FDA in 1978 [39]. 
 Cisplatin exerts its mechanism of cytotoxic action by covalently binding to DNA. When 
intravenously administered cisplatin interacts with plasma proteins (human serum albumin, hemoglobin, 
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transferrin) and is widely distributed into body fluids and tissues. It enters the cell by passive transport 
or by active protein-mediated transport systems, such as copper transport proteins. In the cytoplasm 
cisplatin is hydrolyzed, losing the chlorido ligands, allowing the binding to DNA bases, especially to 
N7-guanidine residues of DNA [40]. Cisplatin, due to its cis conformation, forms mostly intrastrand 
adducts with DNA, causing torsions in the biomolecule’s structure, what triggers programmed cell death 
by recognition of specific proteins as DNA-mismatch repair proteins (MRP) [41] and high-mobility 
group proteins (HMG) [42,43]. 
The trans-isomer, trans-diamminedichloridoplatinum(II) (transplatin), was also evaluated and 
appeared not to be therapeutically active. It forms mostly monofunctional adducts with DNA, which 
makes it easier to be deactivated by glutathione (GSH), for example, stressing the need for a cis-oriented 
geometry capable of bifunctional DNA binding and effective antitumor action. However, platinum 
compounds present many side effects, because platinum(II), being a soft Lewis acid, also binds to 
cysteine residues of proteins all over the body and, in special, glutathione and metallothionein inside the 
cell. Therefore, dosage is limited by general toxicity. Side effects include nausea, vomiting, loss of 
sensation in the extremities and nephrotoxicity [34]. 
 Considering dosage limiting due to general toxicity of cisplatin and knowledge about ligand 
substitution in coordination chemistry, carboplatin was created. Carboplatin (cis-
diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II), [Pt(C6H6O4)(NH3)2], Figure 1b) is 
considered a second generation of cisplatin, in which the chlorido ligands are replaced by the 1,1-
cyclobutanedicarboxylato anion, a bidentate ligand. The hypothesis was that a more kinetically stable 
leaving group would lower the toxicity without affecting the antitumor efficacy, what turned out to be 
correct. Carboplatin is less toxic to the gastrointestinal tract, less neurotoxic and does not cause 
nephrotoxicity. However, other side effects as myelosuppression occur [44]. Even though, higher doses 
can be administered when compared to cisplatin. 
 Although carboplatin is less toxic than cisplatin because of differences in ligand exchange 
kinetics, both cause the same torsion to the DNA molecule [45], therefore having the same mechanism 
of action and presenting the same resistance patterns, because of the same cellular recognition. Examples 
of resistance factors would include efflux pumps, DNA repair systems, anti-apoptotic factors, deficient 
drug uptake, among others [46]. The resistance factors are cell line dependent; for example, cells that 
are deficient in DNA repair systems are more sensitive to cisplatin [47]. Also, cells deficient in MRP 
(mismatch repair proteins) and HMG (high mobility group) proteins are resistant to cisplatin, because 
the DNA torsion is not recognized and cell death is not triggered [48,49]. In this way, a hypothesis would 
be that different DNA torsions would cause different cell recognition and, therefore, different cellular 
responses. Oxaliplatin ([(1R,2R)-Cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II), 
[Pt(C2O4)(C6H14N2)], Figure 1c) is the third generation of cisplatin, in which the amino ligands are 
substituted by a diaminocyclohexane (DACH) and the chlorido ligands are substituted by an oxalato 
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anion. Interestingly, oxaliplatin showed a different pattern of sensitivity to that of cisplatin and 
carboplatin in in vitro tests. Moreover, the cellular accumulation seems to be less dependent on copper 
transporters and MRP do not recognize oxaliplatin-induced DNA adducts. This showed that the 
differences in the DNA intrastrand crosslinks formed by oxaliplatin retains its activity over some cancer 
cells with acquired resistance to cisplatin [44,49]. 
 
Figure 1. Structures of (a) cisplatin, (b) carboplatin, and (c) oxaliplatin. 
 
The understanding of the mechanisms of action of these compounds and the structure-activity 
relationships led to the development of many platinum(II) compounds for the treatment of cancer. 
However, only cisplatin, carboplatin and oxaliplatin are the ones approved worldwide for clinical use. 
Nedaplatin, heptaplatin, and lobaplatin are approved for use only in Japan, South Korea, and China, 
respectively. Many other platinum(II) compounds have been evaluated considering other strategies, as 
trans-geometry complexes with bulky ligands, which form mostly monoadducts with DNA and avoid 
deactivation by metallothioneins and GSH [50–52]. In addition, polynuclear platinum(II) complexes 
were developed, which present different DNA-adduct formation [53–55], therefore resulting in different 
cellular responses and differentiated cytotoxicity. Platinum(IV) compounds were developed as pro-
drugs, in which the intracellular reduction leads to the counter platinum(II) complex, which presents the 
known mechanisms of action. Nevertheless, platinum(IV) compounds are more lipophilic, what 
enhances the drug uptake, and they also suffer less deactivation by GSH and metallothioneins [56–58]. 
Also, these compounds can have linkers to target cancer cells, or bioactive linkers which can be 
intracellularly released and have an additive effect to the platinum(II) compound [59,60]. 
 
Other metals envisaged for cancer treatment 
Cisplatin is the center of metal-based compounds as anticancer drugs in the modern era [29]. 
However, the acquired or intrinsic resistance of some tumors and the side effects of platinum compounds 
are major drawbacks. There is a need for new approaches to circumvent these drawbacks [61]. In this 
way, other metal ions have been explored, considering that metal centers display various oxidation states 
and coordination numbers, as well as geometry diversity, kinetics and thermodynamics features that lead 
to multi-target agents [62]. For platinum compounds DNA is the main target, and other metal-based 
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compounds are known to present novel modes of DNA binding, which are considered “classical non-
platinum metal compounds”. On the other hand, other metal-based compounds can have proteins and 
enzymes as targets, which are considered “non-classical metal compounds” [61]. Other metal ions, some 
used in this work, and others that are very important considering Medicinal Inorganic Chemistry, in spite 
of platinum(II), are described next. 
 
Palladium 
Due to geometric similarities between Pt(II) and Pd(II) coordination compounds, palladium(II) 
complexes have been studied as anticancer drugs, although the chemistry concerning both metals is quite 
different. The aquation and ligand-exchange rates of palladium(II) complexes are about 105 times faster 
when compared to the platinum(II) counterparts, and the first present in general a better solubility. Most 
of the palladium-based compounds can be considered as classical non-platinum, because, in general, 
they have the DNA as the main target. Therefore, some palladium(II) complexes may have potential for 
cancer therapy [63], by tuning the substitution lability using steric and electronic effects of ligands [64]. 
In general, higher activity can be achieved using bulkier ligands (as bipyridine or phenanthroline, for 
example) that hand in a lower reactivity towards GSH, also being able to cause a greater distortion in 
DNA as consequence of palladium-DNA binding [65,66]. 
Nevertheless, there are also palladium(II) candidates which can be considered as non-classical 
metal compounds. As for an example of a palladium(II) compound evaluated in clinical trials, 
padeliporfin (Figure 2) is a photosensitizer based on a Pd(II) center, evaluated for photodynamic therapy 
of prostate cancer [67]. It is a water-soluble compound which is activated locally by the use of low-
power laser light, causing the induction of reactive oxygen species (ROS) [68]. 
  







Although not explored in this work, ruthenium compounds were the first non-platinum 
candidates to reach clinical trials and, therefore, it is important to cite them here. The biological activity 
of ruthenium ions was first examined by Dwyer et al. in the 1950s [69]. Ruthenium complexes are 
among the most studied non-platinum metal compounds with anticancer activities [70], and NAMI-A 
(imidazolium trans-tetrachlorido-(dimethylsulfoxide)imidazole-ruthenate(III), Figure 3a) was the first 
non-platinum candidate to reach clinical trials [71], followed by KP1019 (trans-tetrachloridobis-(1H-
indazole)ruthenate(III), Figure 3b) and its sodium salt KP1339 (Figure 3c) [72]. When compared to 
platinum drugs, these ruthenium(III) compounds present fewer and less side effects. The reduced 
toxicity is attributed, in part, to the ability of Ru(III) to mimic iron binding to serum protein, so these 
compounds possess high affinity to cancer cells with transferrin receptors, increasing the amount that 
reaches cancer cells when compared to healthy cells [29,34]. Also, these compounds do not target 
primarily the DNA, although they present DNA interactions. KP1019, for example, reacts with DNA 
and induces apoptosis via the intrinsic mitochondrial pathway, being accumulated mainly in cell nucleus 
[40]. 
 
Figure 3. Structures of (a) NAMI-A, (b) KP1019, and (c) KP1339. 
 
The activity of these ruthenium(III) compounds is based on the principle “activation by 
reduction”, that is, Ru(III) can be reduced to Ru(II) and then re-oxidized in the cellular environment 
[70]. This leads to the disturbance of redox homeostasis, leading to the generation of ROS. Also, the 
reaction with GSH can induce depletion of the intracellular GSH pools, which renders cells more 
susceptible to endogenous and exogenous oxidative stress [73]. Therefore, both DNA and protein 





 About 3500 years ago gold was used in a variety of medicines in Arabia and China, however 
more as a result of its precious nature than of known medicinal properties [75]. The rational use of gold 
in medicine started in the end of the 19th century, when Robert Koch first described the antimicrobial 
activity of K[Au(CN)2] against tuberculosis [76]. Nevertheless, due the severe toxicities of gold cyanide 
compounds, Jacques Forestier identified the biological activities of thiolate gold compounds, which 
were further applied in the treatment of rheumatoid arthritis (RA) [70]. One of the most representative 
drugs of this type is auranofin (Figure 4), an orally administered thiolate phosphine gold(I) coordination 
compound [77]. Auranofin presents a two-coordination linear geometry. Gold(I) compounds can also 
form trigonal three-coordination and tetrahedral four-coordinated complexes [78]. 
 
Figure 4. Structure of auranofin. 
 
 Gold compounds were considered to be used as antitumor agents since RA patients treated with 
auranofin showed unexpectedly low rates of malignancies [40,70]. The mechanism of antitumor action 
of auranofin is not primarily based on DNA interactions, but on the interaction with cellular redox 
processes by targeting mitochondria [70]. One of the major impacts of Au(I) compounds is the inhibition 
of redox enzymes, such as the seleno-enzyme thioredoxin reductase (TrxR). Such enzymes are essential 
to many cellular processes, particularly in maintaining the ROS levels [79].  Elevated concentrations of 
TrxR have been found in human tumor cells and they have been associated with tumor proliferation, and 
the inhibition of TrxR induces mitochondria-dependent apoptosis [40].  Thus, TrxR inhibition and 
disturbance of mitochondrial respiration lead to an increase in the production of ROS, mitochondrial 
swelling, and a decrease in mitochondrial membrane potential, what leads to apoptosis [70]. This 
dissimilar mechanism of action of auranofin, when compared to cisplatin, concedes auranofin a 
contrasted scope of activity, for example by inducing apoptosis in some cisplatin-resistant cell lines [80]. 




 Because of the context of auranofin, gold(I) phosphine compounds have been evaluated as 
potential anticancer agents [77,81–84]. For example, studies have shown that larger and more lipophilic 
substituents of the phosphine enhance the cytotoxicity of the gold compounds [85], while the thiosugar 
moiety, present in auranofin, is not mandatory for its pharmacological action [86]. As mentioned before, 
gold(I) phosphine compounds have mitochondria as the main target [87,88]. 
 Last but not least, gold(III) compounds have also been evaluated as anticancer drugs. Gold(III) 
is isoelectronic and isostructural to Pt(II), forming square-planar four-coordinate complexes, so it is 
expected that the mechanism of action of gold(III) compounds is also based on DNA interactions. 
Indeed, there is a greater affinity of Au(III) when compared to Au(I) to the DNA, and binding can be 
both electrostatic and covalent [70]. However, gold(III) complexes rapidly react and reduce to gold(I) 
under physiological conditions, so the use of multidentate N,N- or N,N,N- donor ligands, such as 
ethylenediamine (en), diethylenediamine (dien), phenathroline (phen), or terpyridine (terpy) are applied 
for stabilization against ligand exchange and reduction [89]. 
 
Silver 
Silver has been extensively employed as an antimicrobial compound in medicinal chemistry. As 
an example, silver-sulfadiazine (Figure 5) is a coordination compound used in the treatment of burns, in 
order to avoid bacterial infections [90,91]. As an antibacterial agent, Ag(I) ions have been shown to 
interact with DNA, to impair essential enzymes, cause cell wall disruption, induce ROS formation and 
cause mitochondrial dysfunctions [92,93]. These interactions with different cellular components show 
that silver(I) compounds could also be evaluated as anticancer agents [94], and could result in multi-
targeted drugs [62]. In fact, silver(I) compounds have been evaluated as anticancer agents in the past 
years, which exhibit interesting cytotoxic activities, as well as a diversity of coordination geometries, 
with O-, N-, S- and P- donor ligands [95–98]. 
 




An advantage of the use of silver in comparison to other metals is its low toxicity towards 
humans, that is, the human body can tolerate the presence of silver in low doses without any toxic effects 
[96]. Also, a phenomenon termed “the zombie effect” was observed in silver-killed bacteria, in which 
the dead bacteria were able to induce death in viable bacteria. The killed bacteria acted as a reservoir of 
silver ions, and when in contact to viable bacteria the ions diffused or migrated towards the new target 
[96,99]. In principle, this could also occur for tumor cells [96], but no studies regarding this phenomenon 
have been reported for cancer cells so far. In fact, very little is reported regarding the mechanism of 
antitumor action of silver compounds, when compared to other metals, such as platinum and gold. Most 
reports on silver compounds focus on the cytotoxicity, and few really dig into the mechanism of action, 
specially comparing the roles of metal and ligand in the biological activity of the complex. It is known 
that the anticancer action of silver compounds differ from that of platinum derivatives in terms of DNA 
interactions. It seems that silver(I) compounds have a mechanism of action more likely to gold(I), having 
mitochondria as target [96,100]. 
One disadvantage of the use of silver compounds is the bioavailability, since Ag(I) ions are 
rapidly precipitated as AgCl or sequestered as Ag-protein complexes. In this way, encapsulation and 
drug delivery of silver compounds is necessary, especially considering that few is reported about in vivo 
testing, what is necessary for the developing of new pre-clinical silver agents [96,101]. 
 
Ligands 
 Despite the metal ion, ligands play a very important role in the biological activity of metal 
coordination compounds. Ligands (from the Latin word ligare, which means “to bind”) are metal-
binding molecules [102]. The concept of Lewis acid/base can be applied, in which the metal ion is a 
Lewis acid, and the ligand is a Lewis base. Ligands are, most often in Medicinal Inorganic Chemistry, 
organic compounds that can tune physical properties of the complex. For example, in the case of 
platinum(II) compounds, carboplatin has a slower ligand exchange rate than cisplatin, what confers the 
first a higher kinetic stability due to the chelating ligand. As another example, considering the use of 
silver(I) compounds in burns, Ag(I) ions are slowly released to the skin when silver-sulfadiazine is used, 
differently from silver nitrate, which results in lower side effects from the first when compared to the 
second. Sulfadiazine in this case acts as a carrier, despite being a sulfonamide with antibacterial activities 
as well. So, in general, ligands can modify reactivity and lipophilicity, stabilize oxidation states, and 
contribute to substitution inertness [102]. 
 One strategy in the development of metal-based anticancer drugs is the combination of a metal 
ion with a biologically active ligand, in which the ligand itself presents some biological activity. This 
strategy is employed in order to enhance the activities of free metal and free ligand, pursuing an additive 
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or synergistic effect. In this way, uracil derivatives were chosen as ligands in this work: 5-fluorouracil, 
2-thiouracil and 2,4-dithiouracil. 
 
5-Fluorouracil 
5-Fluorouracil (5fu or fuH2, C4H3FN2O2, Figure 6) is a fluoropyrimidine analogue to uracil and 
an important fluorine anticancer agent [103]. It acts by misincorporating itself into RNA and DNA, and 
also inhibiting the nucleotide synthetic enzyme thymidylate synthase, leading to DNA damage [104–
106]. Fluorination of nucleosides is an interesting feature, and it is suggested that the fluorine atom in 
5fu may mimic a hydrogen atom and then turn the substrate (uracil) into an inhibitor (5-fluorouracil) 
[107]. 5-Fluorouracil is widely used in the treatment of cancer, particularly for colorectal, breast, and 
aerodigestive tract tumors [104]. In the viewpoint of coordination chemistry, 5-fluorouracil is a versatile 
ligand and its coordination to metal ions may provide interesting effects among the antiproliferative 
activities of the metal ion and the free drug. The first silver(I), palladium(II) and platinum(II) complexes 
with 5-fluorouracil were reported in the literature in the 1970’s [108–110]. At that time, only the 
synthetic route and elemental and potentiometric studies of the obtained complexes were presented. No 
spectroscopic, structural or biological studies were discussed so far. Considering the cited 
circumstances, these compounds were revisited, and the synthesis, characterization, and antiproliferative 
assays of a silver(I) complex, a palladium(II) complex, and a platinum(II) complex with 5-fluorouracil 
are presented [111,112]. Besides, insights into the mechanism of cell death caused by the silver(I) 
complex over ovarian resistant tumor cells are presented as well. 
 
 







2-Thiouracil and 2,4-Dithiouracil 
2-Thiouracil (tuH2, C4H4N2OS) is an uracil analog that presents a sulfur atom bound to carbon 
C2 instead of an oxygen atom (Figure 7a). 2-Thiouracil and its analogs are used in the treatment of 
hyperthyroidism [113]. Furthermore, 2,4-dithiouracil (dtuH2, C4H4N2S2) is an analog to 2-thiouracil, 
with a sulfur bound to carbon C4 instead of an oxygen atom (Figure 7b). Uracil derivatives, in general, 
present remarkable biological properties [104], and many metal complexes with these ligands are 
reported in the literature [114–118]. However, despite few cases [119,120], no biological studies were 
studied in deep so far. Here, a gold(I) complex with 2-thiouracil and triphenylphosphine and a silver(I) 
complex with 2,4-dithiouracil are presented, besides the evaluation for the first time of these compounds 
as antiproliferative agents. At last, preliminary studies of the cell death mechanism of the gold(I) 
complex with 2-thiouracil over lung tumor cells was also investigated. 
 














The objective of the first part of this Thesis was the synthesis, characterization and evaluation 
of the antiproliferative activities of Ag(I), Au(I), Pd(II), and Pt(II) metal complexes with uracil 
derivatives over a panel of tumor cells. The evaluation of the cell death mechanism of some compounds 




Materials and Methods 
Starting Materials 
5-Fluorouracil (fuH2 or 5fu), 2-thiouracil (tuH2), 2,4-dithiouracil (dtuH2), silver nitrate 
(AgNO3), potassium tetrachloropalladate(II) (K2[PdCl4]), potassium tetrachloroplatinate(II) (K2[PtCl4]), 
potassium tetrachloroaurate(III) (K[AuCl4]), triphenylphosphine (Ph3P), potassium hydroxide (KOH), 
SYBR green (nucleic acid gel stain) 2′,7′-dichlorofluorescein diacetate and rhodamine-123 were 
purchased from Sigma-Aldrich Laboratories (purity >98%). The 1 Kb Plus DNA Ladder (1.0 μg μL-1) 
was purchased from Invitrogen (Thermo Fischer Scientific). All reagents were used without further 
purification. 
Culture medium RPMI 1640 and fetal bovine serum (FBS) were purchased from Gibco (Grand 
Island, New York, USA). Penicillin/streptomycin (1000 U/mL:1000 l g/mL) and trypsin-EDTA 0.25% 
were purchased from Vitrocell (Campinas, São Paulo, Brazil). Guava Nexin Reagent, Guava 
Multicaspase kit (Caspase Reagent Working Solution, Apoptosis Wash Buffer and Caspase 7-AAD 
Reagent Working Solution) and Guava Cell Cycle Reagent were purchased from Merck-Millipore. 
 
Synthesis of the silver(I) complex with 5-fluorouracil 
The complex was prepared by the reaction of AgNO3 (1.0 mmol, 0.17 g, 1 eq.) with fuH2 (1.0 
mmol, 0.13 g, 1 eq.) and KOH (1.0 mmol, 0.057 g, 1 eq.) in aqueous solution. The final volume of the 
synthesis was 10 mL. After 2 h of vigorous stirring at room temperature, a gelatinous white precipitate 
was obtained. The compound was vacuum filtered and washed with water. The final product was dried 
in desiccator with P2O5. Elemental analysis: Calcd. for [Ag3(C4HFN2O2)(C4H2FN2O2)] (%): C, 16.5 ; H, 
0.52 ; N, 9.6. Found (%): C, 16.8 ; H, 0.38 ; N, 9.6. The complex is slighlty soluble in dimethyl sulfoxide 
(DMSO). It is insoluble in water and in other common organic solvents. This complex will be further 
referred to as Ag-5fu. 
 
Synthesis of the palladium(II) complex with 5-fluorouracil 
This complex was prepared by the reaction of K2[PdCl4] (0.25 mmol, 0.082 g, 1 eq.) with fuH2 
(0.50 mmol, 0.065 g, 2 eq.) and KOH (0.50 mmol, 0.028 g, 2 eq.) in aqueous solution. The final volume 
of the synthesis was 5 mL. After 3 h of stirring at room temperature, a yellow to orange precipitate was 
obtained. The compound was vacuum filtered and washed with water, ethanol and diethyl ether. The 
final product was dried in desiccator with P2O5 and under low pressure. Elemental analysis, flame atomic 
spectroscopy and ICP-OES: Calcd. For K[PdCl(C4H2FN2O2)2]·H2O (%): C, 21.0 ; H, 1.32 ; N, 12.3 ; 
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Pd, 23.3 ; K, 8.5. Found (%): C, 20.7 ; H, 1.39 ; N, 12.8 ; Pd, 22.3 ; K, 6.6. The complex is soluble in 
DMSO and dimethylformamide (DMF), however it decomposes in these solvents. It is slightly soluble 
in methanol. It is insoluble in water and in other common organic solvents. This complex will be further 
referred to as Pd-5fu. 
 
Synthesis of the platinum(II) complex with 5-fluorouracil 
This complex was prepared by the reaction of K2[PtCl4] (0.125 mmol, 0.052 g, 1 eq.) with fuH2 
(0.25 mmol, 0.034 g, 2 eq.) and KOH (0.25 mmol, 0.014 g, 2 eq.) in aqueous solution. The final volume 
of the synthesis was 3 mL. After 2 h of stirring in a water bath (70 °C), a cold mixture of ethanol/ethylic 
ether 1:1 was added to the reaction solution, until the formation of a brownish precipitate. The solid was 
separated by centrifugation and washed with the same ethanol/ethylic ether solvent mixture. The final 
product was dried in desiccator under low pressure. Elemental analysis, flame atomic spectroscopy and 
ICP-OES: Calcd. for K2[PtCl2(C4H2FN2O2)2] (%): C, 15.9 ; H, 0.67 ; N, 9.3 ; Pt, 32.4 ; K, 13.0. Found 
(%): C, 15.9 ; H, 0.69 ; N, 9.0 ; Pt, 30.7 ; K, 10.7. The complex is soluble in water and DMSO, however 
it decomposes in these solvents. It is insoluble in other common organic solvents. This complex will be 
further referred to as Pt-5fu. 
 
Synthesis of the silver(I) complex of 2,4-dithiouracil 
The complex was prepared by the reaction of AgNO3 (0.60 mmol, 0.10 g, 2 eq.) with dtuH2 
(0.30 mmol, 0.044 g, 1 eq.) and KOH (1.0 mmol, 0.045 g, 3.3 eq.) in aqueous solution. The final volume 
of the synthesis was 6 mL. After 1 h of stirring at room temperature, an orange precipitate was obtained. 
The compound was vacuum filtered and washed with water. The final product was dried in desiccator 
with P2O5. Elemental analysis and ICP-OES: Calcd. for [Ag2(C4H2N2S2)] (%): C, 13.4 ; H, 0.56 ; N, 7.8. 
Found (%): C, 13.6 ; H, 0.47 ; N, 7.6. The complex is insoluble in water and in common organic solvents, 
such as methanol, ethanol, acetone, acetonitrile (ACN), dichloromethane, chloroform, DMF and DMSO. 
This complex will be further referred to as [Ag2(dtu)]. 
 
Synthesis of the gold(I) complex with 2-thiouracil 
First, the chlorido(triphenylphosphine)gold(I) complex (Ph3P-Au-Cl) was prepared by adding a 
solution of PPh3 (1.0 mmol, 0.26 g, 2 eq.) in chloroform (1.0 mL) to a solution of K[AuCl4] (0.50 mmol, 
0.19 g, 1 eq.) in ethanol/acetone 1:1 (1.0 mL). After 30 min, the Ph3P-Au-Cl was isolated by filtration 
in a Büchner funnel and washed with ethanol. Further, Ph3P-Au-Cl (0.10 mmol, 0.49 g, 1 eq.) dissolved 
in chloroform (1.0 mL) was added to AgNO3 (0.10 mmol, 0.017 g, 1 eq.) in methanol (1.0 mL), 
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producing AgCl, which was centrifuged and discarded. The (triphenylphosphine)gold(I) supernatant 
was reserved for posterior use as the precursor for the synthesis of the 2-
thiouracilato(triphenylphosphine)gold(I) complex. 
Proceeding with the preparation, tuH2 (0.10 mmol, 0.013 g, 1 eq.) was added to a 25 mL round 
bottom flask with methanol (3.0 mL) and triethylamine (0.50 mL) or ammonium hydroxide (10 drops), 
leading to the 2-thiouracilato (tuH) compound. To this solution the (triphenylphosphine)gold(I) 
supernatant was added, and the mixture was refluxed for 18 h. After concentration by evaporation of the 
solvents, the 2-thiouracilato(triphenylphosphine)gold(I) complex precipitated as a pale-yellow solid. 
The solid was washed with cold methanol and diethyl ether and dried under low pressure. Elemental 
analysis: Calcd. for [Au(C18H15P)(C4H3N2OS)] (%): C, 45.1 ; H, 3.09 ; N, 4.78. Found (%): C, 44.7 ; H, 
2.74 ; N, 4.41. Crystals were obtained from slow evaporation of the mother liquor. The complex is 
soluble in chloroform, acetone and methanol. This complex will be further referred to as Ph3P-Au-tuH. 
 
Equipments 
Chemical analyses: Elemental analyses for carbon, hydrogen and nitrogen were performed using a 
Perkin Elmer 2400 CHNS/O Analyzer. Atomic emission spectrometry measurements were performed 
in a flame photometer model Analyser C-910M (São Paulo, Brazil), kindly done by Professor Fabiana 
C. A. Corbi from FATEC/Campinas (Brazil). Inductively coupled plasma atomic emission spectroscopy 
(ICP-OES) measurements were performed in a Perkin Elmer-Optima 8300 equipment. 
 
Thermogravimetric analyses:  Thermogravimetric analyses were performed in a TA Instruments 2050 
TGA equipment in the following conditions: synthetic air, flow rate of 100 mL min-1, and heating rate 
of 5°C min-1, from 25°C to 1000°C. 
 
Mass spectrometric measurements: Electrospray ionization quadrupole time-of-flight mass 
spectrometric (ESI-QTOF-MS) measurements were carried out in a Waters Synapt HDMS instrument 
(Manchester, UK) in the positive mode for Ag-5fu, Pt-5fu and Ph3P-Au-tuH, while for Pd-5fu it was 
performed in the negative mode. Samples of the complexes were dissolved/suspended in the respective 
solvents (Ag-5fu in DMSO; Pd-5fu in methanol; Pt-5fu in water; Ph3P-Au-tuH in methanol) before being 
further diluted in methanol with 0.1% (v/v) formic acid. Such mixtures were then further diluted 100-




Nuclear magnetic resonance measurements: The 13C and 15N nuclear magnetic resonance (NMR) 
spectra of Ag-5fu, Pd-5fu, Pt-5fu and [Ag2(dtu)] were recorded in the solid state on a Bruker 300 MHz 
spectrometer, using the combination of cross-polarization and magic angle spinning (CP/MAS) at 10 
kHz for both 13C and 15N. For Ph3P-Au-tuH, NMR spectra were recorded in solution. Solution-state 
1H 
and 13C NMR of tuH2 and Ph3P-Au-Cl were recorded on a Bruker Avance III 400 MHz. The 
1H and 13C 
NMR of Ph3P-Au-tuH were recorded on a Bruker Avance III 500 MHz. 
31P NMR of both Au(I) 
complexes were recorded on the Bruker Avance III 500 MHz. Samples of the Au(I) complexes were 
analyzed in CDCl3, while tuH2 was recorded in DMSO-d6, and the chemical shifts were given relative 
to tetramethylsilane (TMS) for 1H and 13C and relative to phosphoric acid for 31P. 
 
Infrared spectroscopy: For 5fu, Ag-5fu, Pd-5fu and Pt-5fu the infrared (IR) spectra were measured in 
KBr pellets using a Bomem MB-Series Model B100 FT-IR spectrophotometer in the range 4000-400 
cm–1 with resolution of 4 cm–1 and 16 scans. For tuH2, dtuH2, Ph3P-Au-tuH and [Ag2(dtu)] IR spectra 
were measured on an Agilent Cary 630 FTIR spectrometer, using the Attenuated Total Reflectance 
(ATR) method with a diamond cell. All spectra were recorded from 4000 to 400 cm−1, with 64 scans 
and resolution of 4 cm−1. 
 
Single crystal X-ray diffraction: The crystal structure of the Ph3P-Au-tuH complex was confirmed by 
single crystal X-ray diffraction on a Bruker APEX II DUO area detector diffractometer, equipped with 
a low-temperature device (Oxford Cryosystems CRYOSTREAM 700). Data were collected at 150 K 
crystal temperature, using Cu Kα radiation (λ = 1.54184 Å; Incoatec microfocus X-ray source), based 
on a strategy combining omega and phi scans, width of 0.5° and acquisition time of 10 s per frame. Cell 
refinement and data reduction were performed using SAINT [121] and multi-scan absorption correction 
was performed with SADABS-2014/5 [121]. The structure was solved by direct methods using 
SHELXTL XT-2014/4 [122] and refined by least-squares methods against F2, using SHELXle [123], 
with all non-hydrogen atoms refined anisotropically and all hydrogen atoms added geometrically. 
 
Antiproliferative assays in vitro 
The antiproliferative activities of Ag-5fu, Pd-5fu and Pt-5fu were investigated on nine human 
tumor cell lines: U251 (glioma), MCF-7 (breast), NCI/ADR-RES (ovarian expressing phenotype of 
multiple drugs resistance), 786-O (kidney), NCI-H460 (lung, non-small cells), PC-3 (prostate), 
OVCAR-03 (ovarian), HT-29 (colon adenocarcinoma) and K-562 (chronic myeloid leukemia)], kindly 
provided by Frederick Cancer Research & Development Center, National Cancer Institute, Frederick, 
MA, USA. The non-tumor cell line HaCat (human keratinocyte) used for cell viability was provided by 
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Dr. Ricardo Della Coletta (University of Campinas-UNICAMP, Brazil). The antiproliferative activities 
of [Ag2(dtu)] and Ph3P-Au-tuH were investigated on eight tumor cell lines and also on HaCat. The same 
cells were used as in the assays for Ag-5fu, Pd-5fu and Pt-5fu, despite the prostate (PC-3) cell line. For 
cell culture maintenance and experiments stock cultures were grown in 5 mL of RPMI-1640 
supplemented with 5% fetal bovine serum (RPMI/FBS 5%) at 37 ºC in 5% CO2 with a 1% 
penicillin:streptomycin mixture (1000 U mL-1) (complete medium). 
The Ag-5fu, Pd-5fu, Pt-5fu, [Ag2(dtu)] and Ph3P-Au-tuH compounds were prepared directly in 
complete medium (5 mg mL-1) and then diluted in the same medium, affording the final concentrations 
of 0.025, 0.25, 2.5 and 25 µg mL-1 for Pd-5fu and Pt-5fu, and 0.25, 2.5, 25 and 250 µg mL-1 for Ag-5fu, 
[Ag2(dtu)] and Ph3P-Au-tuH. Free ligands 5fu, tuH2 and dtuH2, the starting metals K2[PdCl4], K2[PtCl4], 
AgNO3 and Ph3P-Au-Cl (final concentrations of 0.025, 0.25, 2.5 and 25 µg mL
-1 for 5fu, Pd(II) and 
Pt(II) salts, and 0.25, 2.5, 25 and 250 µg mL-1 for tuH2, dtuH2, Ag(I) and Au(I), all in complete medium), 
and the chemotherapeutic drugs cisplatin and doxorubicin (final concentrations of 0.025, 0.25, 2.5 and 
25 µg mL-1 in complete medium) were used as controls. 
Cells in 96-well plates (100 µL cells/well, inoculation density: 3.5 to 6.0 x 104 cell mL-1) were 
exposed to different concentrations of sample and controls (100 µL/well) in triplicate, for 48 h at 37 °C 
and 5% of CO2. Before (T0 plate, after 24 h from seeding) and after the sample addition (T1 plates, after 
72 h from seeding), cells were fixed with 50% trichloroacetic acid, washed with water, and cell 
proliferation was determined by the spectrophotometric quantification (540 nm) of cellular protein 
content using the sulforhodamine B assay [124–126]. The GI50 values (concentration that inhibits 50% 
cell growth or cytostatic effect) and TGI values (total growth inhibition, concentration that inhibits 100% 
cell growth or cytotoxic effect) were determined through non-linear regression, type sigmoidal, analyzed 
using Origin 8.0 software [127]. 
 
Gel electrophoresis assay 
For the gel electrophoresis assay, 1.0 mg of a given compound (in this case AgNO3, 5fu or Ag-
5fu) was primarily dissolved in 100 μL of H2O (for AgNO3) or suspended in 100 μL of DMSO (for 5fu 
and Ag-5fu). Then, 10 μL of the solution or suspension containing the respective compounds were mixed 
with 5 μL of pIRES DNA plasmid solution and incubated at 37°C for 1 h. The samples were 
electrophoresed for 10 minutes at 50 V and 1 hour at 100 V using a 0.8% agarose gel matrix in Tris-
Borate-EDTA 0.5x buffer at pH 8.3. After electrophoresis, the gel was stained with 1x SYBR green for 
1 hour and photodocumented using a GelDoc-It Imager [49]. As control pure pIRES DNA plasmid was 
used. A DNA Ladder was used as a weight marker. The pIRES DNA plasmid was kindly provided by 
Professor Marcelo Lancellotti from the Faculty of Pharmaceutical Sciences/UNICAMP, Brazil. 
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Colony formation assay 
NCI/ADR-RES and NCI-H460 cells were seeded in RPMI-1640 supplemented with 5% FBS 
and 1% penicillin:streptomycin (complete medium) T25 flasks (5x104 cells mL-1 and 4x104 cells mL-1, 
respectively, 5 mL/flask) and incubated at 37 ºC in 5% CO2 to reach ~ 80% confluence. For NCI/ADR-
RES, seven T25 flasks were prepared, being one for each treatment (two concentrations of each sample) 
plus one for untreated cells. Then, cells were treated in the flasks with 5fu (0.75 and 1.5 µg mL-1), 
AgNO3 (0.75 and 1.5 µg mL
-1) or Ag-5fu (1.5 and 3.0 µg mL-1) for 24 h. For NCI-H460, five T25 flasks 
were prepared, being one for each treatment (two concentrations of each sample) plus one for untreated 
cells. NCI-H460 cells were treated in the flasks with Ph3P-Au-Cl (5.05 and 10.1 µg mL
-1) and Ph3P-Au-
tuH (6.0 and 12.0 µg mL-1) for 24 h. All compounds were prepared in complete medium. 
After trypsinization, each resulting cell suspension was adjusted to 50 or 100 cells mL-1 (NCI-
H460 and NCI/ADR-RES, respectively) and seeded in complete medium in triplicate in 6-well 
microplates (2 mL/well). For NCI/ADR-RES, cells were allowed to grow during 12 days, with complete 
medium being substituted once after the first 5 days. For NCI-H460, cells were allowed to grow during 
6 days, with complete medium being substituted once. At last, for both cell lines, cells were rinsed with 
DPBS (Dulbecco’s phosphate-buffered saline), fixed with methanol/DPBS 1:1 for 2 minutes, and 
afterwards with methanol for 10 minutes. Cells were stained with 0.1% crystal violet for 30 minutes and 
washed with water. Using a light microscope, the number of colonies was counted, considered as one 
grouping with at least 50 cells. Using these results, plating efficiency (PE) and surviving fraction (SF) 
were calculated according to formulas [128]: 
 
𝑃𝐸 = 100 𝑥 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑜𝑟𝑚𝑒𝑑 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠




𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑓𝑜𝑟𝑚𝑒𝑑 𝑎𝑓𝑡𝑒𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 𝑥 𝑃𝐸
 
 
Flow cytometry: cell culture and treatments 
The human tumor cell lines NCI/ADR-RES (ovarian expressing phenotype of multiple drug 
resistance), NCI-H460 (lung, non-small cells) and OVCAR-8 (ovarian) were used. Stock cultures were 
grown in RPMI-1640 supplemented with 5% FBS and 1% penicillin:streptomycin (complete medium) 
at 37 ºC in 5% CO2. These conditions were used both for cell lines maintenance and for experiments. 
The compounds Ag-5fu, 5fu, AgNO3, Ph3P-Au-tuH and Ph3P-Au-Cl were prepared directly in complete 
medium (1.0 mg mL-1) and then diluted in the same medium, affording the final concentrations for each 
experiment. Only for the measurement of intracellular oxidants the compounds were prepared in DPBS 
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and further diluted in this buffer. In all experiments, cells without treatment were used as control. Flow 
cytometry experiments and analysis were performed using Guava EasyCyte Mini Flow Cytometry 
System (Millipore). A total of 5,000 events per replicate were acquired for flow cytometry assays. 
 
Cell cycle arrest 
NCI/ADR-RES (5x104 cells mL-1) and NCI-H460 cells (4x104 cells mL-1) were seeded on 6-
well microplates (2 mL/well) and incubated. After 24 h, cell medium was changed to RPMI-1640 
supplemented with 1% penicillin:streptomycin without FBS and cells were incubated for more 24 h. 
Then, NCI/ADR-RES cells were treated with 5fu (0.37 and 0.75 µg mL-1), AgNO3 (0.37 and 0.75µg 
mL-1) or Ag-5fu (0.75 and 1.5 µg mL-1) for 36 h, while NCI-H460 cells were treated with Ph3P-Au-tuH 
(6.0 and 12.0 µg mL-1) and Ph3P-Au-Cl (5.05 and 10.1 µg mL
-1) for 18 h. After trypsinization, cells were 
washed with PBS and fixed with ethanol 70% for at least 12 h. After washing with PBS, each treated or 
untreated cellular pellet was suspended in 200 µL Guava Cell Cycle Reagent, kept in the dark during 20 
min at room temperature and analyzed in the flow cytometer. 
 
Mitochondrial membrane depolarization – Rhodamine-123 assay 
NCI/ADR-RES (6x104 cells mL-1), NCI-H460 (4x104 cells mL-1) and OVCAR-8 cells (6x104 
cells mL-1) were seeded on 12-well microplates (1 mL/well) and incubated for 24 h. Then, NCI/ADR-
RES cells were treated with 5fu (1.5 µg mL-1), AgNO3 (1.5 µg mL
-1) or Ag-5fu (3.0 µg mL-1); NCI-
H460 cells were treated with Ph3P-Au-tuH (24.0 µg mL
-1) and Ph3P-Au-Cl (20.2 µg mL
-1); and OVCAR-
8 cells were treated only with Ag-5fu (3.0 µg mL-1). Cells were incubated (37 °C, 5% CO2) for 1, 2 and 
3 h. Afterwards, cells were trypsinized and Rhodamine-123 (Rh123) solution (1 µg mL-1 solution in 
PBS, 200 µL per cell suspension) was added to cells. After 15 min-incubation (37 °C, 5% CO2, in the 
dark), each cell suspension was centrifuged, washed with PBS to eliminate unincorporated probe and 
suspended in fresh PBS (300 µL per suspension) before injection in the flow cytometer.  
 
Phosphatidylserine externalization – Nexin assay 
NCI/ADR-RES (5x104 cells mL-1) and NCI-H460 (4x104 cells mL-1) cells were seeded on 12-
well microplates (1 mL/well) and incubated for 24 h. Then, NCI/ADR-RES cells were treated with 5fu 
(0.75 and 1.5 µg mL-1), AgNO3 (0.75 and 1.5 µg mL
-1) or Ag-5fu (1.5 and 3.0 µg mL-1) for 8 and 24 h, 
while NCI-H460 cells were treated with Ph3P-Au-tuH (12.0 and 24.0 µg mL
-1) and Ph3P-Au-Cl (10.1 
and 20.2 µg mL-1) for 24 h.  In a second experiment, NCI/ADR-RES cells were treated with 5fu (1.5 µg 
mL-1), AgNO3 (1.5 µg mL
-1) or Ag-5fu (3.0 µg mL-1) for 14 and 18 h, and NCI-H460 cells were treated 
with Ph3P-Au-tuH (24.0 µg mL
-1) and Ph3P-Au-Cl (20.2 µg mL
-1) for 18 h. After each exposition time 
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cells were harvested with trypsin-EDTA 0.25%, washed with PBS and re-suspended in 100 µL Guava 
Nexin Reagent (Annexin-V PE/7-AAD) for 20 min at room temperature and in the dark before injection 
in the flow cytometer. 
 
Detection of activated caspases 
NCI/ADR-RES (5x104 cells mL-1) and NCI-H460 (4x104 cells mL-1) cells were seeded on 12-
well microplates (1 mL/well) and incubated for 24 h. NCI/ADR-RES cells were then treated with 5fu 
(1.5 µg mL-1), AgNO3 (1.5 µg mL
-1) or Ag-5fu (3.0 µg mL-1) and incubated for 17 h, while NCI-H460 
cells were treated with Ph3P-Au-tuH (24.0 µg mL
-1) and Ph3P-Au-Cl (20.2 µg mL
-1) and incubated for 
18 h. Afterwards, cells were trypsinized, washed with PBS and re-suspended in 10 µL of Guava Caspase 
Reagent Working Solution. After 1h-incubation in the dark at 37 °C and 5% CO2, cells were washed 
with 100 µL 1x Apoptosis Wash Buffer and re-suspended in 200 µL Caspase/7-AAD Reagent Working 
Solution. After 10 min at room temperature in the dark, each cell suspension was analyzed by the flow 
cytometer. 
 
Measurement of intracellular oxidants – DCFH-DA assay 
NCI/ADR-RES cells (6x104 cells mL-1) were seeded on 12-well microplates (1 mL/well) and 
incubated for 24 h. Afterwards, cells were trypsinized and 2′,7′-dichlorofluorescein diacetate (DCFH-
DA) solution (10 µmol L-1 solution in DPBS with 1% DMSO, 100 µL per cell suspension) was added 
to cells followed by 30 min-incubation (37 °C, 5% CO2) in the dark. Then, cells were treated in 
suspension with 5fu (1.5 µg mL-1), AgNO3 (1.5 µg mL
-1), Ag-5fu (3.0 µg mL-1) or hydrogen peroxide 
(H2O2, 200 µmol L
-1, positive control) and incubated (37 °C, 5% CO2) for 1, 2 or 3 h, before injection 
in the flow cytometer. 
 
Statistical analysis 
Data were expressed as mean ± standard deviation (SD) of at least two independent experiments 
with duplicate or triplicate samples. Statistical analyses were performed using 2-way ANOVA followed 
by Bonferroni test comparing treated cells to untreated ones, and p-values less than 0.05 were regarded 






Characterization and antiproliferative assays of Ag(I), Pd(II) and Pt(II) metal 
complexes with 5-fluorouracil 
 
Results and Discussion 
Synthesis 
Metal complexes of Ag(I), Pd(II) and Pt(II) with 5-fluorouracil were first described in the 
literature  by Gel’fman and Kustova in the 1970’s [108–110]. Some of the coordination compounds 
described by these authors were re-prepared and it was possible to compare the results that will be 
presented in this Thesis with the first data previously published by the authors. 
It is important to emphasize that all synthesis here described were performed in alkaline 
medium, by using KOH for deprotonation of the ligand, since 5-fluorouracil contains two heterocyclic 
nitrogen atoms, which may act as Lewis bases to coordinate to metal ions. Gel’fman and Kustova 
described different methodologies to obtain Pd(II), Ag(I) and Pt(II) complexes, in which they obtained 
different compositions for each metal ion, with many of them containing potassium as a counter ion. In 
addition, the authors suggested different charges for the 5-fluorouracil ligand, with one or two nitrogen 
atoms deprotonated (here described as fuH and fu, respectively). Therefore, flame atomic emission 
spectrometric measurements were performed to determine the presence or absence of potassium in the 
compounds here described. 
 
Ag-5fu complex: for the Ag(I) complex, no potassium content was found. Considering this information 
and the results of elemental analysis of carbon, hydrogen and nitrogen, the molar composition 3:2 
metal/ligand was suggested. To maintain electroneutrality, one 5-fluorouracil ligand is supposed to have 
one nitrogen deprotonated (fuH), while the other has both nitrogen atoms deprotonated (fu). Therefore, 
the minimal formula of the complex can be suggested as [Ag3(fu)(fuH)], which is dissimilar from those 
early described by Gel’fman and Kustova [108]. 
 
Pd-5fu complex: for the Pd(II) complex 6.6% of potassium was found. Considering elemental analysis 
of carbon, hydrogen and nitrogen, and ICP-OES results (palladium content), the molar composition 1:2 
metal/ligand was suggested, with one coordinated chlorido ion and one potassium as a counter ion, and 
one hydration water molecule. To maintain electroneutrality, both ligands are supposed to be 
deprotonated (fuH). Therefore, the minimal formula of the complex can be suggested as 
K[PdCl(fuH)2]·H2O, also being dissimilar from those early described by Gel’fman and Kustova [109]. 
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Pt-5fu: for the Pt(II) complex 30.7% of potassium content was found. Considering the elemental 
analysis of carbon, hydrogen and nitrogen, and ICP-OES results (platinum content), the molar 
composition 1:2 metal/ligand was suggested, with two coordinated chlorido ligands and two potassium 
as counter ions. To maintain electroneutrality, both ligands are supposed to be deprotonated (fuH). 
Therefore, the minimal formula of the complex can be suggested as K2[PtCl2(fuH)2], being the only 
coordination compound here described that is similar from one previously reported by Gel’fman and 
Kustova  [110]. 
 
Thermogravimetric analyses 























Figure 8. Thermogravimetric curves of Ag-5fu (black), Pd-5fu (red), and Pt-5fu (blue). 
 
Figure 8 shows the thermogravimetric curves for Ag-5fu, Pd-5fu, and Pt-5fu. For Ag-5fu, the 
decomposition of the complex starts at 250 °C and continues until 380 °C, with weight loss of 48.0%. 
Such weight loss is attributed to two 5-fluorouracil ligands (anal. calcd. for the loss of fuH and fu, 
44.2%). The final residue of 49.7% was assigned to metallic silver (calcd. 55.7%). 
For Pd-5fu, the complex loses 6.0% of weight until 200 °C, which is consistent with one 
hydration water molecule as proposed by elemental analysis (calcd. 3.9%). Decomposition of the ligand 
starts at 250 °C until 360 °C, with 52.2% weight loss, which is attributed to two 5-fluorouracil ligands. 
In this case, while the ligand decomposes the formation of PdCl2 and K2O is suggested, with the oxygen 
being provided by the ligand (anal. calcd. for the loss of two fuH, 44.2%). At 350 °C there is a residue 
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of 40.1% (suggested formation of PdCl2 and K2O), and from 350 °C to 745 °C there is the decomposition 
of PdCl2 and suggested formation of PdO [129].  
For Pt-5fu, the decomposition of the complex starts at 270 °C and continues until 390 °C with 
weight loss of 36.8%. Such weight loss is attributed to two 5-fluorouracil ligands (anal. calcd. for the 
loss of two fuH, 42.9%). At 390 °C until 770 °C there is a residue of 55.2%, consistent with the suggested 
formation of PtCl2 and K2O (calcd. 59.8%).  
 
Mass spectrometric studies 
High-resolution mass spectrum of the Ag-5fu complex is shown in Figure 9-a. The most 
abundant peak was observed at m/z 580.7721, being consistent with the formation of the 
[Ag3(C4HFN2O2)(C4H2FN2O2)+H]
+ ion. The presence of this peak confirmed the 3:2 metal/ligand 
composition as earlier suggested by thermal and elemental analyses. Other peaks at m/z 474.8398, 




+. The presence of species with 
four silver atoms led us to consider a polymeric arrangement for the silver(I) complex with 5-
fluorouracil. The multiple species observed in the spectrum of the complex may be result of the polymer 
fragmentation. Such remark was reported previously in the literature for silver complexes [130]. 
 A comparison between the theoretical and experimental isotopic pattern for the 
[Ag3(C4HFN2O2)(C4H2FN2O2)+H]
+ ion is presented in Figures 9-b and 9-c. The mass error for this ion 
was +63 ppm [C8H4F2N4O4Ag3]
+ (calcd. m/z 580.7350, exp. m/z 580.7721), considering the 





Figure 9. Mass spectra for the Ag-5fu complex. (a) ESI(+)QTOF mass spectrum from m/z 450 to 930, 
showing the [Ag3(fu)(fu-H)+H]
+ ion as the most abundant species. (b) Calculated and (c) experimental 
isotope pattern comparison for the [Ag3(fu)(fu-H)+H]
+ ion at m/z 580.7721 (mass error +63 ppm). 
 




























High-resolution mass spectrum of the Pd-5fu complex is shown in Figure 10-a. The most 
abundant peak was observed at m/z 400.8918, being consistent with the formation of the 
[PdCl(C4H2FN2O2)2]
- ion. The presence of this peak confirmed the 1:2 metal/ligand composition as 
earlier suggested by thermal and elemental analyses. A comparison between the theoretical and 
experimental isotopic pattern for the [PdCl(C4H2FN2O2)2]
- ion is presented in Figures 10-b and 10-c. 
The mass error for this ion was -0.75 ppm [C8H4F2ClN4O4Pd]
- (calcd. m/z 400.8921, exp. m/z 400.8918), 
considering the monoisotopic ion. Table 3 shows the different species of the isotopic pattern of Pd-5fu. 
 
Figure 10. Mass spectra for the Pd-5fu complex. (a) ESI(-)QTOF mass spectrum from m/z 200 to 1000, 
showing the [PdCl(C4H2FN2O2)2]
-  ion as the most abundant species. (b) Calculated and (c) experimental 
isotope pattern comparison for the [PdCl(C4H2FN2O2)2]


































High-resolution mass spectrum of the Pt-5fu complex is shown in Figure 11-a, presenting many 
ions with high abundance. This may be due to the decomposition of the complex in solution; however, 
the decomposition products could not be assigned. The [K2PtCl2(fuH)2+K]
+ ion is present in the ESI+ 
mass spectra (Figure 11-c), however with low abundance. The presence of this peak confirmed the 1:2 
metal/ligand composition as earlier suggested by thermal and elemental analyses. A comparison between 
the theoretical and experimental isotopic pattern for the [K2PtCl2(C4H2FN2O2)2+K]
+ ion is presented in 
Figures 11-b and 11-c. The mass error for this ion was -4.68 ppm [C8H4F2K3Cl2N4O4Pt]
+ (calcd. m/z 
640.8115, exp. m/z 640.8085), considering the monoisotopic ion. Table 4 shows the different species of 




Figure 11. Mass spectra for the Pt-5fu complex. (a) ESI(+)QTOF mass spectrum from m/z 450 to 1000. 
(b) Calculated and (c) experimental isotope pattern comparison for the [K2PtCl2(C4H2FN2O2)2+K]
+  ion 













































Solid-state NMR spectroscopy 
Nuclear magnetic resonance (NMR) studies of the metal complexes with 5fu were carried out 
in solid state due to the insolubility of the Ag-5fu complex in common solvents, and also because both 
Pd-5fu and Pt-5fu decompose in the solvents in which they are soluble. The 13C and 15N solid-state NMR 
spectra of free 5fu, Ag-5fu, Pd-5fu and Pt-5fu are shown in Figures 12 and 13, respectively, and 
assignments are in Table 5. 
 




Figure 13. Solid-state 15N NMR spectra of (a) 5fu, (b) Ag-5fu, (c) Pd-5fu, and (d) Pt-5fu. 
 











N1 160 134 162 162 
C2 151 160 159 160 
N3 126 123 107 159 
C4 164 167 161 167 
C5 141 143 144 143 
C6 132 128 127 126 
 
For 13C-NMR spectrum of Ag-5fu, the highest shift is observed for carbon C2 (Δ = 9 ppm) when 
compared to free 5fu, while other carbons showed only minor differences. Considering that carbon C2 
is bounded to an oxygen, it is suggested that this oxygen atom (O2) coordinates to silver(I). Considering 
now the 15N-NMR spectrum an upfield shift is observed for the signals of the nitrogen atoms when the 
spectra of the Ag-5fu complex and the ligand are compared, and for N1 it is more pronounced (Δ = -26 
ppm) when compared to N3 (Δ = -3 ppm). These results suggested that the coordination of the ligand to 
silver also occurs by the nitrogen atoms, being more pronounced for nitrogen atom N1. 
Concerning the 15N-NMR spectra of Pt-5fu and Pd-5fu, the highest shifts are observed for 
nitrogen atom N3, with Δ = -19 ppm for Pd-5fu and Δ = 33 ppm for Pt-5fu. Both complexes showed the 
same shift for nitrogen atom N1, with Δ = 2 ppm. These results show that 5fu may coordinate by nitrogen 
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N3 to Pd(II) and Pt(II). It is interesting that for the Pd(II) complex nitrogen N3 is shielded, while for the 
Pt(II) complex nitrogen N3 is unshielded. 
 
Infrared spectroscopy 
The infrared (IR) spectra of 5fu, Ag-5u, Pd-5fu and Pt-5fu are presented in Figure 14. 
Considering the structure of 5fu, the characteristic absorption bands of the ligand in the IR spectrum can 
be assigned to the following vibration modes: ν(N-H) at 3184 cm-1 and 3138 cm-1 [131], ν(=C-H) at 
3069 cm-1, ν(C=O) at 1725 cm-1 and 1675 cm-1 (carbons C2 and C4, respectively, numeration as in Table 
4), δ(C-N-H) at 1635 cm-1 (shoulder), ν(C-N) at 1430 cm-1 and ν(C-F) at 1248 cm-1 [132]. In this way, 
we can conclude that 5fu is in the keto form in the solid state. 


































Figure 14. Infrared spectra of 5fu (black), Ag-5fu (red), Pd-5fu (blue), and Pt-5fu (green), from 4000-
400 cm-1. 
 
For all complexes a broad band is observed in the region of the N-H group from 3200 to 3000 
cm-1. Due to the enlargement of the bands, no conclusions can be taken for the N-H stretching modes. 
The ν(C=O) modes are observed in the region 1664-1619 cm-1 for Ag-5fu, 1676-1655 cm-1 for Pd-5fu, 
and 1663-1623 cm-1 for Pt-5fu. These results lead to the conclusion that the 5fu ligand remains in the 
keto form after complexation. Since one nitrogen atom of the ligand remains protonated in the complexes 
55 
 
(fuH), a δ(C-N-H) band is observed at 1589 cm-1 for Ag-5fu, 1618 cm-1 for Pd-5fu, and 1596 cm-1 for 
Pt-5fu. The ν(C-N) is observed at 1410 cm-1 for Ag-5fu, 1412 cm-1 for Pd-5fu, and 1421 cm-1 for Pt-5fu. 
The ν(C-F) is observed at 1280 cm-1 for Ag-5fu, 1271 cm-1 for Pd-5fu, and 1267 cm-1 for Pt-5fu. We can 
infer that coordination causes modifications in the vibrational modes of the chemical groups of 5-
fluorouracil, so the shifts in the IR spectrum of the complex, when compared to the ligand, reinforce the 
coordination of 5-fluorouracil to the metal ions.  
Considering the experimental data set, a structural proposition for the silver(I) complex with 5-
fluorouracil is presented in Figure 15. For the palladium(II) and platinum(II) complexes no structural 
propositions could be done. 
 
Figure 15. Coordination structure proposal for [Ag3(fu)(fuH)] complex. 
 
Antiproliferative assays 
All three metal complexes were evaluated concerning their in vitro antiproliferative activities 
over nine human tumor cell lines and over one non-tumor cell, and they were compared to the controls 
(free 5fu, metal reagents and cisplatin). The Ag-5fu, Pd-5fu and Pt-5fu complexes were evaluated by 
the GI50 parameter (concentration that inhibits 50% cell growth), because of the antiproliferative profile 
of 5fu (for comparison). GI50 data are presented in Table 6, while graphics of the antiproliferative profiles 









Table 6. GI50 values in µg mL
-1 of the in vitro antiproliferative activity of free 5fu, Ag-5fu, Pd-5fu,      
Pt-5fu, K2[PdCl4], K2[PtCl4]. 
Compounds 
Cell lines*  
2 M A 7 4 P O H K Cat 
5fu 0.78 0.061 2.3 0.17 0.085 0.51 0.091 0.42 0.19 0.087 
Ag-5fu 1.13 <0.25 0.36 0.29 0.46 2.28 0.39 0.34 0.25 <0.25 
Pd-5fu 3.22 0.11 >25 0.73 0.44 2.05 1.15 2.57 >25 0.41 
Pt-5fu >25 8.14 >25 >25 5.69 >25 4.99 22.2 >25 10.0 
AgNO3 3.37 1.66 3.21 3.56 5.75 2.99 2.88 2.87 0.48 2.7 
K2[PdCl4] >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
K2[PtCl4] 7.30 4.74 5.99 5.07 5.73 3.09 5.78 5.69 2.50 3.50 
Cisplatin 1.28 2.17 2.49 1.12 0.18 2.61 3.21 5.11 2.42 1.14 
*Human tumor cell lines: 2: U251 (glioma); M = MCF-7 (breast); A = NCI/ADR-RES (ovarian 
multidrug resistant); 7 = 786-0 (renal); 4 = NCI-H460 (lung, non-small cells); P = PC-3 (prostate); O = 
OVCAR-3 (ovarian); H = HT29 (colon); K = K562 (leukemia); Non-tumor human line: Cat = HaCat 





Figure 16. Cell growth profiles after 48h-exposition 5fu (A), Ag-5fu (B), AgNO3 (C) and cisplatin (D). 
For Ag-5fu a measurement error was observed for MCF-7 cells at 25 µg mL-1 and for all cell lines at 
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Considering Figure 16, silver nitrate showed a cytocidal effect (negative values for cell growth) 
at the highest concentration (25 µg mL-1), while 5fu was mainly a cytostatic agent. For all tested cell 
lines, Ag-5fu presented lower GI50 values than those observed for AgNO3. Moreover, GI50 values for 
Ag-5fu were lower than those of 5fu for ovarian multidrug resistant (NCI/ADR-RES) tumor cells and 
similar to 5fu for K562 (leukemia), HT29 (colon) and 786-0 (renal) cells. Similarly to 5fu, the Ag-5fu 
complex also inhibited cell proliferation of the immortalized keratinocytes (HaCat). 
Comparing 5fu with cisplatin, it is interesting to observe that the differences in cell growth 
profiles (Figures 16-A and 16-D, respectively) and in GI50 values (Table 5) reflect the differences in the 
mechanism of action between the two compounds. According to Zaharevitz et al. [133], similarities and 
differences in the antiproliferative profile in a tumor cell panel could be an important indicative of the 
mechanism of action by comparison with known chemotherapeutics. Cisplatin is a DNA-reactive drug 
inducing DNA damage by coordination of Pt(II) ions with nitrogen bases (mainly guanine), while 5fu is 
a DNA replication disruptor by inhibiting thymidylate synthase enzyme [103,106,134]. Moreover, in 
the Ag-5fu complex, the silver(I) ions can have multiple mechanisms, for example being able to bind 
proteins and DNA [92]. 
The combination of Ag(I) and 5-fluorouracil may thus be responsible for the increasing on the 
antiproliferative activity on ovarian multidrug resistant (NCI/ADR-RES) tumor cell line observed for 
Ag-5fu (GI50 = 0.36 µg mL
-1) when compared to the free ligand. 5-Fluorouracil is not commonly used 
in the treatment of ovarian tumors [106]. Therefore, the activity observed by the Ag-5fu complex may 
be related to a combination effect of the silver(I) ions and 5-fluorouracil, with the release of the 
individual compounds inside the cell. Since NCI/ADR-RES is resistant to cisplatin [135], this result is 
of high significance. Therefore, this complex was chosen to be further studied regarding the mechanism 
of cell death of Ag-5fu in NCI/ADR-RES cells. 
Considering the metal complexes of Pd(II) and Pt(II) with 5fu, they did not show relevant 
antiproliferative activities, in a different way from Ag-5fu. Although Pd-5fu showed a better activity 
(lower GI50 values) when compared to K2[PdCl4], it has a minor activity when compared to free 5fu. The 
best result for Pd-5fu was over the MCF-7 (breast cancer) tumor cell line (GI50 = 0.11 µg mL
-1). In the 
case of Pt-5fu, the complex decomposes in aqueous medium and this may be the reason for its lack of 
activity when compared to free 5fu and K2[PtCl4]. The antiproliferative profile in this case is a 
combination of all the decomposition sub products, which probably did not reach the concentration to 
inhibit proliferation. The best obtained results for Pt-5fu were over the OVCAR-3 (ovarian cancer) and 
NCI-H460 (lung cancer) tumor cells (GI50 = 4.99 and 5.69 µg mL
-1, respectively). 
The selectivity index (SI) is a parameter which can be used to compare the toxicity of 
compounds towards non-tumor and tumor cells [136]. Here, it can be calculated by the ratio between 
the GI50 of a non-tumor line (HaCat) and the GI50 of tumor lines. The higher the SI values, the greater 
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the selectivity of a compound towards a tumor cell when compared to a normal one. According to the 
literature, considerable SI values would be higher than 2.0 or 3.0, which means that a compound would 
be twice or three times more toxic to a tumor cell when compared to a non-tumor one [136]. The SI 
values for 5fu, Ag-5fu, Pd-5fu, Pt-5fu and cisplatin are presented in Table 7. Pd-5fu was shown to be 
selective over the MCF-7 (breast) tumor cells (SI = 3.7), while Pt-5fu was selective over the OVCAR-3 
(ovarian) tumor cells (SI = 2.0) and cisplatin was very selective over the NCI-H460 (lung) tumor cells 
(SI = 6.3). 
 
Table 7. SI values for 5fu, Ag-5fu, Pd-5fu, Pt-5fu and cisplatin. 
Compounds 
Cell lines*  
2 M A 7 4 P O H K  
5fu 0.11 1.4 0.037 0.51 1.0 0.17 0.96 0.21 0.46  
Ag-5fu <0.22 1.0 <0.69 <0.86 <0.54 <0.11 <0.64 <0.73 <1.0  
Pd-5fu 0.13 3.7 <0.02 0.56 0.93 0.20 0.36 0.16 <0.02  
Pt-5fu <0.40 1.23 <0.40 <0.40 1.8 <0.40 2.0 0.45 <0.40  
Cisplatin 0.89 0.52 0.46 1.0 6.3 0.44 0.35 0.22 0.47  
*Human tumor cell lines: 2: U251 (glioma); M = MCF-7 (breast); A = NCI/ADR-RES (ovarian 
multidrug resistant); 7 = 786-0 (renal); 4 = NCI-H460 (lung, non-small cells); P = PC-3 (prostate); O = 
OVCAR-3 (ovarian); H = HT29 (colon); K = K562 (leukemia); Non-tumor human line: HaCat 















Three complexes with 5-fluorouracil were synthesized and characterized by chemical and 
spectroscopic techniques. The silver(I) complex, Ag-5fu, presented a 3:2 metal/ligand composition, with 
formula [Ag3(C4HFN2O2)(C4H2FN2O2)]. The palladium(II) complex, Pd-5fu, presented a 2:1 
metal/ligand composition, with formula K[PdCl(C4H2FN2O2)2], while the platinum(II) complex, Pt-5fu, 
also presented a 2:1 metal/ligand composition, with formula K2[PtCl2(C4H2FN2O2)2]. Antiproliferative 
activity assays were performed with free 5-fluorouracil, the metal complexes and their respective metal 
salts, and results were also compared to cisplatin. The Ag-5fu complex presented the best 
antiproliferative profile, and its activity seems to be a combination of the activities of 5fu and silver(I), 
probably due to the release of the individual compounds inside the cell. Also, Ag-5fu presented a better 
activity than free 5fu and cisplatin over the NCI/ADR-RES cell line. The Pd-5fu complex presented a 
better activity than its respective metal salt, K2[PdCl4], although not presenting a better activity than free 
5fu and cisplatin. Best antiproliferative results were found for the MCF-7 cell line for Pd-5fu. The Pt-
5fu complex did not show considerable antiproliferative results, probably due to hydrolyzation of the 
complex in solution, and did not present a better activity than K2[PtCl4]. The best results for Pt-5fu were 
for the NCI-H460 cell line. Although not very cytotoxic when compared to Ag-5fu, Pd-5fu and Pt-5fu 
presented selectivity over MCF-7 and OVCAR-3 tumor cells, respectively. Data for the silver(I) 
complex with 5-fluorouracil presented in this section was published in Journal of Fluorine Chemistry 












Characterization and antiproliferative assays of the Au(I) complex with 2-
thiouracil and the Ag(I) complex with 2,4-dithiouracil 
 
Results and Discussion 
Synthesis of the [Ag2(dtu)] complex 
A silver(I) complex with 2,4-dithiouracil (dtuH2) was described in 1972 by Dwivedi and 
Agarwala [137]. In this paper, the authors described different metal complexes with dtuH2, and there 
was no indication of the used amounts of metal salt or ligand in synthesis, nor specification of which 
silver metal salt was used for preparing the silver(I) complex. Mostly, the authors described the results 
of elemental analysis (of nitrogen, sulfur and silver) and assignments of the major infrared bands. By 
elemental analysis they conclude that the complex has a 2:1 silver/dithiouracil composition. 
Consequently, this was the stoichiometry chosen for the synthesis of the silver(I) complex here 
presented. Elemental analyses (CHN and ICP-OES) corroborate with 2:1 metal/ligand composition, with 
electroneutrality achieved with complete deprotonation of the ligand (dtu, charge -2) and two silver(I) 
ions. 
 
Thermogravimetric analysis of the [Ag2(dtu)] complex 
The thermogravimetric analysis for the [Ag2(dtu)] complex is shown in Figure 19. The 
decomposition of the complex starts at 270 °C and continues until 660 °C with weight loss of 33.8%. 
Such weight loss is attributed to one dithiouracil ligand (calcd. for loss of dtu, 39.7%). The final residue 
of 64.7% was assigned to metallic silver (calcd. 60.3%). This analysis reinforces the 2:1 metal/ligand 
composition of the [Ag2(dtu)] complex. 
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Figure 19. Thermogravimetric analysis of [Ag2(dtu)]. 
 
Infrared spectroscopy of the [Ag2(dtu)] complex 
The infrared (IR) spectra of dtuH2 and [Ag2(dtu)] complex are presented in Figure 20. The IR 
spectrum of the complex was analyzed in comparison to the spectrum of the ligand. Considering the 
structure of dtuH2, the characteristic absorption bands of the ligand in the IR spectrum can be assigned 
to the following vibration modes: ν(N-H) at 3077 cm-1, and ν(C=S) at 1610 cm-1 and 1563 cm-1. 
In the spectrum of the complex no absorption bands are observed in the region of the N-H group 
from 3200 to 3000 cm-1, confirming the total deprotonation of the ligand. Moreover, the ν(C=S) 
stretching mode is shifted to lower energies, to 1526 cm-1 and 1492 cm-1. This shift may be due to 
coordination of the thiol groups to silver(I) since the new S–Ag bond weakens the C=S bond. 
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Figure 20. Infrared spectra of dtuH2 (black) and [Ag2(dtu)] (red). 
 
Solid-state NMR spectroscopy of the [Ag2(dtu)] complex 
Nuclear magnetic resonance (NMR) studies of the [Ag2(dtu)] complex were carried out in solid 
state due to the insolubility of the complex in common solvents. Figure 21 shows the 13C NMR spectrum 
of the complex in comparison to the one of the free ligand.  
 
 





The 13C NMR spectrum of tuH2 shows the following chemical shifts (and assignments): 120 
ppm (C6), 139 ppm (C5), 172 ppm (C2), 188 ppm (C4) 37. For the [Ag2(dtu)] complex the chemical 
shifts are 118 ppm (C6), 155 ppm (C5) and 177 ppm (C2 + C4). Considering the lack of information 
from the 15N NMR spectrum, and that carbon C6 in the 13C NMR spectrum showed the minor chemical 
shift, coordination may not occur near this environment, so it probably does not occur by nitrogen N1. 
As thiol groups present high affinity for soft metal ions, as silver(I), it is probable that the ligand 
coordinated by these S-donor groups. In fact, carbons C2 and C4, which are bonded to the sulfur atoms, 
seemed to aggregate in one broad signal at 177 ppm. Also, the highest shift is observed for carbon C5 
(Δ = 16 ppm), which is close to a sulfur atom (possible coordination site).  
 
Synthesis of the Ph3P-Au-tuH complex 
This complex was already reported in the literature by Hoskins et al., however only the crystal 
structure and IR spectroscopic studies of the crystal were presented by that time [138]. The synthesis 
previously described involves the mixture of 2-thiouracil and chlorido(triphenylphosphine)gold(I) in 
methanol and alkaline medium. The authors obtained a precipitate, which was recrystallized, and the 
obtained crystals are used for posterior analyses. Here, the synthesis described involves the use of silver 
nitrate to eliminate the chloride from chlorido(triphenylphosphine)gold(I) before reaction with 2-
thiouracil, because some previous attempts of synthesis showed some 
chlorido(triphenylphosphine)gold(I) residue without the use of silver nitrate. Despite the crystal 
structure solved by single-crystal X-ray diffraction, all other analyses were done with the precipitate and 
not with the crystals. The synthesis of the complex was performed in alkaline medium, with 
deprotonation of 2-thiouracil (tuH2) to the thiouracilato (tuH) anion, which corroborates elemental 
analysis (only one deprotonation). Thus, electroneutrality is achieved with one tuH (charge -1) and one 
gold(I). 
 
Infrared spectroscopy of the Ph3P-Au-tuH complex 
Considering free tuH2, this molecule can present keto/enol and thione/thiol tautomeric forms 
(Figure 22), which is of high importance for the determination of the coordination sites. Using infrared 
spectroscopy to determine the tautomeric form of free tuH2 in the solid state (Figure 23), we were able 
to determine the prevalence of the keto/thione form of tuH2 by the presence of the ν(N-H) band of tuH2 




Figure 22. Tautomeric forms of 2-thiouracil, (a) keto/enol form, (b) thione/thiol form. 












Figure 23. Infrared spectra of tuH2 (black) and Ph3P-Au-tuH (red). 
 
Previous computational studies of 2-thiouracil showed that deprotonation of the nitrogen atom 
N1 is more favorable than for the nitrogen atom N3 (see Figure A1 in Appendix for atom numbering) 
[139]. In this way, deprotonation will enhance the basicity of the ligand, favoring a nucleophilic attack 
on gold(I). Considering deprotonation at nitrogen atom N1, three possible coordination sites are 
expected: O-, N- and S- (Figure 24). Previous computational studies have also shown that the negative 
charge is largely localized on the sulfur atom, which might be a more favorable coordination site [139]. 
Considering hard-hard and soft-soft interactions, gold(I) is a soft acid and it is readily coordinated to 
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triphenylphosphine, which enhances its softness. Consequently, it is most probable that tuH will 
coordinate by the S-donor atom, which is the softest base. An example from the literature shows that 
mercaptothiazoline, a molecule which also presents thione/thiol tautomeric forms, can coordinate to 
gold(I) through a N-donor group when gold(I) is coordinated to cyanide, but coordinates through the S-
donor group when gold(I) is coordinated to triphenylphosphine [140,141]. Here, however, just observing 
the IR spectra of the complex it is not possible to address the coordination site of the tuH2 ligand. 
 
Figure 24. Resonance structures of tuH with deprotonation of nitrogen atom N1. 
 
Crystal structure of the Ph3P-Au-tuH complex 
Crystals of the Ph3P-Au-tuH complex suitable for single-crystal X-ray diffraction were obtained 
by slow evaporation of a methanol/chloroform mixture. The details about the analyzed crystal, data 
























Table 8. Crystallographic data, data collection and refinement for the Ph3P-Au-tuH crystal. 
(a) Crystal data 
C22H18AuN2OPS Dx = 1.876 Mg m
−3 
Mr = 586.38 Cu Kα radiation, λ = 1.54178 Å 
Monoclinic, P21/n Cell parameters from 120 reflections 
a = 17.4687 (8) Å θ = 8.0–37.5° 
b = 11.2334 (5) Å µ = 15.10 mm−1 
c = 21.1684 (10) Å T = 150 K 
β = 91.401 (2)° Plate, colorless 
V = 4152.7 (3) Å3 0.12 × 0.11 × 0.06 mm 
Z = 8  
F(000) = 2256  
 
(b) Data collection 
Absorption correction: multi-scan  
SADABS (Bruker, 2010) 
Rint = 0.053 
Tmin = 0.524, Tmax = 0.753 θmax = 68.2°, θmin = 4.7° 
27145 measured reflections h = −20 21 
7386 independent reflections k = −13 13 









Refinment on F2 H-atom parameters not refined 
Least-squares matrix: full w = 1/[σ2(Fo
2) + (0.1264P)2]  
where P = (Fo
2 + 2Fc
2)/3 
R[F2 > 2σ(F2)] = 0.053 (Δ/σ)max = 0.001 
wR(F2) = 0.160 Δρmax = 3.82 e Å
−3 
S = 1.07 Δρmin = −3.02 e Å
−3 
7386 reflections  
508 parameters  
 
The crystal structure here presented belongs to P21/n space group, whose asymmetric unit 
contains two Ph3P-Au-tuH complex units (Figure 25-a). The tuH ligand coordinates to gold(I) by the 
sulfur atom, showing that the thiol form is predominant upon coordination, as expected. Each Ph3P-Au-
tuH complex unit is composed by one triphenylphosphine, one gold(I), and one 2-thiouracilato ligand 
(tuH, charge -1) (Figure 25-b). For clarity, it is important to emphasize that atom numbering for the 








Figure 25. (a) The two Ph3P-Au-tuH complex units in the asymmetric unit of the crystal, with selected 
atoms labels and 50% probability displacement ellipsoids. Ph3P-Au-tuH complex unit 1 containing Au1 
and Ph3P-Au-tuH complex unit 2 containing Au2. H-bond (N1―H1A∙∙∙N4) shown in green dashed line.  
(b) The structure of the Ph3P-Au-tuH complex unit 1 with atom labels and 50% probability displacement 
ellipsoids. 
 
Triphenylphosphine, gold(I) and tuH are in an almost linear geometry (P1—Au1—S1 angle of 
176.31(6) ° for unit 1, and P2—Au2—S2 angle of 175.90(6) ° for unit 2). Au1—P1 and Au1—S1 bond 
lengths are similar to each other (2.253(2) Å and 2.307(2) Å, respectively), and the same is observed for 
Au2—P2 and Au2—S2 (2.254(2) Å and 2.306(2) Å, respectively). These bond lengths and angles are 
in agreement with the structure previously described by Hoskins and Zhenrong [138]. The differences 
in the P—Au—S angles of the two Ph3P-Au-tuH units in the asymmetric unit of the crystal may be due 
to the different orientations of the phenyl groups and different intermolecular interactions from each 
Ph3P-Au-tuH motif, as also observed in the structure previously reported [138]. 
In the crystal, nitrogen atom N4 is deprotonated, confirming the (-1) charge of the tuH ligand. 
The two Ph3P-Au-tuH complex units interact via a classical intermolecular hydrogen bond 
(N1―H1A∙∙∙N4), while neighbor asymmetric units are connected by other two classical intermolecular 
hydrogen bonds (N3―H3A∙∙∙O2), building up a chain of unit 1 – unit 2 – unit 2 – unit 1 sequence (Figure 
26). It is important to mention that the N3―H3A∙∙∙O2 H-bond is also observed for the 2-
thiouracilato(triethylphosphine)gold(I) complex previously reported [142]. Hydrogen bonds for the 




Figure 26. Crystal packing of Ph3P-Au-tuH showing hydrogen bonds (N1―H1A∙∙∙N4 and 
N3―H3A∙∙∙O2 as green dashed lines) that form unit 1 – unit 2 – unit 2 – unit 1 sequences, with two 
sequences represented. Labels for selected atoms to allow identification of units 1 and 2 and 50% 
probability displacement ellipsoids. 
 
Table 9. Hydrogen-bond geometry of Ph3P-Au-tuH crystal. 
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
N1—H1a···N4 0.94(10) 2.02(10) 2.955(9) 171(8) 
N3—H3a···O2 0.88 1.84 2.716(9) 178 
 
Based on the bond distances from the X-ray data, the predominant tautomer form of the ligand 
upon coordination to gold(I) can be determined. The most relevant bond distances are presented in   





Table 10. Bond lengths in thiouracil moieties of units 1 and 2 of Ph3P-Au-tuH complex in the crystal 
(atom labels as depicted in Figure 25-b) in comparison to the crystal structure of free tuH2 [143]. 
Atoms 
Complex unit 1 / Complex unit 2 
Bond lengths (Å) 
Bond lengths (Å) of tuH2 
[143] 
S1-C19 / S2-C41 1.754 (7) / 1.749 (8) 1.683(3) 
N1-C19 / N3-C41 1.348 (9) / 1.355 (9) 1.357(3) 
N1-C22 / N3-C42 1.408 (9) / 1.387 (10) 1.389(4) 
N2-C19 / N4-C41 1.322 (9) / 1.319 (10) 1.338(4) 
N2-C20 / N4-C44 1.371 (10) / 1.371 (11) 1.373(4) 
O1-C22 / O2-C42 1.228 (10) / 1.237 (9) 1.227(4) 
C20-C21 / C43-C44 1.337 (12) / 1.357 (11) 1.338(5) 
C21-C22 / C42-C43 1.430 (12) / 1.432 (12) 1.432(5) 
 
Considering the carbon-sulfur bond, C—S single bonds are of 1.82 Å, while C=S double bonds 
are of 1.61 Å [144]. In the crystal here presented the C19—S1 bond is of 1.75 Å, therefore being an 
intermediate between a single and a double bond. When compared to free tuH2, an elongation of the C—
S bond is observed upon coordination of the sulfur atom to gold(I), which can also be interpreted as the 
changing from a double bond to a single bond. Therefore, free tuH2 is in the thione form, while upon 
complexation to gold(I) the thiol form is preferable. Now, considering the carbon-nitrogen bonds, C—
N single bonds are of 1.46 Å and C=N double bonds are of 1.21 Å [144]. Here, the C19—N2 bond (1.32 
Å) has a greater double bond character, so the predominant tautomer of the ligand upon coordination 
would be the thiol form (see Figure 24). For the free ligand this bond is longer, showing the shift from 
a single bond to a double one. The C20—N2 (1.37 Å) bond has a greater single bond character. Also, 
for the carbon-oxygen bond, C—O single bonds are of 1.42 Å and C=O double bonds are of 1.21 [144]. 
Here the C22—O1 (1.23 Å) is a double bond, proving that the ligand is in the keto/thiol form. When 
compared to the free ligand no major changes were observed for the C—O bond (free ligand is also in 
the keto form). For carbon-carbon bonds, C—C single bonds are of 1.53 Å and C=C double bonds are 
of 1.34 Å [144]. Here, the C—C bonds have a greater double bond character and did not change upon 
coordination. The different bond distances of the complex when compared to the free ligand show the 




Mass spectrometric studies of the Ph3P-Au-tuH complex 
High-resolution mass spectrum of the Ph3P-Au-tuH complex is shown in Figure 27. The peak at 
m/z 587.0639, which is one of the most abundant species, is consistent with the formation of the 
[Au(C4H3N2OS)(C18H15P)+H]+ ion. The presence of this peak confirmed the 1:1 metal/ligand 
composition as suggested before. Other peaks at m/z 459.0456 and 721.1308 were attributed to the 
[Au(C18H15P)]+ and [Au(C18H15P)2]+ species, respectively, due to fragmentation and recombination of 
the gold(I) complex in solution. 
A comparison between the theoretical and experimental isotopic pattern for the 
[Au(C4H3N2OS)(C18H15P)+H]+  ion is also presented. The mass error for this ion was -3.1 ppm, (calcd. 
m/z 587.0621, exp. m/z 587.0639), considering the monoisotopic ion. 
 
Figure 27. Mass spectra for the Ph3P-Au-tuH complex. (a) ESI(+)QTOF mass spectrum from m/z 430 
to 800, showing the [(C18H15P)Au(C4H3N2OS)+H]+ ion as one of the most abundant species. (b) 
Calculated and (c) experimental isotope pattern comparison for the [(C18H15P)Au(C4H3N2OS)+H]+  ion 





Solution NMR spectroscopy of the Ph3P-Au-tuH complex 
Solution state 1H, 13C and 31P NMR spectra of Ph3P-Au-Cl and Ph3P-Au-tuH were acquired to 
confirm the coordination of 2-thiouracil to (triphenylphosphine)gold(I). 1H and 13C NMR spectra of free 
tuH2 were recorded in DMSO-d6, because of the high solubility of the ligand in this solvent. 
1H NMR 
spectra are presented in Figure 28 and assignments are in Table 11.  
 
 
Figure 28. 1H NMR spectra of (a) Ph3P-Au-tuH complex in CDCl3, with an inset of the 9.0-11.0 ppm 
region; (b) Ph3P-Au-Cl complex in CDCl3; (c) tuH2 free ligand in DMSO-d6. In (a) and (b) the signal at 
7.28 ppm is referred to CHCl3. 
 










1 12.38 - - s 
3 12.38 - 10.17 s 
5 5.82 - 6.07 d 
6 7.41 - 7.69 d 
Ph - 7.52 7.55 m 
 
It is possible to notice the disappearance of the hydrogen H1 in the Ph3P-Au-tuH complex 
spectrum, confirming the ligand deprotonation. Also, the presence of the hydrogen atoms H3, H5, H6 
(a)
(b)












of the ligand and also the hydrogen atoms of triphenylphosphine (Ph) confirmed the formation of Ph3P-
Au-tuH complex. The 13C NMR spectra and assignments are presented in Figure 29 and Table 12, 
respectively. 
 
Figure 29. 13C NMR spectra of (a) Ph3P-Au-tuH complex in CDCl3; (b) Ph3P-Au-Cl complex in CDCl3; 
(c) tuH2 free ligand in DMSO-d6. 
 










2 176.6 - 169.0 s 
4 161.5 - 163.3 s 
5 105.8 - 109.8 s 
6 142.6 - 154.3 s 
a - 128.7 129.0 d 
b - 132.0 132.0 d 
c - 129.3 129.4 d 
d - 134.2 134.3 d 
  
Comparing the 13C NMR spectra of the Ph3P-Au-Cl and Ph3P-Au-tuH complexes, carbons from 


















only carbon C2 from the Ph3P-Au-tuH complex was shifted to an upper field when compared to the free 
ligand (tuH). Carbon C2 is the one directly bonded to the sulfur atom which coordinates to gold(I). Other 
carbons (C4, C5, C6) follow the trend of being unshielded upon coordination of the thiol group to 
gold(I). At last, Figure 30 presents the 31P spectra of Ph3P-Au-Cl and Ph3P-Au-tuH, in which the 
phosphorous atom is shifted to a lower field upon coordination of the 2-thiouracilato ligand to gold(I). 
As the chlorido ion is a α,π-donor ligand, the electronic density of gold(I) and consequently of the 
phosphorous atom is higher in the Ph3P-Au-Cl complex when compared to Ph3P-Au-tuH. 
 
Figure 30. 31P NMR spectra in CDCl3 of (a) Ph3P-Au-tuH complex; b) Ph3P-Au-Cl complex. The 
phosphorous atom is shifted to a lower field upon coordination of the 2-thiouracilato ligand to gold(I). 
 
Antiproliferative assays 
The antiproliferative activities of [Ag2(dtu)] and Ph3P-Au-tuH were compared to controls (dtuH2 
and AgNO3 for [Ag2(dtu)], and tuH2, Ph3P-Au-Cl and doxorubicin for Ph3P-Au-tuH) through the TGI 
parameter (concentration that inhibits 100% cell growth), provided by in vitro evaluation assay. Here 
the TGI was chosen due to the antiproliferative profile of the gold(I) complexes and lack of activity of 
the ligands and silver(I) complex. The obtained data are provided in Table 13 and Figures 31 and 32. 









Table 13. TGI values in µg mL-1 of the in vitro antiproliferative activity of dtuH2, [Ag2(dtu)], AgNO3, 
tuH2, Ph3P-Au-tuH, Ph3P-Au-Cl, and doxorubicin. 
Compounds 
Cell lines*  
2 M A 7 4 O H K Cat 
dtuH2 141.4 >250 >250 >250 >250 >250 >250 >250 >250 
[Ag2(dtu)] >250 >250 >250 >250 >250 >250 >250 >250 >250 
AgNO3 7.2 3.0 33.7 22.8 23.8 6.1 13.6 1.1 38.4 
tuH2 >250 >250 >250 >250 >250 >250 >250 >250 >250 
Ph3P-Au-tuH 1.5 5.1 11.0 2.3 26.7 10.4 28.5 <0.25 6.1 
Ph3P-Au-Cl 2.3 4.7 10.5 4.0 >250 5.9 >250 3.3 14.5 
Doxorubicin 0.81 0.57 >25 1.1 >25 1.8 >25 1.2 0.58 
*Human tumor cell lines: 2: U251 (glioma); M = MCF-7 (breast); A = NCI-ADR/RES (multidrug 
resistant ovarian); 7 = 786-0 (renal); 4 = NCI-H460 (lung, non-small cells); O = OVCAR-3 (ovarian); 
H = HT29 (colon); K = K562 (leukemia); Non-tumor human line: Cat = HaCat (immortal keratinocyte). 





Figure 31. Cell growth profiles after 48h-exposition to dtuH2 (A), [Ag2(dtu)] (B), and AgNO3 (C). For 
AgNO3 measurement errors were observed for MCF-7 and K-562 cells at 2.5 µg mL
-1 and for all cell 


































































































Figure 32. Cell growth profiles after 48h-exposition to tuH2 (A), Ph3P-Au-tuH (B), Ph3P-Au-Cl (C) and 
doxorubicin (D). For Ph3P-Au-tuH measurement errors were observed for MCF-7 and K-562 cells at 2.5 
µg mL-1 and for OVCAR-3, K-562, 786-0 and U251 cells at concentrations above 25 µg mL-1. For Ph3P-
Au-Cl measurement errors were observed for most cell lines at concentrations above 25 µg mL-1. Errors 
were observed due to the colorimetric assay. 
  
Considering dtuH2 and the [Ag2(dtu)] complex (Figure 31), none of them presented considerable 
antiproliferative effects. The dtuH2 ligand presented some activity only at the highest tested 
concentration, while the [Ag2(dtu)] complex was not active, despite AgNO3 has shown to be quite 
cytotoxic. The poor solubility of the [Ag2(dtu)] complex may be responsible for its lack of activity. 
Considering tuH2, Ph3P-Au-tuH and Ph3P-Au-Cl, free tuH2 did not present antiproliferative 
activity, even at the highest tested concentration (Figure 32-A). On the other hand, Ph3P-Au-tuH and 
Ph3P-Au-Cl complexes showed cytocidal effects (negative values for cell growth) for almost all cell 
lines, with Ph3P-Au-tuH being cytotoxic at lower concentrations (2.5 µg mL
-1, Figure 32-B) when 
compared to Ph3P-Au-Cl (25 µg mL
-1, Figure 32-C). Both compounds were also cytotoxic for the non-
tumor line (HaCat). 
In general, the Ph3P-Au-tuH and Ph3P-Au-Cl complexes presented TGI values of the same order 
of magnitude. Therefore, both complexes presented the same activity for glioma (U251), breast (MCF-































































































































The Ph3P-Au-tuH complex was more active against leukemia (K-562, TGI <0.25 µg mL
-1), lung (NCI-
H460; TGI = 26.7 µg mL-1) and colon (HT-29; TGI = 28.5 µg mL-1) tumor cells than the Ph3P-Au-Cl 
complex. Also, the Ph3P-Au-tuH complex was more active against leukemia than doxorubicin (Figure 
32-D), which is an antitumor drug used in clinics. 
As discussed before, the selectivity index (SI) is a parameter which can be used to compare the 
toxicity of compounds towards non-tumor and tumor cells [136]. In this case, it can be calculated by the 
ratio between the TGI of a non-tumor line (HaCat) and the TGI of tumor lines. Again, the higher the SI 
values, the greater the selectivity of a compound towards a tumor cell when compared to a normal one 
(considerable SI values would be higher than 2.0 or 3.0). The SI values for Ph3P-Au-tuH, Ph3P-Au-Cl 
and doxorubicin can be found in Table 14. The best SI values for Ph3P-Au-tuH complex were found for 
the glioma (U251, SI = 4.07), renal (786-0, SI = 2.65) and leukemia lines (K-562, SI = 24.4). 
 
Table 14. SI values for Ph3P-Au-tuH, Ph3P-Au-Cl and doxorubicin. 
Compounds 
Cell lines* 
2 M A 7 4 O H K  
Ph3P-Au-tuH 4.07 1.20 0.55 2.65 0.23 0.59 0.21 24.40  
Ph3P-Au-Cl 6.30 3.09 1.38 3.63 0.06 2.46 0.06 4.39  
Doxorubicin 0.72 1.02 0.02 0.53 0.02 0.32 0.02 0.48  
*Tumor human cell lines: 2: U251 (glioma); M = MCF-7 (breast); A = NCI/ADR-RES (multidrug 
resistant ovarian); 7 = 786-0 (kidney); 4 = NCI-H460 (lung, non-small cells); O = OVCAR-3 
(ovarian); H = HT29 (colon); K = K562 (leukemia); Non-tumor human line: HaCat (immortal 
keratinocyte). SI = TGI(HaCat)/TGI(tumor line) 
 
According to the literature, the chlorido(triphenylphosphine)gold(I) (Ph3P-Au-Cl) compound is 
able to induce apoptosis in breast tumor cells (MCF-7) with low level of ct-DNA interaction, and Ph3P-
Au-Cl interacts with sulphydryl groups present in serum albumin (BSA) [145]. These activities could 
partially explain the antiproliferative effect observed for Ph3P-Au-Cl. It is possible that some of the 
effects caused by Ph3P-Au-Cl can also be promoted by the Ph3P-Au-tuH complex. Therefore, these 






Two complexes with thiouracils were synthesized and characterized by elemental and 
spectroscopic techniques. The silver(I) complex with 2,4-dithiouracil, [Ag2(dtu)], presented a 2:1 metal 
ligand composition, with formula [Ag2(C4H2N2S2)]. The triphenylphosphinegold(I) complex with 2-
thiouracil, Ph3P-Au-tuH, presented a 1:1 metal/ligand composition, with formula 
[Au(C4H2N2OS)(C18H15)]. For the latter complex the crystal structure shows the coordination of the 2-
thiouracilato ligand to gold(I) by its thiol group. Antiproliferative activity assays were performed with 
the metal complexes and also with the free ligands, 2-thiouracil and 2,4-dithiouracil, silver nitrate (metal 
salt) and chloridotriphenylphosphinegold(I) precursor complex (Ph3P-Au-Cl). The results were also 
compared to doxorubicin. The [Ag2(dtu)] complex presented no antiproliferative activity, probably due 
to its lack of solubility. The Ph3P-Au-tuH complex and its precursor complex, Ph3P-Au-Cl, showed 
noticeable antiproliferative profiles. The Ph3P-Au-tuH complex showed a better activity than 
doxorubicin over the K562 cell line. Data obtained for the gold(I) complex with 2-thiouracil presented 
















Studies of the cell death mechanism caused by Ag-5fu and Ph3P-Au-tuH 
complexes in ovarian and lung tumor cells 
 
A short introduction to flow cytometry 
Flow cytometry is a technique in which it is possible to measure multiple physical characteristics 
of a single cell simultaneously as the cell flows in suspension. Its working depends on the light scattering 
features of the cells under investigation, which may be derived, for example, from dyes targeting either 
extracellular molecules located on the surface or intracellular molecules inside the cell. In this way, flow 
cytometry can measure the fluorescence characteristics of a single cell in a fluid stream when they pass 
through a light source [146]. 
The principle of flow cytometry is related to light scattering and fluorescence emission, which 
occurs as light from a laser strikes the moving cells. The fluorescence emission that derives from a 
fluorescence probe will be proportional to the amount of fluorescent probe bound to the cell or cellular 
component. Therefore, it is possible to determine the influence of a compound in a cell or on cell 
components by choosing the appropriate dyes for each of them and using flow cytometry to study the 
extent of this influence. 
 
Results and Discussion 
The noteworthy antiproliferative activities observed for Ag-5fu and Ph3P-Au-tuH complexes led 
to further in vitro studies of these compounds. In this way, different cell lines were chosen to be studied 
for each compound. For the Ag-5fu complex the NCI/ADR-RES cells (multidrug resistant ovarian tumor 
cells) were chosen, because the Ag-5fu complex was shown to be more active than cisplatin over this 
cell line, showing that Ag-5fu may overcome the resistance mechanism. Also, 5fu and AgNO3 were 
used as controls, in order to understand the role of each one of them in the activity of the complex. Now, 
for the Ph3P-Au-tuH complex the NCI-H460 cells (lung tumor cells, non-small) were chosen and 
compared to Ph3P-Au-Cl, because the Ph3P-Au-tuH complex was shown to be more active than Ph3P-
Au-Cl over this cell line, and also because the results could be further compared to in vivo lung tumor 
models, as a possible further investigation. Free 2-thiouracil was not tested, because it did not present 
antiproliferative activity in the highest tested concentration. 
The compounds were evaluated by the colony formation capacity and flow cytometry assays to 
analyze cell cycle and cell death induction [phosphatidylserine residues (PS) exposition, multicaspases 
activation, production of reactive oxygen species (ROS) and mitochondrial membrane depolarization]. 
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For Ag-5fu preliminary studies of interaction with plasmid DNA by gel electrophoresis were done and 
are also presented. 
 
Gel electrophoresis assay 
In order to investigate the mechanism of action of the Ag-5fu complex, preliminary studies about 
the interaction of this compound with biomolecules such as DNA are of interest. Considering the 
differences in cell growth profiles observed in the antiproliferative assays, the mechanism of action of 
the Ag-5fu complex may differ from that of cisplatin. As already mentioned, the main target of cisplatin 
is DNA, where Pt(II) ions form covalent bonds with nitrogen bases [46]. Therefore, a preliminary gel 
electrophoresis assay was performed to evaluate a possible interaction of Ag-5fu with DNA [48,49]. 
K2[PdCl4], K2[PtCl4], AgNO3, 5fu and Ag-5fu were mixed and incubated with pIRES DNA 
plasmid (pIRES: internal ribosome entry site plasmid). Pure pIRES DNA plasmid was used as control 
and K2[PdCl4] and K2[PtCl4] were controls of compounds that interact with DNA. DNA Ladder was 
used as a weight marker, based on the number of nucleotide base pairs (bp). The compounds were 
electrophoresed in agarose gel and the results are presented in Figure 33. 
 
 Figure 33. Electrophoresis agarose gel. Control (Ctrl) is pure pIRES DNA plasmid, (1) AgNO3, (2) 
K2[PdCl4], (3) K2[PtCl4], (4) 5fu, (5) Ag-5fu. OC is the open circular form of the plasmid DNA (slower 
migration) and CCC is the supercoil form (faster migration). Ladder shows bands of 12000 bp to 1650 
bp. Separate parts of the figure are from the same gel. 
 
The pIRES DNA plasmid presents four different forms (control, Figure 33) in the 
electrophoresis agarose gel. The form which presents the slower migration is the open circular form 
(OC) and the form which presents the faster migration is the supercoil form (CCC). We can observe that 
5fu has a minor interaction with the DNA in the open circular form (absence of the band, Figure 33), 
when compared to K2[PdCl4] and K2[PtCl4], while AgNO3 and Ag-5fu do not seem to interact with 
DNA, due to the presence of all four bands (same pattern as the control). The observed results suggest 
83 
 
that the mechanism of antiproliferative action of the complex is dissimilar from that of cisplatin and 
does not involve interaction with DNA. 
 
Cell cycle arrest 
We investigated the influence of Ag-5fu and its precursors (5fu and AgNO3) on NCI-ADR/RES 
cell cycle, and the influence of Ph3P-Au-tuH and Ph3P-Au-Cl on NCI-H460 cell cycle. Divided in two 
steps (interphase and mitosis), the cell cycle comprises the molecular events that occur since the 
formation of a cell until its division into new cells. While in the interphase cell grows and prepares itself 
for a new division (divided into G1, S and G2 phases), mitosis is the proper cell division process, 
characterized by the formation of new cells (division of both nuclei and cytoplasm) [147]. According to 
literature, the doubling time (i.e. the period required to complete one cell cycle) varies depending on the 
cell line, and for NCI/ADR-RES it is reported as 34 h, while for NCI-H460 it is of 17.8 h [148]. The 
most used method to cell cycle evaluation is flow cytometry analysis of the DNA content. By using a 
fluorescent DNA dye, for example propidium iodide (PI), it is possible to observe three different cell 
subpopulations named G1 (DNA = 2n), S (2n < DNA < 4n)  and G2/M (DNA = 4n) phases according 
to the DNA quantity [149]. Figure 34 shows the results on NCI/ADR-RES cell cycle after treatment 
with Ag-5fu, 5fu and AgNO3 (histograms are in Figures A2 to A4, Appendix), while Figure 35 shows 
the results on NCI-H460 cell cycle after treatment with Ph3P-Au-tuH and Ph3P-Au-Cl (histograms are 

































































































Figure 34. Influence of Ag-5fu, 5fu and AgNO3 on NCI/ADR-RES cell cycle. NCI/ADR-RES cells 
were treated for 36 h with Ag-5fu (0.75 and 1.5 µg mL-1), 5fu (0.37 and 0.75 µg mL-1) or AgNO3 (0.37 
and 0.75 µg mL-1). Cell subpopulation (%) after propidium iodide staining: G1 (DNA = 2n), S (2n < 
DNA < 4n) and G2/M (DNA = 4n) phases. Statistical analysis: 2way-ANOVA followed by Bonferroni 


























































































Figure 35. Influence of Ph3P-Au-tuH and Ph3P-Au-Cl on NCI-H460 cell cycle. NCI-H460 cells were 
treated for 18 h with Ph3P-Au-tuH (6.0 and 12.0 µg mL
-1), or Ph3P-Au-Cl (5.05 and 10.1 µg mL
-1). Cell 
subpopulation (%) after propidium iodide staining: G1 (DNA = 2n), S (2n < DNA < 4n) and G2/M 
(DNA = 4n) phases. Statistical analysis: 2way-ANOVA followed by Bonferroni test (*p < 0.05, and 
***p < 0.001, relative to untreated cells). 
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Regarding NCI/ADR-RES cells, (Figure 34) when compared to the untreated ones (control), 
both Ag-5fu and 5fu promoted cell cycle arrest at G1 phase (G1 = 51% for untreated cells, 66% for Ag-
5fu and 67% for 5fu-treated cells, respectively), independent on the concentration. No significant 
changes induced by AgNO3 were observed, independent on the concentration (G1 = 50%). According 
to the literature, DNA damage caused by 5fu can activate the p53 protein [106,150], which influences 
proliferation by acting predominantly in the G1 phase of cell cycle progression [151], as already 
observed on smooth muscle cells treated with 5fu [152]. The results on cell cycle (Figure 34) may 
suggest that the effect of Ag-5fu on NCI/ADR-RES cells could be due to 5fu, since both compounds 
present the same pattern of cell cycle arresting, without participation of silver(I) ions. 
Now, for NCI-H460 cells, both Ph3P-Au-tuH and Ph3P-Au-Cl caused arrest at G1 phase (G1 = 
44% for untreated cells, 48% for Ph3P-Au-tuH and 52% for Ph3P-Au-Cl), and for Ph3P-Au-tuH the effect 
was greater at the highest concentration. It seems here that the phosphinegold(I) moiety is causing the 
effect on NCI-H460 cell cycle. 
 
Colony formation assay 
To expand the knowledge about how the compounds are acting on cells, we evaluated their 
influence on the colony forming ability. The colony formation assay determines the ability of one cell 
to proliferate, retaining its reproductive ability to form a colony after ceasing the sample exposition. By 
counting the aggregates of at least 50 cells (named one colony), this assay allowed to infer whether the 
sample promotes reversible or irreversible effects on cell proliferation [128,153,154]. Figure 36 shows 
the survival fraction of NCI/ADR-RES cells for cells treated with Ag-5fu, 5fu, and AgNO3 (number of 
























































































Figure 36. Survival fraction of NCI/ADR-RES cells for cells treated with Ag-5fu, 5fu, and AgNO3 in 
the concentration range of 0.75 – 3.0 µg mL-1. Control shows the plating efficiency (PE). 
 
Considering the NCI/ADR-RES doubling time (34 h), even after about 8 cell cycles, Ag-5fu 
was able to totally inhibit colony formation [Survival Fraction (SF) = 6.5 and 0% at 1.5 and 3.0 µg mL-
1, respectively] after one single exposition, being the effect dependent on complex concentration. 
Besides, 5fu almost totally inhibited colony formation only at the higher concentration (SF = 41 and 
1.2% at concentrations 0.75 and 1.5 µg mL-1, respectively) (Figure 35), while AgNO3 partially inhibited 
NCI/ADR-RES colony formation (SF = 52 and 32% at 0.75 and 1.5 µg mL-1, respectively). 
Figure 37 shows the survival fraction of NCI-H460 cells for cells treated with Ph3P-Au-tuH and 
Ph3P-Au-Cl (number of counted colonies is in Table A4, Appendix; Figures A10 and A11 show pictures 




















































































Figure 37. Survival fraction of NCI-H460 cells for cells treated with Ph3P-Au-tuH and Ph3P-Au-Cl in 
the concentration range of 6.0 – 12.0 µg mL-1. Control shows the plating efficiency (PE). 
 
Considering the NCI-H460 doubling time (17.8 h), even after about 8 cell cycles, Ph3P-Au-tuH 
was able to almost totally inhibit colony formation after one single exposition only at the highest 
concentration (SF = 32% and 1% at 6.0 and 12.0 µg mL-1, respectively). Ph3P-Au-Cl presented the same 
pattern of effect (SF = 18% and 2% at concentrations 5.05 and 10.1 µg mL-1, respectively), however 
being more potent than Ph3P-Au-tuH at the lowest concentration. 
The results indicate that the antiproliferative effect of Ag-5fu, Ph3P-Au-tuH and Ph3P-Au-Cl 
cannot be reverted by cells after complex removal. Moreover, for Ag-5fu, considering the effect of both 
precursors (5fu and AgNO3), the inhibition of colony formation promoted by Ag-5fu could be partially 
explained by a combination effect of silver(I) ions and 5fu. Considering the results of cell cycle arrest 
and of colony formation, it is possible to infer that the increasing survival of the NCI/ADR-RES cells 
observed at G1 phase after Ag-5fu or 5fu treatments, and of the NCI-H460 cells at G1 phase after 
treatment with Ph3P-Au-tuH or Ph3P-Au-Cl, may actually be cells entering G0 phase, since cell 
replication was not observed in the colony formation assay. Therefore, we started to evaluate whether 






Mitochondrial membrane depolarization – Rhodamine-123 assay 
The depolarization of the mitochondrial membrane is an indicative of early stages of cell death 
[155]. One strategy to evaluate this event by flow cytometry is using the fluorescent probe Rhodamine 
123 (Rh123). When mitochondrial membranes show the normal polarization, Rh123 accumulates within 
mitochondria, while the depolarization process results in loss of Rh123 with consequent decrease of 
intracellular fluorescence [156,157]. For the interpretation of the obtained results, cells were divided 
into three subpopulations according to the respective fluorescence intensities as M1 (100-101, total 
depolarization), M2 (101-103, partial/transient depolarization) and M3 (103-104, normal polarization). 
Figure 38 shows cell population of NCI/ADR-RES cells stained with Rh123 after 1 h, 2 h and 3 
h of treatment with Ag-5fu, 5fu and AgNO3. After 1h-exposition, only AgNO3 promoted a significant 
increase in M2 population (91%) when compared to untreated cells (83%). As the exposure time 
increased up to 3 h, Ag-5fu promoted M1 population increasing (M1 = 25 and 28% for Ag-5fu-treated 
cells after 2 h and 3 h, respectively) followed by M2 subpopulation decreasing (M2 = 78 and 53% for 
Ag-5fu-treated cells after 2 h and 3 h, respectively) in comparison to untreated cells (M1 = 13 and 10%, 
M2 = 91 and 82% for untreated cells after 2 h and 3 h, respectively). In addition, 5fu did not promote 







































































































































































Figure 38. Cell population of NCI/ADR-RES stained with Rh123. NCI/ADR-RES cells were treated 
for 1 h, 2 h and 3 h with Ag-5fu (3.0 µg mL-1), 5fu (1.5 µg mL-1) and AgNO3 (1.5 µg mL
-1). Cell 
subpopulation (%) in M1, M2 and M3 after Rh123 staining. M1 is the fluorescence intensity between 
100-101 (total depolarization), while M2 is the fluorescence intensity between 101-103 (partial/transient 
depolarization), and M3 is the fluorescence intensity between 103-104 (normal polarization). Statistical 





The obtained results (Figure 38) were suggestive to the disruption of the mitochondrial 
membrane potential of NCI/ADR-RES cells by Ag-5fu. However, one limitation of this protocol regards 
on the presence of P-glycoprotein (P-gp) in the chosen cell line. The P-glycoprotein promotes drug efflux 
from the intracellular environment and Rh123 can be used to evaluate this characteristic (a decrease in 
the intracellular fluorescence is proportional to P-gp activation) [158]. Considering that NCI/ADR-RES 
cells express multiple drug resistance because of the super expression of P-gp [159,160], a reduction in 
the fluorescent intensity after Rh123 staining may indicate the Ag-5fu-induced mitochondrial membrane 
depolarization or just the P-gp activity promoting Rh123 and drug efflux. To clarify this question and 
considering that NCI/ADR-RES cells derive from OVCAR-8 cells, which do not super express P-gp 











































































































Figure 39. Cell population of OVCAR-8 stained with Rh123. OVCAR-8 cells were treated for 1 h, 2 h 
and 3 h with Ag-5fu (3.0 µg mL-1). Cell subpopulation (%) in M1, M2 and M3 after Rh123 staining. M1 
is the fluorescence intensity between 100-101 (total depolarization), while M2 is the fluorescence 
intensity between 101-103 (partial/transient depolarization), and M3 is the fluorescence intensity between 
103-104 (normal polarization). Statistical analysis: 2way-ANOVA followed by Bonferroni test (*p < 
0.05, **p < 0.01, ***p < 0.001, relative to untreated cells). 
 
Ag-5fu was able to promote depolarization of the mitochondrial membrane in OVCAR-8 cells, 
as observed by M1 subpopulation increasing after 2h-treatment (34% of cells treated with Ag-5fu 
compared to 11% of untreated cells). This result corroborates the hypothesis of Ag-5fu-induced 
mitochondrial membrane depolarization in NCI/ADR-RES cells rather than just P-gp-induced Rh123 
efflux. Depolarization of the mitochondrial membrane was reported before for silver(I) complexes 
[161,162]. However, in a different way from the other assays here reported, only the Ag-5fu complex 
promoted the depolarization, which was not observed for the free ligand or the free metal ion. It seems 
that the combination of ligand (5fu) and silver(I) plays an important role for mitochondrial membrane 
depolarization of NCI/ADR-RES cells. 
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For NCI-H460 cells and Ph3P-Au-tuH and Ph3P-Au-Cl compounds, the Rh123 assay was also 
performed and, in this case, it will show loss of Rh123 from the mitochondria if depolarization occurs, 
with a decrease of intracellular fluorescence. P-gp is not super expressed in this cell line, therefore not 
evaluated here. Figure 40 shows cell population of NCI-H460 cells stained with Rh123 after 1 h, 2 h 
and 3 h of treatment with Ph3P-Au-tuH and Ph3P-Au-Cl. 
It is interesting that only Ph3P-Au-tuH caused depolarization of the mitochondrial membrane 
within 1 h (37% of cells treated with Ph3P-Au-tuH compared to 24% of untreated cells) and 2h (33% of 
cells treated with Ph3P-Au-tuH compared to 23% of untreated cells) of treatment, while Ph3P-Au-Cl did 






























































































































































Figure 40. Cell population of NCI-H460 stained with Rh123. NCI-H460 cells were treated for 1 h, 2 h 
and 3 h with Ph3P-Au-tuH (24.0 µg mL
-1) and Ph3P-Au-Cl (20.2 µg mL
-1). Cell subpopulation (%) in 
M1, M2 and M3 after Rh123 staining. M1 is the fluorescence intensity between 100-101 (total 
depolarization), while M2 is the fluorescence intensity between 101-103 (partial/transient 
depolarization), and M3 is the fluorescence intensity between 103-104 (normal polarization). Statistical 
analysis: 2way-ANOVA followed by Bonferroni test (*p < 0.05, **p < 0.01, relative to untreated cells). 
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Phosphatidylserine externalization – Nexin assay 
There are many different mechanisms of cell death [163]. Apoptosis is the cell death mechanism 
that occurs naturally when cells get old and start developing problems. It is an active and regulated 
process of cellular dismantling that avoids eliciting inflammation [164]. It is important to notice that 
cancer cells do not trigger cell death, so they proliferate indefinitely. Considering this, one desired 
feature of an anticancer compound is to induce cell death through modulating an endogenous “suicide” 
mechanism, such as apoptosis or autophagy [165]. Phosphatidylserine (PS) is a phospholipid contained 
in the inner side of the cell membrane, and the exposure or externalization of PS to the outer side is a 
cellular event involved in some cell death mechanisms, such as apoptosis [156,166]. This characteristic 
allowed the development of assays to evaluate mechanisms of regulated cell death by assessing PS 
externalization. One strategy is based on the high affinity of Annexin-V for PS residues. As Annexin-V 
is not fluorescent by itself, it is chemically coupled to a fluorescent probe. Moreover, to differentiate 
whether PS residues were in the inner or in the outer side of the cell membrane, a second dye, such as 
7-aminoactinomycin D (7-AAD), with low permeability through unimpaired plasmatic membrane and 
high DNA affinity, is used to evaluate the membrane integrity [167]. 
As a dynamic process, we evaluated the PS externalization in NCI/ADR-RES cells induced by 
Ag-5fu, 5fu and AgNO3 after different exposition times (8 h, 14 h, 18 h and 24 h), and in NCI-H460 
cells induced by Ph3P-Au-tuH and Ph3P-Au-Cl (18 h and 24 h). Figure 41 shows phosphatidylserine 
externalization of NCI/ADR-RES after 18 h of treatment with Ag-5fu, 5fu and AgNO3. For 8 h, 14 h 




































































Figure 41. Influence of Ag-5fu, 5fu, and AgNO3 on phosphatidylserine externalization. NCI/ADR-RES 
cells were treated for 18h with Ag-5fu (3.0 µg mL-1), 5fu (1.5 µg mL-1) or AgNO3 (1.5 µg mL
-1). Cell 
subpopulation (%) after Annexin-V and 7-AAD staining. Statistical analysis: 2way-ANOVA followed 
by Bonferroni test (***p < 0.001, relative to untreated cells). 
 
The obtained results show that silver(I) ions and Ag-5fu induced PS externalization on 
NCI/ADR-RES cells [Annexin-V(+)/7-AAD(-) = 2% in untreated cells, 8 and 11% in cells treated with 
AgNO3 and Ag-5fu, respectively]. Also, the PS externalization effect was greater (p < 0.001) for Ag-
5fu (49%) when compared to AgNO3 (28%) after 18 h for cells with both PS externalization and loss of 
membrane integrity [Annexin-V(+)/7-AAD(+)]. Moreover, 5fu did not alter the PS externalization 
profile observed for untreated NCI/ADR-RES cells after 18h-treatment. 
After 18h-exposition, both Ag-5fu and AgNO3 induced significant increasing on the 
subpopulations showing PS externalization, with or without loss of membrane integrity, in comparison 
to untreated cells (Figure 41). The obtained results suggest that the silver(I) ions present in the metal 
complex contributed to Ag-5fu-induced PS externalization on NCI/ADR-RES cells. According to the 
literature, 24h-exposition to AgNO3 (10 µM) induced programed cell death in Vitis vinifera cells [168]. 
Depending on the cell line and the exposition period, 5fu may (as in colon carcinoma cells after 1 – 3 
days of treatment) or may not (as in smooth muscle cells after 24h-exposition) cause PS externalization 
apoptosis [152]. 
Figure 42 shows phosphatidylserine externalization of NCI-H460 cells after 18 h of treatment 
with Ph3P-Au-tuH and Ph3P-Au-Cl. For 24 h exposition time, see Figure A16 in Appendix, and for dot-






























































Figure 42. Influence of Ph3P-Au-tuH and Ph3P-Au-Cl on phosphatidylserine externalization. NCI-H460 
cells were treated for 18 h with Ph3P-Au-tuH (24.0 µg mL
-1) or Ph3P-Au-Cl (20.2 µg mL
-1). Cell 
subpopulation (%) after Annexin-V and 7-AAD staining. Statistical analysis: 2way-ANOVA followed 
by Bonferroni test (*p < 0.05 and ***p < 0.001, relative to untreated cells). 
 
Both Ph3P-Au-tuH and Ph3P-Au-Cl compounds induced PS externalization in NCI-H460 cells 
after 18 h of treatment [Annexin-V(+)/7-AAD(-) = 7% in untreated cells, 11 and 14% in cells treated 
with Ph3P-Au-tuH and Ph3P-Au-Cl, respectively]. The effect was greater (P < 0.05) for cells treated with 
Ph3P-Au-Cl with both PS externalization and loss of membrane integrity [Annexin-V(+)/7-AAD(+) = 
6% in untreated cells, 15 and 19% in cells treated with Ph3P-Au-tuH and Ph3P-Au-Cl, respectively]. 
 
Detection of activated caspases 
As suggested by PS externalization, it seems that the compounds are inducing cell death in the 
NCI cells by apoptosis. This mechanism of regulated cell death begins with cellular signalization in the 
cytosol mediated by a group of proteases called caspases, which are triggered in response to pro-
apoptotic signals. Once activated, caspases cleave protein substrates leading to the eventual dismantling 
of the cell, as cytosol condensation and nuclear membrane disintegration. Caspases can be divided into 
“initiators”, which regulate apoptosis upstream (caspases 8, 9, and 10) and “effectors”, which are 
responsible for proteolytic cleavages that lead to cell disassembly (caspases 3, 6, and 7) [169]. To 
evaluate the multicaspases activation (initiators and effectors) we choose the method based on the 
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unspecific caspase inhibitor SR-VAD-FMK dye (SR: sulforhodamine B; VAD: trimer Val-Ala-Asp; 
FMK: fluoromethylketone) [170] that binds covalently to active caspases. Once again, 7-AAD was used 
as an indicator of membrane integrity [156]. 
Figure 43 shows the caspases activation of NCI/ADR-RES after 17 h of treatment with Ag-5fu, 































































Figure 43. Influence of Ag-5fu, 5fu, and AgNO3 on caspases activation. NCI/ADR-RES cells were 
treated for 17h with Ag-5fu (3.0 µg mL-1), 5fu (1.5 µg mL-1) and AgNO3 (1.5 µg mL
-1). Cell 
subpopulation (%) after SR-VAD-FMK and 7-AAD staining. Statistical analysis: 2way-ANOVA 
followed by Bonferroni test (*p < 0.05, **p < 0.01, ***p < 0.001, relative to untreated cells). 
 
Ag-5fu and AgNO3 promoted significant reduction on NCI/ADR-RES cells subpopulation 
without caspase activation and loss of membrane integrity [SR-VAD-FMK (-)/7-AAD (-) = 92, 74 and 
28%, for untreated cells, AgNO3 and Ag-5fu treatments, respectively). Besides, both Ag-5fu and AgNO3 
increased NCI/ADR-RES cell subpopulation with both caspase activation and loss of membrane 
integrity after 17h-exposition [SR-VAD-FMK (+)/7-AAD (+) = 4, 19 and 64% for untreated cells, 
AgNO3 and Ag-5fu treatments, respectively]. As expected, 5fu did not promote caspases activation on 
NCI/ADR-RES cells after 17 h of treatment. In agreement with the PS externalization results, Ag-5fu 
and AgNO3 promoted significant reduction on NCI/ADR-RES cells subpopulation without caspase 
activation and loss of membrane integrity [SR-VAD-FMK (-)/7-AAD (-)]. Besides, both Ag-5fu and 
AgNO3 increased NCI/ADR-RES cell subpopulation with both caspase activation and loss of membrane 
integrity after 17 h-exposition [SR-VAD-FMK (+)/7-AAD (+)]. As observed in colony formation and 
97 
 
PS externalization assays, the caspase activation by Ag-5fu was much more intense than that promoted 
by AgNO3 (Figure 43). Furthermore, the loss of membrane integrity occurred almost simultaneously 
with PS externalization and caspases activation. These characteristics reinforce the suggestion that Ag-
5fu might be inducing apoptosis on NCI/ADR-RES cells. 
Figure 44 shows the caspases activation of NCI-H460 cells after 18 h of treatment with Ph3P-
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Figure 44. Influence of Ph3P-Au-tuH and Ph3P-Au-Cl on caspases activation. NCI-H460 cells were 
treated for 18 h with Ph3P-Au-tuH (24.0 µg mL
-1) and Ph3P-Au-Cl (20.2 µg mL
-1). Cell subpopulation 
(%) after SR-VAD-FMK and 7-AAD staining. Statistical analysis: 2way-ANOVA followed by 
Bonferroni test (***p < 0.001, relative to untreated cells). 
 
Both compounds promoted reduction on NCI-H460 cells subpopulation without caspase 
activation and loss of membrane integrity [SR-VAD-FMK (-)/7-AAD (-) = 79, 64 and 37%, for untreated 
cells, Ph3P-Au-tuH and Ph3P-Au-Cl, respectively). Also, both increased NCI-H460 cell subpopulation 
with both caspase activation and loss of membrane integrity after 18h-exposition [SR-VAD-FMK (+)/7-
AAD (+) = 12, 29 and 56% for untreated cells, Ph3P-Au-tuH and Ph3P-Au-Cl treatments, respectively]. 
Again, effect was greater (P < 0.001) for cells treated with Ph3P-Au-Cl with both caspases activation 
and loss of membrane integrity. These results, together with PS externalization, reinforce the suggestion 




Measurement of intracellular oxidants – DCFH-DA assay 
Considering the previous experiments (mitochondrial membrane depolarization, PS 
externalization, caspases activation), it was observed that the metal compounds here evaluated induced 
cell death in the tested cells by apoptosis. This regulated cell death mechanism can be initialized by two 
different ways. The extrinsic apoptosis is initiated by extracellular microenvironment perturbations and 
propagated by caspase activation, while the intrinsic apoptosis can be initiated both by extra or 
intracellular microenvironment perturbations, and limited by caspase activation [155]. 
In this context, we evaluated whether Ag-5fu and its precursors 5fu and AgNO3 induce the 
production of intracellular reactive oxygen species (ROS) as an initiation event of regulated cell death 
in NCI/ADR-RES cells. The NCI-H460 cells treated with Ph3P-Au-tuH and Ph3P-Au-Cl were not 
evaluated so far. One protocol used to evaluate intracellular ROS generation is based on the probe 2′,7′-
dichlorofluorescein diacetate (DCFH-DA) [171]. This probe can readily diffuse into the cells and get 
deacetylated by intracellular enzymes (esterases) to the non-fluorescent 2,7-dichlorodihydrofluorescein 
(DCFH). In a proportional way, DCFH is oxidized by intracellular hydrogen peroxide into the highly 
fluorescent 2,7-dichlorofluorescein (DCF) [156,172]. In addition, cells treated with hydrogen peroxide 
were used as a positive control. Based on DCF fluorescence, cells can be divided into two subpopulations 
of increasing fluorescence, named as M1 (fluorescence intensity between 100 and 101, non-marked 
cells), and M2 (fluorescence intensity between 101 and 104, marked with DCF because of high 
concentration of intracellular ROS). 
Figure 45 shows the intracellular ROS formation in NCI/ADR-RES after 1 h, 2 h and 3 h of 













































































































































































































































































































Figure 45. Influence of Ag-5fu, 5fu, and AgNO3 on intracellular ROS formation in NCI/ADR-RES. 
NCI/ADR-RES cells were treated for 1 h, 2 and 3 h with Ag-5fu (3.0 µg mL-1), 5fu (1.5 µg mL-1), 
AgNO3 (1.5 µg mL
-1) and H2O2 (200 µM). Cell subpopulation (%) in M1 and M2 after DCFH-DA 
staining. M1 is the fluorescence intensity between 100 and 101 (non-marked cells), while M2 is the 
fluorescence intensity between 101 and 104 (marked with DCF). Statistical analysis: 2way-ANOVA 
followed by Bonferroni test (***p < 0.001, relative to untreated cells).  
  
As expected, hydrogen peroxide promoted a significant increase on intracellular ROS 
concentration as observed by increased M2 subpopulations in comparison to the untreated NCI/ADR-
RES cells (M2 = 30 and 82% for untreated cells and H2O2-treated cells after 1 h, respectively). In 
addition, Ag-5fu, 5fu or AgNO3 did not promote any alteration on intracellular ROS concentration 
(Figure 42). In this way, the observed results suggest that up to 3h-treatment the Ag-5fu complex did 







The antiproliferative activity of Ag-5fu over multi-resistant ovarian tumor cells (NCI/ADR-
RES) was shown to be a combination of the activities of free 5fu and silver(I) ions. The Ag-5fu complex 
may induce regulated cell death in NCI-ADR/RES cells considering mitochondrial membrane 
depolarization, PS externalization and multicaspases activation. Moreover, the Ag-5fu complex 
promoted cell cycle arrest at G1 and inhibited colony formation, indicating that the cancer cells, which 
do not go through a regulated cell death pathway, lost their proliferation ability. However, the 
mechanism of cell death could not be completely elucidated. The production of ROS by the complex 
was not observed, what means that the reason for cell death triggering is still unknown. Moreover, the 
differentiation between intrinsic and extrinsic apoptosis could not be done.  
Furthermore, the Ph3P-Au-tuH complex showed a higher antiproliferative activity when 
compared to Ph3P-Au-Cl over NCI-H460 cells. Both compounds induced regulated cell death in NCI-
H460 cells, considering PS externalization and multicaspases activation. Both compounds promoted cell 
cycle arrest at G1 and inhibited colony formation. For the gold(I) complexes only Ph3P-Au-tuH showed 
mitochondrial membrane depolarization. Again, the mechanism of cell death could not be completely 
elucidated for the same reasons observed for Ag-5fu. 
Data for the silver(I) complex with 5-fluorouracil presented in this section was published in 















PART 2: Thiosemicarbazones and their metal complexes 
 
This part of the Thesis was done in a 9-month internship in the Institute of Inorganic Chemistry 
of the University of Vienna (Vienna, Austria), under the supervision of Ass. Prof. Dr. Christian Kowol 
(Keppler Group). The biological investigations were done in the Institute for Cancer Research of the 
Medical University of Vienna, under the supervision of Assoc. Prof. Dr. Petra Heffeter. The internship 
was funded by OeAD (Austrian service center for European and international mobility and cooperation 
programmes in the fields of education, science and research). 
 
Introduction 
α-(N)-Heterocyclic thiosemicarbazones (TSCs) are an important class of metal chelating agents. 
They are formed by condensation of carbonyl compounds and thiosemicarbazides, resulting in N,N,S-
donor ligands [173]. TSCs, as well as their metal complexes, are widely investigated as antibacterial, 
antiviral, and anticancer agents [174]. More specifically, concerning the anticancer activities of TSCs, 
the investigations started in 1956, when Brockman et al. observed the antileukemic activity of pyridine-
2-carboxaldehyde thiosemicarbazone [175]. At that time, no evidences were found concerning the mode 
of action of this compound. In 1958, French and Freedlander observed the activity of glyoxal bis-
(thiosemicarbazones) against Sarcoma 180 and proposed a possible mechanism of action involving 
inactivation or translocation of metal ions in the tumor due to chelation by α-(N)-heterocyclic 
thiosemicarbazones [176]. 
As a result of the first investigations, many TSCs were studied for their anticancer activities. For 
example, 2-keto-3-ethoxybutyraldehyde bis(thiosemicarbazone) (KTS) was shown to be active against 
several tumors in rats [177] and studies showed the dependence of KTS’s activity with the presence of 
metal ions such as copper(II) and zinc(II) in the animals’ diet [178]. Further research indicated the 
antitumor activity of the Cu(II)KTS metal complex, confirming the dependence of the interaction of the 
TSC with copper as being part of the mechanism of action [179]. Also, the Zn(II)KTS complex presented 
antitumor activity [180], although being less active than the Cu(II)KTS complex and considered to 
potentiate the activity of Cu(II)KTS [179]. In addition, Booth and Sartorelli [181] observed a greater 
assimilation of copper by neoplasic cells treated with Cu(II)KTS than with CuCl2, due to the greater 
lipid solubility of the metal complex. Besides, they detected at least three distinct copper-induced 
biochemical lesions by Cu(II)KTS. Moreover, studies by Petering et al. with bis(thiosemicarbazonato) 
copper(II) complexes described a correlation between the cytotoxicity and the reactivity toward thiol 
groups, with the antitumor activity being related to the reduction of Cu(II) to Cu(I) [182,183]. 
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Regarding the mechanism of action of TSCs, Moore et al. showed the interference of 1-
formylisoquinoline thiosemicarbazone (IQ-1) with the biosynthesis of DNA [184]. This was found to 
be due to the inhibition of the ribonucleotide diphosphate reductase (RR) enzyme. The inhibition was 
thought to be related to the binding of IQ-1 to an iron-containing form of RR or by formation of an iron-
complex with IQ-1, which binds to the RR. Further studies by Thelander and Graslund indicated the 
target of IQ-1 to be the tyrosine free radical of a subunit of RR. It was suggested that the active form of 
the drug is the iron(II) complex [Fe(II)IQ-1], which reacts with molecular oxygen, leading to reversible 
destruction of the tyrosine free radical [185]. Regarding the redox properties of iron complexes, the 
pathway most likely involves the oxidation of Fe(II) to Fe(III), with the release of one electron and 
inactivation of the tyrosine free radical, followed by the reduction of the Fe(III) complex by cellular 
thiols [186,187]. Therefore, the redox activity of the metal complexes seems to be correlated with their 
cytotoxicity [187–189]. 
The first member of the α-(N)-heterocyclic thiosemicarbazone series to be clinically evaluated 
was 5-hydroxy-2-formylpyridine thiosemicarbazone (5-HP, Figure 46-a) in 1972 [190]. However, the 
promising antineoplasic activity found in animals could not be found in humans. 5-HP presented low 
affinity to the human ribonucleotide reductase (RR) enzyme, with rapid excretion, due to the formation 
of the O-glucuronide conjugate. Therefore, structure-activity relationships investigations were 
performed in order to develop second generation α-(N)-heterocyclic thiosemicarbazones with greater 
affinity for the target [187]. 
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; Figure 46-b) was the most 
investigated TSC, and it was evaluated in several phase I and II clinical trials against a number of 
different cancers [191]. Despite these numerous clinical trials, Triapine showed only promising activity 
against advanced leukemia but failed against a variety of solid tumors [192]. The reasons are currently 
widely unknown and might be due to the inappropriate drug delivery and/or fast excretion/metabolism. 
Since 2004 Richardson et al. developed a series of di-2-pyridylketone thiosemicarbazones [193,194], 
the DpT series, which are ligands similar to Triapine, but with much higher cytotoxic activity in the 
nanomolar range due to a terminal dimethylation. Terminal nitrogen dimethylation of α-N-heterocyclic 
thiosemicarbazones was found to enhance the toxicity of the compounds, and also of their metal 
complexes [195–197]. Recently, the Richardson group developed a new analog, di-2-pyridilketone 4-
cyclohexyl-4-methyl-3-thiosemicarbazone, known as DpC (Figure 46-c) [183,198] which due to its 






Figure 46. Molecular structures of (a) 5-HP, (b) Triapine and (c) DpC. 
 
More recently, Cotinga Pharmaceuticals (formerly Critical Outcome Technologies Inc., Boston, 
MA, United States) developed a third generation TSC known as COTI-2 (4-(pyridine-2-yl)-N-{[(8E)-
5,6,7,8-tetrahydroquinolin-8-ylidene]amino}piperazine-1-carbothiamide; Figure 47) which entered 
phase I clinical trials for the treatment of gynecologic malignancies in 2017 [200]. It is a small molecule 
and an anticancer drug candidate, designed using a computational platform, which can be obtained in a 
three-step synthesis procedure [201,202]. Biological investigations revealed that COTI-2 possesses high 
efficacy against multiple cancers both in vitro and in vivo. Additionally, COTI-2 demonstrated a low 
toxicity profile in mice and better efficacy when compared to standard chemotherapeutic agents, as 
cetuximab and erlotinib, for example. Regarding the mechanism of action, it was found that COTI-2 
activates the caspase signaling cascade, inducing apoptosis in cancer cells [202]. In addition, it was 
found that COTI-2 is more active in mutant p53 tumors, and it increases intracellular zinc concentrations 




Figure 47. Molecular structure of COTI-2. 
 
Nevertheless, studies about structure-activity relationships of COTI-2 or metal complexes with 
this molecule have not been reported so far. Therefore, considering the background of α-N-heterocyclic 
thiosemicarbazones and their importance in metal metabolism, the synthesis of the first metal complexes 
with COTI-2 are presented, with the biologically relevant ions Fe(III), Cu(II) and Zn(II), which could 
help elucidate the biological properties of this compound. Also, new COTI-derivatives (COTI-NH2, 
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COTI-NMe2, COTI-Nchexyl, Figure 48) were prepared, and the cytotoxic activities of these compounds 
were evaluated, in order to try to address structure-activity relationships. 
 
 
Figure 48. The COTI-derivatives: (a) COTI-NH2 [2-(6,7-dihydroquinolin-8(5H)-ylidene)hydrazine-1-
carbothioamide], (b) COTI-NMe2 [2-(6,7-dihydroquinolin-8(5H)-ylidene)-N,N-dimethylhydrazine-1-






The objective of the second part of this Thesis was the synthesis, characterization and evaluation 
of the cytotoxic activities of COTI-2 and new COTI-derivatives, and of Fe(III), Cu(II), and Zn(II) metal 




Materials and Methods 
Starting Materials 
N-(2-pyridyl)piperazine was purchased from Alfa Aesar; 1,1’-thiocarbonyldiimidazole, 
hydrazine hydrate, N-methylcyclohexylamine, carbon disulfide,  sodium chloroacetate and zinc(II) 
chloride were purchased from Sigma-Aldrich; 5,6,7,8-tetrahydroquinolin-8-one was purchased from 
abcr; hydrazinecarbothioamide was purchased from Fluka; 4,4-dimethyl-3-thiosemicarbazide was 
purchased from TCI; copper(II) chloride dehydrate was purchased from Merck; iron(III) nitrate 
nonahydrate was purchased from Acros Organics. All reagents were used without further purification. 
 
Equipments 
Chemical analyses: Elemental analyses were performed on a Perkin Elmer 2400 CHNS Elemental 
Analyzer at the Microanalytical Laboratory of the University of Vienna. 
 
Mass spectrometric measurements: Electrospray ionization (ESI) mass spectra were recorded on a 
Bruker anaZon SL ion trap mass spectrometer in positive mode by direct infusion (COTI-2, COTI-
NMe2, Cu-COTI-2, Zn-COTI-2). High resolution mass spectra were measured on a Bruker maXis UHR 
ESI time of flight mass spectrometer (COTI-NH2, COTI-Nchexyl, Fe-COTI-2) [M = metal; HL = 
protonated ligand; L = deprotonated ligand]. Spectra are shown in Figures A20 to A26 in Appendix. 
 
Nuclear magnetic resonance measurements: One- and two-dimensional 1H-NMR and 13C-NMR 
spectra were recorded on a Bruker Avance III 600 MHz spectrometer at 298 K. For 1H-NMR spectra 
the solvent residual peak was taken as internal reference [s = singlet; d = doublet; t = triplet; quint = 
quintet; dd = doublet of doublets; ddd = doublet of doublet of doublets; br = broad signal; m = multiplet; 
py = pyridine; compound numbering for NMR can be found in Appendix, Figures A27 to A30]. Spectra 
for the final products (COTI-2, COTI-derivatives and Zn-COTI-2) are shown in Figures A31 to A47, in 
Appendix. 
 
Single crystal X-ray diffraction: The X-ray intensity data were measured on a Bruker D8 Venture 
diffractometer equipped with multilayer monochromator, MoKα for COTI-2 and CuKα for Cu-COTI-
2, INCOATEC micro focus sealed tube and Oxford cooling system. The structures were solved by direct 
methods and refined by full-matrix least-squares techniques. Non-hydrogen atoms were refined with 
anisotropic displacement parameters. Hydrogen atoms were inserted at calculated positions and refined 
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with riding model. The following software was used: Bruker SAINT software package [204] using a 
narrow-frame algorithm for frame integration, SADABS [205] for absorption correction, OLEX2 [206] 
for structure solution, refinement, molecular diagrams and graphical user-interface, Shelxle [207] for 
refinement and graphical user-interface SHELXS-2015 [208] for structure solution, SHELXL-2015 
[209] for refinement, Platon [210] for symmetry check. Experimental parameters for COTI-2 and Cu-




The compound was prepared in three steps according to the patent US8034815B2 [201]. 
Synthesis of 1H-imidazol-1-yl-(4-(pyridin-2-yl)piperazin-1-yl)methanethione (1a): 
Thiocarbonyldiimidazole (0.89 g, 5.0 mmol, 1eq.) was dissolved in dichloromethane (30 mL) 
and N-(2-pyridyl)piperazine (762 µL, 5.0 mmol, 1eq.) was added. The solution was stirred for 20 hours 
and further washed three times with water. The organic phase was dried over magnesium sulphate, which 
was filtered off, and the solvent was evaporated. The resulting yellow oil of 1a was dried under vacuum 
and used in the next step without further purification. Yield: 1.36 g (99%). 1H-NMR (DMSO-d6): δ = 
2.77 (m, 2H, piperazine), 3.38 (m, 2H, piperazine), 6.70 (ddd, 1H, py), 6.84 (d, 1H, py), 7.06 (dd, 1H, 
imidazole), 7.56 (t, 1H, imidazole), 7.59 (ddd, 1H, py), 8.08 (t, 1H, imidazole), 8.15 (ddd, 1H, py). 
 
Synthesis of 4-(pyridin-2-yl)-piperazine-1-carbothiohydrazide (1b): 
The compound 1a (1.36 g, 5.0 mmol, 1 eq.) was dissolved in ethanol (20 mL) and hydrazine 
hydrate was added (267 µL, 5.5 mmol, 1.1 eq.). The mixture was stirred under reflux for 2 h, and a white 
solid of 1b was formed which was collected by filtration, washed with cold ethanol, dried under vacuum 
and used in the next step without further purification. Yield: 0.77 g (65%). 1H-NMR (DMSO-d6): δ = 
3.53 (m, 2H, piperazine), 3.85 (m, 2H, piperazine), 4.84 (br, 1H, NH), 6.66 (ddd, 1H, py), 6.83 (d, 1H, 




The compound 1b (0.77 g, 3.26 mmol, 1 eq.) was suspended in ethanol (25 mL) and 5,6,7,8-
tetrahydroquinolin-8-one was added (0.48 g, 3.26 mmol, 1 eq.). The mixture was stirred under reflux 
for 20 h, resulting in a yellow solid, which was collected by filtration, washed with cold ethanol and 
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diethyl ether, and dried under vacuum. Yield: 1.01 g (85%). Elemental analysis: Calcd. For C19H22N6S 
(%): C, 62.27 ; H, 6.05 ; N, 22.9 ; S, 8.75. Found (%): C, 61.87 ; H, 5.93 ; N, 22.58 ; S, 8.61. MS in 
ACN/MeOH + 1% H2O (positive): m/z 367.60, [HL + H]
+ ; 389.6, [HL + Na]+. 1H-NMR (DMSO-d6): 
Major isomer (91%) δ = 1.98 (quint, 2H, CH2, H6), 2.90 (t, 2H, CH2, H7), 3.09 (t, 2H, CH2, H5), 3.56 
(t, 2H, CH2, H12,13), 4.10 (s, 2H, CH2, H11,14), 6.66 (dd, 1H, CH, H16), 6.85 (d, 1H, CH, H18), 7.45 
(dd, 1H, CH py, H2), 7.56 (ddd, 1H, CH, H17), 7.78 (dd, 1H, CH py, H3), 8.13 (dd, 1H, CH, H19), 8.59 
(dd, 1H, CH py, H1), 14.57 (s, 1H, NH, N3). 13C NMR (125.75 MHz, DMSO-d6): δ = 20.2 (CH2, C6), 
26.3 (CH2, C5), 27.2 (CH2, C7), 44.4 (CH2, C12,13), 47.9 (CH2, C11,14), 107.1 (Cpy, C18), 113.1 (Cpy, 
C16), 125.4 (Cpy, C2), 136.4 (Cq, C4), 137.6 (Cpy, C17), 137.8 (Cpy, C3), 148.3 (Cq, C9), 148.2 (Cpy, C1), 
143.3 (C=N, C8), 147.6 (Cpy, C19), 158.8 (Cq, C15), 184.0 (C=S, C10). 
1H-NMR (DMSO-d6): Minor 
isomer (9%) δ = 15.52 (s, 1H, NH, N3). Crystals were obtained from slow evaporation of the mother 
liquor. 
 
Synthesis of 2-(6,7-dihydroquinolin-8(5H)-ylidene)hydrazine-1-carbothioamide (COTI-NH2) 
This compound was synthesized by a procedure from reference [211] with slight modifications 
to avoid column chromatography.  
Hydrazinecarbothioamide (0.37 g, 4.0 mmol, 1 eq.) was suspended in isopropanol (10 mL), and 
the mixture was stirred at 80 ºC. Then, 5,6,7,8-tetrahydroquinolin-8-one (0.59 g, 4.0 mmol, 1 eq.) was 
added, and the mixture was stirred under reflux for 5 h. A pale-yellow solid was formed, which was 
collected by filtration, washed with cold isopropanol and dried under vacuum. Yield: 0.65 g (74%). 
Elemental analysis: Calcd. For C10H12N4S (%): C, 54.52 ; H, 5.49 ; N, 25.43 ; S, 14.55. Found (%): C, 
54.53 ; H, 5.48 ; N, 25.35 ; S, 14.59. MS in ACN/MeOH + 1% H2O (positive): m/z 243.0675, [HL + 
Na]+. 1H NMR (DMSO-d6): δ = 1.93 (quint, 2H, CH2, H6), 2.69 (m, 2H, CH2, H7), 2.91 (t, 2H, CH2, 
H5), 7.47 (dd, 1H, CH py, H2), 7.85 (dd, 1H, CH py, H3), 7.96 (s, 1H, NH2, N4), 8.37 (s, 1H, NH2, N4), 
8.61 (dd, 1H, CH py, H1), 14.28 (s, 1H, NH, N3). 13C NMR (DMSO-d6): δ = 22.2 (CH2, C6), 28.9 (CH2, 
C5), 33.4 (CH2, C7), 124.4 (Cpy, C2), 137.7 (Cq, C4), 138.6 (Cpy, C3), 139.2 (C=N, C8), 145.9 (Cpy, C1), 
148.7 (Cq, C9), 178.2 (C=S, C10). No isomerization was observed for this compound. 
 
Synthesis of 2-(6,7-dihydroquinolin-8(5H)-ylidene)-N,N-dimethylhydrazine-1-carbothioamide 
(COTI-NMe2) 
5,6,7,8-Tetrahydroquinolin-8-one (0.37 g, 2.5 mmol, 1 eq.) was dissolved in isopropanol (10 
mL) and concentrated HCl (1 drop) was added. Then, 4,4-dimethyl-3-thiosemicarbazide (0.30 g, 2.5 
mmol, 1 eq.) was added, and the mixture was stirred under reflux for 5 h. A yellow solid was formed, 
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which was collected by filtration, washed with cold isopropanol and diethyl ether, and dried under 
vacuum. Yield: 0.45 g (71%). Elemental analysis: Calcd. For C12H16N4S·0.25H2O (%): C, 57.00 ; H, 
6.58 ; N, 22.16 ; S, 12.68. Found (%): C, 57.25 ; H, 6.42 ; N, 25.53 ; S, 12.44. ESI-MS in ACN/MeOH 
+ 1% H2O (positive): m/z 271.20, [HL + Na]
+. Major isomer (67%) 1H-NMR (DMSO-d6): δ = 1.93 
(quint, 2H, CH2, H6), 2.72 (t, 2H, CH2, H7), 2.91 (t, 2H, CH2, H5), 3.34 (s, 6H, N(CH3)2, H11,12), 7.47 
(dd, 1H, CH py, H2), 7.88 (dd, 1H, CH py, H3), 8.62 (dd, 1H, CH py, H1), 14.48 (s, 1H, NH, N3). 13C 
NMR (DMSO-d6): δ = 22.1 (CH2, C6), 28.8 (CH2, C5), 33.4 (CH2, C7), 40.7 (CH3, C11,12), 124.1 (Cpy, 
C2), 136.0 (Cq, C4), 138.7 (Cpy, C3), 141.1 (C=N, C8), 145.4 (Cpy C1), 148.4 (Cq, C9), 179.9 (C=S, 
C10). Minor isomer (33%) 1H-NMR (DMSO-d6): δ = 1.96 (quint, 2H, CH2, H6), 2.88 (t, 2H, CH2, H7), 
3.05 (t, 2H, CH2, H5), 3.34 (s, 6H, N(CH3)2, H11,12), 7.42 (dd, 1H, CH py, H2), 7.76 (dd, 1H, CH py, 
H3), 8.57 (dd, 1H, CH py, H1), 15.51 (s, 1H, NH, N3). 13C NMR (DMSO-d6): δ = 20.0 (CH2, C6), 26.3 
(CH2, C5), 27.4 (CH2, C7), 40.7 (CH3, C11,12), 125.1 (Cpy, C2), 137.1 (Cq, C4), 137.7 (Cpy, C3), 141.6 




The first two steps were prepared according to a modified procedure from reference [212]. 
Synthesis of 2-((cyclohexyl(methyl)carbomothioyl)thio)acetic acid (2a):  
N-Methylcyclohexylamine (1.3 mL, 10.0 mmol, 1 eq.) was added to 1M NaOH (12 mL), 
resulting in a white suspension. This suspension was stirred while 0.6 mL of carbon disulfide (10.0 
mmol, 1 eq.) was added dropwise. A yellow precipitate was formed, and the mixture was stirred for 20 
min. Then, sodium chloroacetate (1.16 g, 10.0 mmol, 1 eq.) in water (8 mL) was added. The mixture 
was stirred for 18 h at room temperature. After that, concentrated HCl (30 drops) was added to the yellow 
solution and the resulting white precipitate (2a, see Figure 50) was separated by filtration, washed with 
water, dried under vacuum and used in the next step without further purification. Yield: 1.89 g (76%). 
1H-NMR (DMSO-d6): δ = 1.16-1.83 (m, 10H, CH2 cyclohexyl), 3.20 (s, 3H, NCH3), 4.09 (s, 2H, CH2), 
4.34-5.27 (m, 1H, CH cyclohexyl), 12.78 (br, 1H, OH). 
 
Synthesis of N-cyclohexyl-N-methylhydrazinecarbothioamide (2b): 
Compound 2a (1.04 g, 4.23 mmol, 1 eq.) was dissolved in hydrazine hydrate (5 mL, 0.10 mol, 
excess) and 2 mL of water was added. The mixture was stirred at 50-60 ºC for 2 h. A white precipitate 
(2b, see Figure 50) was formed, which was filtered, washed with water, dried under vacuum and used 
in the next step without further purification. Yield: 1.05 g (75%). 1H-NMR (DMSO-d6): δ = 1.04-1.76 
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(m, 10H, CH2 cyclohexyl), 2.85 (s, 1H, CH cyclohexyl), 3.34 (s, 3H, NCH3), 4.70 (s, 1H, NH), 4.85 (s, 




Compound 2b (0.58 g, 3.12 mmol, 1 eq.) was suspended in isopropanol (8 mL), and the mixture 
was stirred at 80 ºC. Then, 5,6,7,8-tetrahydroquinolin-8-one (0.46 g, 3.12 mmol, 1 eq.) was added, and 
the mixture was stirred under reflux for 3 h. A yellow solid was formed, which was separated by 
filtration, washed with cold isopropanol and dried under vacuum. Yield: 0.59 g (60%). Elemental 
analysis: Calcd. For C17H24N4S (%): C, 64.52 ; H, 7.64 ; N, 17.70 ; S, 10.13. Found (%): C, 64.24 ; H, 
7.64 ; N, 17.65 ; S, 9.94. ESI-MS in ACN/MeOH + 1% H2O (positive): m/z 339.1607, [HL + Na]
+.  1H-
NMR (DMSO-d6): Major isomer (97%) δ = 1.12 (m, 2H, CH2, H14), 1.50 (m, 2H, CH2, H12,16), 1.64 
(m, 2H, CH2, H13,15), 1.96 (quint, 2H, CH2, H6), 2.88 (t, 2H, CH2, H7), 3.04 (t, 2H, CH2, H5), 3.23 (s, 
3H, NCH3, H17), 5.09 (s, 1H, CH, H11), 7.41 (dd, 1H, CH py, H2), 7.76 (dd, 1H, CH py, H3), 8.58 (dd, 
1H, CH py, H1), 14.65 (s, 1H, NH, N3). 13C NMR (DMSO-d6): δ = 20.0 (CH2, C6), 25.1 (CH2, C13,15), 
25.4 (CH2, C14), 26.2 (CH2, C5), 27.2 (CH2, C7), 29.5 (CH2, C12,16), 30.1 (CH3, C17), 58.4 (CH, C11), 
125.0 (Cpy, C2), 135.9 (Cq, C4), 137.7 (Cpy, C3), 144.2 (Cq, C9), 148.2 (Cpy, C1), 148.4 (C=N, C8), 183.8 
(C=S, C10). 1H-NMR (DMSO-d6): Minor isomer (3%) δ = 15.38 (s, 1H, NH, N3). 
 
Synthesis of the iron(III) complex with COTI-2 (Fe-COTI-2) 
COTI-2 (0.20 g, 0.54 mmol, 2 eq.) was suspended in methanol (10 mL) and stirred at 50 ºC. 
Next, a solution of iron(III) nitrate nonahydrate (0.13 g, 0.30 mmol, 1.1 eq.) in methanol (2 mL) was 
added dropwise. A dark green solution was formed, which was stirred under reflux for 2 h. The solvent 
volume was reduced by evaporation under reduced pressure and the solution was cooled in the freezer 
overnight. On the next day a dark brown-greenish solid was formed, which was filtered, washed with 
cold methanol, and dried under vacuum. Yield: 21%. Elemental analysis: Calcd. For 
[Fe(C19H22N6S)2](NO3)3·3H2O (%): C, 44.36 ; H, 4.90 ; N, 20.42 ; S, 6.23. Found (%): C, 44.61 ; H, 
4.48 ; N, 20.08 ; S, 6.17. ESI-MS in ACN/MeOH + 1% H2O (positive): m/z 393.60, [ML(HL)]
2+ ; 786.24, 
[ML2]






Synthesis of the copper(II) complex with COTI-2 (Cu-COTI-2) 
Copper(II) chloride dihydrate (0.17 g, 1.0 mmol, 1,1 eq.) was dissolved in methanol (10 mL) at 
40 ºC, and concentrated HCl (134 µL) was added. Next, a suspension of COTI-2 (0.30 g, 0.8 mmol, 1 
eq.) was added dropwise to the copper(II) solution. A dark green solid was formed. The mixture was 
stirred for 2 h, and the solid was filtered and washed with cold methanol and diethyl ether and dried 
under vacuum. Yield: 0.28 g (72%). Elemental analysis: Calcd. For [CuCl2(C19H22N6S)] (%): C, 45.56; 
H, 4.43; N, 16.78; S, 6.40. Found (%): C, 45.25; H, 4.41; N, 16.47; S, 6.14. ESI-MS in ACN/MeOH + 
1% H2O (positive): m/z 214.5, [M(HL)]
2+ ; 428.09, [ML]+. The synthesis was repeated without HCl, 
yielding the same complex (Calcd. For [CuCl2(C19H22N6S)·0.25H2O] (%): C, 45.15; H, 4.49; N, 16.63; 
S, 6.34. Found (%): C, 44.85; H, 4.39; N, 16.47; S, 6.36). Green crystals were obtained by slow 
evaporation of the mother-liquor from the synthesis without HCl. The complex is partially soluble in 
DMSO. 
 
Synthesis of the zinc(II) complex with COTI-2 (Zn-COTI-2) 
COTI-2 (0.10 g, 0.28 mmol, 1 eq.) was suspended in methanol (5 mL) at 50 ºC under stirring. 
Next, a solution of zinc(II) chloride (0.06 g, 0.31 mmol, 1.1 eq.) in methanol (5 mL) was added dropwise 
at 50 ºC. A pale-yellow solid was formed, which was stirred at 50 ºC for 20 min. The solid was separated 
by filtration, washed with cold methanol and diethyl ether, and dried under vacuum. Yield: 0.10 g (71%). 
Elemental analysis: Calcd. For [ZnCl2(C19H22N6S)]·0.5H2O (%): C, 44.59 ; H, 4.53 ; N, 16.42 ; S, 6.26. 
Found (%): C, 44.72 ; H, 4.24 ; N, 16.20 ; S, 6.23. ESI-MS in ACN/MeOH + 1% H2O (positive): m/z 
429.38, [ML]+. 1H-NMR (D2O): δ = 1.96 (quint, 2H, CH2, H6), 2.92 (t, 2H, CH2, H7), 2.97 (t, 2H, CH2, 
H5), 3.79 (m, 2H, CH2, H12,13), 4.18 (m, 2H, CH2, H11,14), 6.92 (t, 1H, CH, H16), 7.21 (m, 1H, CH, 
H18), 7.48 (dd, 1H, CH py, H2), 7.70 (d, 1H, CH py, H3), 7.84 (dd, 1H, CH, H19), 7.95 (t, 1H, CH, 
H17), 8.34 (d, 1H, CH py, H1). The complex is slighlty soluble in DMSO and partially soluble in water. 
 
Cell culture 
 The following human cell line and chemoresistant sublines were used: the colon carcinoma cell 
line SW480 (from American Type Culture Collection, Manassas, VA), and the drug resistant lines 
SW480/COTI and SW480/tria (generated by continuous exposure of SW480 cells to increasing 
concentrations of COTI-2 and Triapine, respectively). Cells were grown in minimal essential medium 
with 10% fetal bovine serum (FBS). To maintain the resistance of the chemoresistant lines, compounds 
(COTI-2 and Triapine) were administered to the cells once a week at the day after passage, when cells 




 Cells were seeded (2x104 cells/well for SW480 and SW480/COTI; 3x104 cells/well for 
SW480/tria) in 100 µL/well in 96-well plates and allowed to attach for 24 h at 37 ºC and 5% CO2. 
Compounds were diluted in DMSO and then further diluted in growth medium (DMSO concentration < 
1%), being added in 100 µL/well, affording the final concentrations of 0, 0.005, 0.01, 0.05, 0.1, 1, 5, 10 
and 20 µM, depending on the compound and the cell line (see Table A6, Appendix). Afterwards, cells 
were exposed for 72 h, being incubated at 37 ºC and 5% CO2. The proportion of viable cells was 
determined by 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium assay (MTT) following the 
manufacturer’s recommendations (EZ4U, Biomedica, Vienna, Austria). Cytotoxicity was expressed as 
IC50 values (drug concentrations inducing 50% reduction of cell survival in comparison to the control 






Results and Discussion 
Syntheses and characterizations 
  COTI-2 and three derivatives with N4-modifications were synthesized by different methods. 
COTI-2 was obtained in a three-step procedure, starting with the piperazine insertion to 
thiocarbonyldiimidazole (1a, Figure 49). Next, the COTI-2 thiosemicarbazide (1b, Figure 49) was 
prepared by reaction of 1a with hydrazine hydrate, and at last, 1b was condensed with the appropriate 




Figure 49. Synthetic route for COTI-2 
 
For the COTI-Nchexyl derivative a different route was used, starting with the obtainment of the 
differentiated N4-moiety by reacting carbon disulfide with N-methyl-cyclohexylamine and sodium 
chloroacetate (2a, Figure 50). The thiosemicarbazide (2b, Figure 50) was obtained by reacting 2a with 
hydrazine hydrate, and the COTI-Nchexyl was obtained by the condensation of 2b with the ketone. 
COTI-NH2 and COTI-NMe2 were obtained by the simple condensation of the ketone with the 

































Figure 50. Synthetic route for COTI-Nchexyl. 
 
The 1H NMR spectra of the different COTI-derivatives in dimethylsulfoxide-d6 (DMSO-d6) 
show interesting trends. Despite COTI-NH2, which only shows one isomer in solution, COTI-2 and the 
other two N4-substituted compounds show two isomers. Due to the high chemical shifts observed for 
the N-H proton (in the range of 14.5 - 15.5 ppm), it can be affirmed that the Z-isomer and E’-isomer are 
observed, which present intramolecular hydrogen bonding [213]. For the E-isomer (no intramolecular 
hydrogen bonding) it is reported that the N-H signal appears around 9.0 ppm [213], and it was not 
observed for COTI-2 or the COTI-derivatives here presented (the different isomers for COTI-2 are 
represented in Figure 51). 
 
Figure 51. Different possible isomers of COTI-2. 
 
The metal compounds were obtained by reaction of COTI-2 with appropriate metal salts. For 





























with 1:2 metal ligand ratio, with two protonated ligands and a (+3) charge, with three nitrates as counter-
ions. This composition is different from what was observed for the iron(III) complex with Triapine, in 
which both ligands are deprotonated and the complex presents a (+1) charge and one nitrate as counter-
ion [195]. For the copper(II) and zinc(II) complexes (Cu-COTI-2 and Zn-COTI-2, respectively) COTI-
2 was reacted with  the CuCl2·2H2O and ZnCl2 metal salts, yielding complexes with 1:1 metal ligand 
ratios, where two chloride ions are coordinated to the metal center, in addition to one protonated ligand. 
This composition was observed for other Cu(II) and Zn(II) thiosemicarbazone complexes [214,215]. 
Regarding the mass spectra, the isotopic patterns of the signals fit well with the theoretical 
isotopic distributions of the complexes. In this way, considering the compositions based on elemental 
analysis and mass spectrometry, Figure 52 shows the proposed structures for the complexes.  
 
Figure 52. Proposed structures for Fe(III), Cu(II), and Zn(II) complexes with COTI-2. 
 
Single crystal X-ray diffraction 
 Crystals were obtained for COTI-2 and Cu-COTI-2, which were suitable for analysis by single 
crystal X-ray diffraction technique. The solved structure for COTI-2 crystal is presented in Figure 53, 







Figure 53. ORTEP plot of COTI-2 with atom numbering. Ellipsoids are drawn at 50% probability level. 
Selected bond lengths (Å) and bond angles (º): C8–N2 1.300(9), N2–N3 1.354(3), N3–C10 1.351(8), 
C10–S 1.717(1), C10–N4 1.361(4); N1–C9–C8 116.3, N2–N3–C10 112.0. 
 
Table 15. Crystal data for COTI-2. 
Chemical formula C19H22N6S Crystal system triclinic 
Formula weight 
[g/mol] 
366.48 Space group P-1 
Temperature [K] 100 Z 2 
Measurement 
method 










Crystal size / [mm
3
] 0.1 × 0.08 × 0.04   7.7749(2) 89.3429(7) 
Crystal habit clear brown block   16.8747(3) 80.2082(8) 






















Table 16. Data collection and structure refinement for COTI-2. 
Index ranges 
-9 ≤ h ≤ 9, -10 ≤ k ≤ 
10, -23 ≤ l ≤ 22 
Theta range for 
data collection 
[°] 
4.892 to 60.168 
Reflections number              30290 
Data / restraints 
/ parameters 
5204/0/239 
Refinement method Least squares 
Final R indices 
all data 
R1 = 0.0711, 
wR2 = 0.1308 
Function minimized Σ w(Fo
2 - Fc
2)2  I>2σ(I) 
R1 = 0.0565, 









Largest diff. peak 







COTI-2 crystalized in the triclinic P1̅ space group. Selected bond distances and angles are 
quoted in the legend of Figure 53. COTI-2 crystal adopted the E’-isomeric form [213] (also observed in 
NMR spectrum, see Figure 51), in which an intramolecular hydrogen bonding is observed between N1, 
S1, and the hydrogen H–N2. The parameters for this hydrogen bonding (bond lengths and angles) are as 
follows: N1···H 2.28 Å, N1···N2 2.67 Å, N2–H···N1 106.8 °, S1···H 2.35 Å, N2···S1 2.85 Å, N2–
H···S1 116.4 °, N2–H 0.880(0) Å. Also, the piperazine moiety is in a chair configuration, while the 
cyclohexyl from the tetrahydroquinolin moiety is in a half-chair configuration. 
The structure for Cu-COTI-2 crystal is presented in Figure 54, and Tables 17 and 18 show the 
crystal data, data collection and structure refinement details for Cu-COTI-2. It is important to note here 
that the crystal structure obtained for Cu-COTI-2 differs from the one proposed for the powder sample 
(see Figure 52), since crystals were obtained from slow evaporation of the mother-liquor and 





Figure 54. ORTEP plot of the asymmetric unit of Cu-COTI-2 crystals with atom numbering. Ellipsoids 
are drawn at 50% probability level. Selected bond lengths (Å) and bond angles (º): Cu–Cl 2.255(8), N1–
Cu 2.029(9) Å, N2–Cu 1.961(3), S1–Cu 2.268(2) Å, Cl–Cu–S 97.8, N1–Cu–N2 80.9, N2–Cu–S 84.2, 
N1–Cu1–Cl 96.3. 
 
Table 17. Crystal data for Cu-COTI-2. 
Chemical formula C19H21ClCuN6S Crystal system triclinic 
Formula weight 
[g/mol] 
464.47 Space group P-1 
Temperature [K] 100 Z 2 
Measurement 
method 










Crystal size / [mm
3
] 0.2 × 0.15 × 0.05   10.6920(3) 83.7478(8) 
Crystal habit clear green block   11.7233(3) 86.5583(8) 





















Table 18. Data collection and structure refinement for Cu-COTI-2. 
Index ranges 
-9 ≤ h ≤ 9, -13 ≤ k 




8.314 to 144.116 





Refinement method Least squares 
Final R indices 
all data 
R1 = 0.0319, wR2 = 
0.0811 
Function minimized Σ w(Fo
2 - Fc
2)2  I>2σ(I) 












Largest diff. peak 







Cu-COTI-2 also crystalized in the triclinic P1̅ space group. While Figure 54 shows the 
asymmetric unit of the complex, Figure 55 shows two bridging chlorido anions which are observed in 
between the copper(II) centers, what has already been reported for copper(II) complexes [216–219]. 
Selected bond distances and angles are quoted in the legend of Figure 54, and are in agreement with 
distances and angles of the copper(II) complex with Triapine previously reported [214]. The copper-
copper distance is Cu···Cu 3.52 Å and the angle in between the copper ion and the chloride ligands is 
of Cl–Cu–Cl’ 191.2 °. The copper(II) ion here presents the coordination number of five, being in a 
square-pyramidal geometry, where N1, N2, S1 and Cl1 are the base of the pyramid (forming the 
asymmetric unit of the complex), and the Cl’ from another unit is in the axial position (2.749 Å). The 
C10–S1 bond length is of 1.754 Å, showing the elongation of the C–S bond due to coordination to Cu(II) 







Figure 55. Structure of the Cu-COTI-2 complex, showing the bridging chlorido ions (in green) between 
the copper(II) centers (in purple). Hydrogen atoms were omitted for clarity and only non-carbon atoms 
are discriminated. 
 
Cytotoxicity in SW480 cells 
 Cytotoxicity of COTI-2, COTI-derivatives and metal complexes was determined by 
concentration-response curves (0.005 – 20 µM, depending on the compound – concentration range for 
each compound can be found in Table A6 in Appendix) based on the MTT assay. Results are 











Table 19. Cytotoxic activity of COTI-2, COTI-derivatives and metal complexes with COTI-2 over 



















 (parental x tria) 
COTI-2 0.56 ± 0.16 6.87 ± 0.29 12.2 0.41 ± 0.16 0.7 
COTI-NH2 7.78 ± 1.03 4.39 ± 0.56 0.6 >20 >2.6 
COTI-NMe2 0.07 ± 0.01 0.08 ± 0.01 1.1 0.07 ± 0.01 1.0 
COTI-Nchexyl 0.64 ± 0.10 3.98 ± 0.40 6.2 0.71 ± 0.17 1.1 
Fe-COTI-2 7.10 ± 1.32 7.46 ± 0.78 1.1 3.23 ± 0.10 0.5 
Cu-COTI-2 0.06 ± 0.01 0.46 ± 0.05 8.0 0.07 ± 0.01 1.1 
Zn-COTI-2 0.12 ± 0.06 4.00 ± 0.28 33.0 0.13 ± 0.07 1.0 
Triapine 0.77 ± 0.18 0.81 ± 0.08 1.1 >20 >26 
a) IC50 values were calculated from concentration-response curves. Values are given as mean ± 
SD of three independent experiments, in triplicates. 
b) Differences in sensitivity calculated by dividing the IC50 values of the chemoresistant subline by 
those of the parental line. 
 
The SW480/COTI resistant cell line was generated by continuous exposure of SW480 cells to 
increasing concentrations of COTI-2 over a period of approximately one year. COTI-2 was administered 
to the cells once a week at the day after passage, when cells had attached to the cell culture flasks, which 
was the same protocol adopted to generate the SW480/tria cells [220]. 
As observed in Table 18, the SW480/COTI presented a 12-fold resistance to COTI-2 when 
compared to the parental line. Interestingly, the SW480/COTI line also presented resistance to COTI-
Nchexyl (6-fold), Cu-COTI-2 (8-fold), and Zn-COTI-2 (33-fold). However, it was not resistant to COTI-
NMe2, which was the only compound active over the SW480/COTI line in the nanomolar range (IC50 = 
0.08 µM). This shows that the terminal dimethylation not only enhanced the activity of the 
thiosemicarbazone [195], as it could overcome the resistance mechanism [196]. 
The SW480/COTI line was also not resistant to Fe-COTI-2, however it presented high IC50 
values when compared to the other compounds (12-7 fold when compared to COTI-2 against the SW480 
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line, and 1.1-fold when compared to COTI-2 against the SW480/COTI line). The same was observed 
for COTI-NH2, but in this case it presented a collateral sensitivity, being more active in the SW480/COTI 
than in the parental line (0.6-fold), what was unexpected. Also, this compound was the only COTI-
derivative to which the SW480/tria cells were resistant (2.6-fold). This is probably due to the terminal-
NH2 of COTI-NH2 and Triapine, showing that this structural feature may be related to the acquired 
resistance to Triapine. 
Despite COTI-NH2, COTI-2 and the other compounds did not present cross-resistance to 
Triapine. These results can be better observed in the dose-response curves, which are comprised in 




Figure 56. Concentration-response curves for COTI-2, COTI-NH2, COTI-NMe2 and COTI-Nchexyl 
over the SW480 line and the chemoresistant lines SW480/COTI and SW480/tria. 




























































Figure 57. Concentration-response curves for Triapine, Fe-COTI-2, Cu-COTI-2 and Zn-COTI-2 over 
the SW480 line and the chemoresistant lines SW480/COTI and SW480/tria. 
 
It was previously shown that the SW480/tria line overexpresses P-gp, this being an acquired 
resistance mechanism of SW480 to Triapine [220]. It can be supposed that ABC-transporter 
overexpression may be related to the acquired resistance of SW480/COTI, since this was previously 
observed for thiosemicarbazones [196,221]. Due to the absence of cross-resistance between Triapine 
and COTI-2, the resistance mechanism of SW480/COTI may not be overexpression of P-gp, but of 
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 COTI-2, as well as three COTI-derivatives with N4-terminal modifications, COTI-NH2, COTI-
NMe2 and COTI-Nchexyl, were synthesized and characterized, as well as three metal complexes of 
Fe(III), Cu(II) and Zn(II) with COTI-2. All compounds had their cytotoxic activities evaluated in SW480 
cells by the MTT assay. For the parental cell line COTI-NMe2 (IC50 = 0.07 µM), Cu-COTI-2 (IC50 = 
0.06 µM), Zn-COTI-2 (IC50 = 0.12 µM) presented a better activity when compared to COTI-2 (IC50 = 
0.56 µM). The COTI-NH2 compound presented cross-resistance to Triapine, showing that the terminal-
NH2 may play a role in Triapine resistance. The SW480/COTI line presented a 12.2-fold resistance to 
COTI-2 when compared to the parental line, and the COTI-NMe2 could overcome the resistance of 
SW480/COTI (IC50 = 0.08 µM), showing that the terminal dimethylation not only enhanced the activity 






















In the first part of the Thesis five complexes with 5-fluorouracil, 2-thiouracil and 2,4-dithiouracil 
were described. The Ag-5fu, complex presented a 3:2 metal/ligand composition, with formula 
[Ag3(C4HFN2O2)(C4H2FN2O2)]. The Pd-5fu presented a 2:1 metal/ligand composition, with formula 
K[PdCl(C4H2FN2O2)2], and the Pt-5fu complex also presented a 2:1 metal/ligand composition, with 
formula K2[PtCl2(C4H2FN2O2)2]. The [Ag2(dtu)] complex presented a 2:1 metal ligand composition, 
with formula [Ag2(C4H2N2S2)], and the triphenylphosphinegold(I) complex with 2-thiouracil, Ph3P-Au-
tuH, presented a 1:1 metal/ligand composition, with formula [Au(C4H2N2OS)(C18H15)]. For this last 
complex the crystal structure shows the coordination of the 2-thiouracilato ligand to gold(I) by its thiol 
group. The Ag-5fu complex presented the best antiproliferative profile among the complexes with 5fu, 
and its activity seems to be a combination of the activities of 5fu and silver(I). Also, Ag-5fu presented 
a better activity than free 5fu and cisplatin over the NCI/ADR-RES cell line. Considering the complexes 
with thiouracils, the [Ag2(dtu)] complex presented no antiproliferative activity, probably due to its lack 
of solubility. The Ph3P-Au-tuH complex and its precursor complex, Ph3P-Au-Cl, showed interesting 
antiproliferative profiles, while the Ph3P-Au-tuH complex showed a better activity than doxorubicin 
over the K562 cell line and a better activity when compared to Ph3P-Au-Cl over the NCI-H460 line. 
The Ag-5fu and Ph3P-Au-tuH complexes were chosen to have their mechanisms of cell death 
studied in NCI/ADR-RES and NCI-H460 cells, respectively. Both compounds were evaluated by colony 
formation capacity and flow cytometry assays to analyze cell cycle and cell death induction 
[phosphatidylserine residues exposition, multicaspases activation, and mitochondrial membrane 
depolarization]. It was shown that the Ag-5fu complex may induce regulated cell death in NCI-
ADR/RES cells considering mitochondrial membrane depolarization, PS externalization and 
multicaspases activation. Moreover, the Ag-5fu complex promoted cell cycle arrest at G1 and inhibited 
colony formation, indicating that the cancer cells, which do not go through a regulated cell death 
pathway, lost their proliferation ability.  
Considering Ph3P-Au-tuH and Ph3P-Au-Cl, both compounds induced regulated cell death in 
NCI-H460 cells, considering PS externalization and multicaspases activation. Also, both compounds 
promoted cell cycle arrest at G1 and inhibited colony formation. For the gold(I) complexes only Ph3P-
Au-tuH showed mitochondrial membrane depolarization. 
The second part of the Thesis was based on the thiosemicarbazone COTI-2. COTI-2 and COTI-
derivatives, as well as the first metal complexes of Fe(III), Cu(II), and Zn(II) with COTI-2, were 
synthesized and characterized. All compounds had their cytotoxic activities evaluated in vitro by the 
MTT assay over the SW480 tumor cell line, and SW480 chemoresistant lines. COTI-2 presented a 12.2-
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fold resistance when comparing the SW480 parental line to the SW480/COTI resistant one. Despite 
COTI-NH2, all other COTI-derivatives and the metal complexes did not present cross-resistance to 
Triapine. The COTI-NMe2 not only presented an enhanced activity when compared to COTI-2, as it 
could overcome the resistance mechanism of the SW480/COTI line. The Cu-COTI-2 complex presented 






[1] INCA, O que é câncer, (2019). https://www.inca.gov.br/o-que-e-cancer (accessed August 5, 
2019). 
[2] National Cancer Institute, What is cancer?, (2015). https://www.cancer.gov/about-
cancer/understanding/what-is-cancer (accessed August 5, 2019). 
[3] American Cancer Society, Oncogenes and tumor suppressor genes, (2014). 
https://www.cancer.org/cancer/cancer-causes/genetics/genes-and-cancer/oncogenes-tumor-
suppressor-genes.html (accessed October 1, 2019). 
[4] The Cancer Atlas, Major cancer risk factors include tobacco, infections, diet and body 
composition, and UV radiation, (2019). http://canceratlas.cancer.org/risk-factors/cancer-risk-
factors/ (accessed August 5, 2019). 
[5] INCA, O que causa câncer, (2018). https://www.inca.gov.br/causas-e-prevencao/o-que-causa-
cancer (accessed August 5, 2019). 
[6] The Cancer Atlas, Smoking causes more than 16 types of cancer and accounts for a fifth of all 
global cancer deaths, (2019). http://canceratlas.cancer.org/risk-factors/tobacco/ (accessed 
August 5, 2019). 
[7] The Cancer Atlas, UV radiation causes cancers of the skin—the most common cancers, (2019). 
http://canceratlas.cancer.org/risk-factors/ultraviolet-radiation/ (accessed August 5, 2019). 
[8] National Cancer Institute, Infectious agents, (2019). https://www.cancer.gov/about-
cancer/causes-prevention/risk/infectious-agents (accessed August 5, 2019). 
[9] The Cancer Atlas, Many of the most common cancers are attributable to infection, (2019). 




[10] National Cancer Institute, Risk factors for cancer, (2015). https://www.cancer.gov/about-
cancer/causes-prevention/risk (accessed December 4, 2018). 
[11] World Health Organization, All cancers fact sheet, (2018). 
http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf (accessed August 
5, 2019). 
[12] World Health Organization, Brazil fact sheets on cancer, (2018). 
http://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf (accessed August 5, 
2019). 
[13] INCA, Estatísticas do câncer, (2019). https://www.inca.gov.br/numeros-de-cancer (accessed 
August 5, 2019). 
[14] American Cancer Society, Early History of Cancer, (2018). 
https://www.cancer.org/cancer/cancer-basics/history-of-cancer/what-is-cancer.html (accessed 
August 5, 2019). 
[15] Akulapalli Sudhakar, History of Cancer, Ancient and Modern Treatment Methods, J Cancer Sci 
Ther. 1 (2009) 1–4. doi:10.4172/1948-5956.100000e2.History. 
[16] American Cancer Society, Cancer in the Sixteenth to Eighteenth Centuries, (2014). 
https://www.cancer.org/cancer/cancer-basics/history-of-cancer/sixteenth-to-eighteenth-
centuries.html (accessed August 5, 2019). 
[17] American Cancer Society, Cancer in the Nineteenth Century, (2014). 
https://www.cancer.org/cancer/cancer-basics/history-of-cancer/nineteenth-century.html 
(accessed August 5, 2019). 
[18] D. Hanahan, R.A. Weinberg, The Hallmarks of Cancer, Cell. 100 (2000) 57–70. 
doi:10.1007/s00262-010-0968-0. 




[20] National Cancer Institute, Types of Cancer Treatment, (2019). https://www.cancer.gov/about-
cancer/treatment/types (accessed August 5, 2019). 
[21] V.T. DeVita, E. Chu, A history of cancer chemotherapy, Cancer Res. 68 (2008) 8643–8653. 
doi:10.1158/0008-5472.CAN-07-6611. 
[22] Cancer Treatment Centers of America, Chemotherapy, (2019). 
https://www.cancercenter.com/treatments/chemotherapy/ (accessed August 5, 2019). 
[23] S.Y. Qin, Y.J. Cheng, Q. Lei, A.Q. Zhang, X.Z. Zhang, Combinational strategy for high-
performance cancer chemotherapy, Biomaterials. 171 (2018) 178–197. 
doi:10.1016/j.biomaterials.2018.04.027. 
[24] M.W. English, Principles of chemotherapy, Paediatr. Child Health (Oxford). 20 (2010) 123–128. 
doi:10.1016/j.paed.2009.10.003. 
[25] E. Dickens, S. Ahmed, Principles of cancer treatment by chemotherapy, Surg. (United Kingdom). 
36 (2018) 134–138. doi:10.1016/j.mpsur.2017.12.002. 
[26] H.S. Walter, S. Ahmed, Targeted therapies in cancer, Surg. (United Kingdom). 36 (2018) 134–
138. doi:10.1016/j.mpsur.2017.12.010. 
[27] L. Chiang, M. R. Jones, C. L. Ferreira, T. Storr, Multifunctional Ligands in Medicinal Inorganic 
Chemistry- Current Trends and Future Directions, Curr. Top. Med. Chem. 12 (2012) 122–144. 
doi:10.2174/156802612799078973. 
[28] I. Ott, R. Gust, Non platinum metal complexes as anti-cancer drugs, Arch. Pharm. (Weinheim). 
340 (2007) 117–126. doi:10.1002/ardp.200600151. 
[29] U. Ndagi, N. Mhlongo, M. Soliman, Metal complexes in cancer therapy – an update from drug 
design perspective, Drug Des. Devel. Ther. 11 (2017) 599–616. doi:10.2147/DDDT.S119488. 




[31] Q.P.D. D. Chen, V. Milacic, M. Frezza, Metal Complexes, their Cellular Targets and Potential 
for Cancer Therapy, Curr. Pharm. Des. (2009) 777–791. doi:10.2174/138161209787582183. 
[32] H.J. Klasen, Historical review of the use of silver in the treatment of burns. I. Early uses, Burns. 
26 (2000) 117–130. doi:https://doi.org/10.1016/S0305-4179(99)00108-4. 
[33] T.C. Johnstone, K. Suntharalingam, S.J. Lippard, Third row transition metals for the treatment 
of cancer, Philos. Trans. A. 373 (2014) 1–12. doi:10.1098/rsta.2014.0185. 
[34] C.S. Allardyce, P.J. Dyson, Metal-based drugs that break the rules, Dalt. Trans. 45 (2016) 3201–
3209. doi:10.1039/c5dt03919c. 
[35] B. Rosenberg, L. VanCamp, J.E. Trosko, V.H. Mansou, Platinum compounds: a new class of 
potent antitumor agents, Nature. 222 (1969) 385–386. 
[36] S. Dasari, P.B. Tchounwou, Cisplatin in cancer therapy: Molecular mechanisms of action, Eur. 
J. Pharmacol. 740 (2014) 364–378. doi:10.1016/j.ejphar.2014.07.025. 
[37] B. Rosenberg, L. Van Camp, T. Krigas, Inhibition of Cell Division in Escherichia coli by 
Electrolysis Products from a Platinum Electrode, Nature. 205 (1965) 698–699. 
doi:10.1038/205698a0. 
[38] B. Rosenberg, L. VanCamp, The Successful Regression of Large Solid Sarcoma 180 Tumors by 
Platinum Compounds, Cancer Res. 30 (1970) 1799–1802. 
[39] Food and Drug Administration, FDA Approved Drug - Cisplatin, (1978). 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplN
o=018057 (accessed December 19, 2018). 
[40] F. Trudu, F. Amato, P. Vaňhara, T. Pivetta, E.M. Peña-Méndez, J. Havel, Coordination 
compounds in cancer: Past, present and perspectives, J. Appl. Biomed. 13 (2015) 79–103. 
doi:10.1016/j.jab.2015.03.003. 
[41] J.A. Mello, S. Acharya, R. Fishe, J.M. Essigmann, The mismatch-repair protein hMSH2 binds 
selectively to DNA adducts of the anticancer drug cisplatin, Chem. Biol. 3 (1996) 579–589. 
131 
 
[42] S.J. Lippard, U.-M. Ohndorf, M.A. Rould, Q. He, C.O. Pabo, Basis for recognition of cisplatin-
modified DNA by high-mobility-group proteins, Nature. 399 (1999) 708–712. 
doi:10.1038/21460. 
[43] E.R. Jamieson, S.J. Lippard, Structure, Recognition, and Processing of Cisplatin − DNA 
Adducts, (1999). 
[44] L. Kelland, The resurgence of platinum-based cancer chemotherapy., Nat. Rev. Cancer. 7 (2007) 
573–584. doi:10.1038/nrc2167. 
[45] R.J. Knox, F. Friedlos, D.A. Lydall, J.J. Roberts, Mechanism of Cytotoxicity of Anticancer 
Platinum Drugs: Evidence and cis-Diammine Differ Only in the Kinetics of Their Interaction 
with DNA, Cancer Res. 46 (1986) 1972–1979. 
[46] D.J. Stewart, Mechanisms of resistance to cisplatin and carboplatin, Crit. Rev. Oncol. Hematol. 
63 (2007) 12–31. doi:10.1016/j.critrevonc.2007.02.001. 
[47] R.E. Meyn, S.F. Jenkins, L.H. Thompson, Defective Removal of DNA Cross-Links in a Repair-
Deficient Mutant of Chinese Hamster Cells, Cancer Res. 42 (1982) 3106–3110. 
[48] D. Fink, S. Nebel, S. Aebi, H. Zheng, B. Cenm, A. Nehmã, D. Christen, S.B. Howell, The Role 
of DNA Mismatch Repair in Platinum Drug Resistance, Cancer Res. 56 (1996) 4881–4886. 
[49] Z.Z. Zdraveski, J.A. Mello, C.K. Farinelli, J.M. Essigmann, M.G. Marinus, MutS preferentially 
recognizes cisplatin-over oxaliplatin-modified DNA, J. Biol. Chem. 277 (2002) 1255–1260. 
doi:10.1074/jbc.M105382200. 
[50] N. Farrell, L. Kelland, J. Roberts, M. Van Beusichem, Trans geometry in platinum antitumor 
complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine 






[51] M. Van Beusichem, N. Farrell, Activation of the Trans Geometry in Platinum Antitumor 
Complexes. Synthesis, Characterization, and Biological Activity of Complexes with the Planar 
Ligands Pyridine, N-Methylimidazole, Thiazole, and Quinoline. Crystal and Molecular Structure 
of Trans-Dich, Inorg. Chem. 31 (1992) 634–639. doi:10.1021/ic00030a021. 
[52] V. Brabec, K. Neplechova, J. Kasparkova, N. Farrell, Steric control of DNA interstrand cross-
link sites of trans platinum complexes: Specificity can be dictated by planar nonleaving groups, 
J. Biol. Inorg. Chem. 5 (2000) 364–368. doi:10.1007/PL00010665. 
[53] J.B. Mangrum, N.P. Farrell, Excursions in polynuclear platinum DNA binding, Chem. Commun. 
46 (2010) 6640–6650. doi:10.1039/c0cc01254h. 
[54] S. Komeda, Y. Qu, J.B. Mangrum, A. Hegmans, L.D. Williams, N.P. Farrell, The phosphate 
clamp as recognition motif in platinum-DNA interactions, Inorganica Chim. Acta. 452 (2016) 
25–33. doi:10.1016/j.ica.2016.04.052. 
[55] N.P. Farrell, Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor 
selectivity and new targets, Chem. Soc. Rev. 44 (2015) 8773–8785. doi:10.1039/C5CS00201J. 
[56] M.D. Hall, H.R. Mellor, R. Callaghan, T.W. Hambley, Basis for Design and Development of 
Platinum(IV) Anticancer Complexes, J. Med. Chem. 50 (2007) 3403–3411. 
doi:10.1021/JM070280U. 
[57] A. Eastman, Glutathione-mediated activation of anticancer platinum(IV) complexes, Biochem. 
Pharmacol. 36 (1987) 4177–4178. doi:10.1016/0006-2952(87)90581-8. 
[58] M.D. Hall, W. Hambley, Platinum(IV) antitumour compounds: Their bioinorganic chemistry, 
Coord. Chem. Rev. 232 (2002) 49–67. doi:10.1016/S0010-8545(02)00026-7. 
[59] T.C. Johnstone, K. Suntharalingam, S.J. Lippard, The Next Generation of Platinum Drugs: 





[60] K.R. Barnes, A. Kutikov, S.J. Lippard, Synthesis, characterization, and cytotoxicity of a series 
of estrogen-tethered platinum(IV) complexes, Chem. Biol. 11 (2004) 557–564. doi:10.1016/j. 
[61] S.H. van Rijt, P.J. Sadler, Current applications and future potential for bioinorganic chemistry in 
the development of anticancer drugs, Drug Discov. Today. 14 (2009) 1089–1097. 
doi:10.1016/j.drudis.2009.09.003. 
[62] Z.-F. Chen, C. Orvig, H. Liang, Multi-Target Metal-Based Anticancer Agents, Curr. Top. Med. 
Chem. 17 (2017) 3131–3145. doi:10.2174/1568026617666171004155437. 
[63] T. Lazarević, A. Rilak, Ž.D. Bugarčić, Platinum, palladium, gold and ruthenium complexes as 
anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives, Eur. J. Med. 
Chem. 142 (2017) 8–31. doi:10.1016/j.ejmech.2017.04.007. 
[64] Z.D. Bugarcic, J. Bogojeski, R. van Eldik, Kinetics, mechanism and equilibrium studies on the 
substitution reactions of Pd(II) in reference to Pt(II) complexes with bio-molecules, Coord. 
Chem. Rev. 292 (2015) 91–106. doi:10.1016/j.ccr.2015.02.016. 
[65] E.Z. Jahromi, A. Divsalar, A.A. Saboury, S. Khaleghizadeh, H. Mansouri-Torshizi, I. Kostova, 
Palladium complexes: new candidates for anti-cancer drugs, J. Iran. Chem. Soc. 13 (2016) 967–
989. doi:10.1007/s13738-015-0804-8. 
[66] M.N. Alam, F. Huq, Comprehensive review on tumour active palladium compounds and 









[67] A.R. Azzouzi, S. Vincendeau, E. Barret, A. Cicco, F. Kleinclauss, H.G. van der Poel, C.G. Stief, 
J. Rassweiler, G. Salomon, E. Solsona, A. Alcaraz, T.T. Tammela, D.J. Rosario, F. Gomez-
Veiga, G. Ahlgren, F. Benzaghou, B. Gaillac, B. Amzal, F.M.J. Debruyne, G. Fromont, C. 
Gratzke, M. Emberton, Padeliporfin vascular-targeted photodynamic therapy versus active 
surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, 
randomised controlled trial, Lancet Oncol. 18 (2017) P181-191. doi:10.1016/S1470-
2045(16)30661-1. 
[68] National Cancer Institute, Padeliporfin, (2019). 
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/padeliporfin (accessed 
August 5, 2019). 
[69] B.F.P. Dwyer, E.C.G.Y. Arfas, W.P. Rogers, J.H. Koch, Biological activity of complex ions, 
Nature. 170 (1952) 190–191. 
[70] U. Jungwirth, C.R. Kowol, B.K. Keppler, C.G. Hartinger, W. Berger, P. Heffeter, Anticancer 
Activity of Metal Complexes: Involvement of Redox Processes, Antioxid. Redox Signal. 15 
(2011) 1085–1127. doi:10.1089/ars.2010.3663. 
[71] N. Graf, S.J. Lippard, Redox activation of metal-based prodrugs as a strategy for drug delivery, 
Adv. Drug Deliv. Rev. 64 (2012) 993–1004. doi:10.1016/j.addr.2012.01.007. 
[72] K.D. Mjos, C. Orvig, Metallodrugs in medicinal inorganic chemistry, Chem. Rev. 114 (2014) 
4540–4563. doi:10.1021/cr400460s. 
[73] R. Trondl, P. Heffeter, C.R. Kowol, M.A. Jakupec, W. Berger, B.K. Keppler, NKP-1339, the 
first ruthenium-based anticancer drug on the edge to clinical application, Chem. Sci. 5 (2014) 
2925–2932. doi:10.1039/c3sc53243g. 
[74] E. Reisner, V.B. Arion, B.K. Keppler, A.J.L. Pombeiro, Electron-transfer activated metal-based 




[75] C. Orvig, M.J. Abrams, Medicinal Inorganic Chemistry: Introduction, Chem. Rev. 99 (1999) 
2201–2203. doi:10.1021/cr980419w. 
[76] R.E.F. de Paiva, P.P. Corbi, Bioinorganic applications of gold and platinum coordination 
compounds: a brief historical overview and recent advances in 2017, Int. J. Adv. Med. 
Biotechnol. 1 (2018) 1–6. 
[77] J.H. Bormio Nunes, D.A. Simoni, L.E.O. Braga, A.L.T.G. Ruiz, J. Ernesto de Carvalho, P.P. 
Corbi, Synthesis, characterization, crystal structure and in vitro antiproliferative assays of the 2-
thiouracilato(triphenylphosphine)gold(I) complex, J. Mol. Struct. 1178 (2019) 169–178. 
doi:10.1016/j.molstruc.2018.10.026. 
[78] C. Shaw, Gold-based therapeutic agents, Chem. Rev. 99 (1999) 2589–2600. 
doi:10.1021/cr980431o. 
[79] C. Roder, M.J. Thomson, Auranofin: Repurposing an Old Drug for a Golden New Age, Drugs R 
D. 15 (2015) 13–20. doi:10.1007/s40268-015-0083-y. 
[80] C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli, M.P. Rigobello, Inhibition of 
thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer 
cells, Free Radic. Biol. Med. 42 (2007) 872–881. doi:10.1016/j.freeradbiomed.2006.12.021. 
[81] J.S. Darc Chaves, F. Neumann, T. Martins Francisco, C. Cimini Corrêa, M. Teresa Paz Lopes, 
H. Silva, A.S. Paula Fontes, M. V de Almeida, Synthesis and cytotoxic activity of gold(I) 
complexes containing phosphines and 3-benzyl-1,3-thiazolidine-2-thione or 5-phenyl-1,3,4-








[82] J.S. Darc Chaves, L. Guimar, A. Tunes, C.J. Hebert de Franco, T. Martins Francisco, C. Cimini 
Corr, S.M. Murta, R. Lima Monte-Neto, H. Silva, A.S. Paula Fontes, M. V de Almeida, Novel 
gold(I) complexes with 5-phenyl-1,3,4-oxadiazole-2-thione and phosphine as potential 
anticancer and antileishmanial agents, Eur. J. Med. Chem. 127 (2017) 727–739. 
doi:10.1016/j.ejmech.2016.10.052. 
[83] V. Gandin, A.P. Fernandes, M.P. Rigobello, B. Dani, F. Sorrentino, F. Tisato, M. Bjö Rnstedt, 
A. Bindoli, A. Sturaro, R. Rella, C. Marzano, Cancer cell death induced by phosphine gold(I) 
compounds targeting thioredoxin reductase, Biochem. Pharmacol. 79 (2010) 90–101. 
doi:10.1016/j.bcp.2009.07.023. 
[84] M.P. Chrysouli, C.N. Banti, N. Kourkoumelis, N. Panayiotou, G.S. Markopoulos, A.J. 
Tasiopoulos, S.K. Hadjikakou, Chloro(triphenylphosphine)gold(I) a forefront reagent in gold 
chemistry as apoptotic agent for cancer cells, J. Inorg. Biochem. 179 (2018) 107–120. 
doi:10.1016/j.jinorgbio.2017.11.004. 
[85] H. Scheffler, Y. You, I. Ott, Comparative studies on the cytotoxicity, cellular and nuclear uptake 
of a series of chloro gold(I) phosphine complexes, Polyhedron. 29 (2010) 66–69. 
doi:10.1016/j.poly.2009.06.007. 
[86] C.J. Lima, L. Rodríguez, Phosphine-Gold (I) Compounds as Anticancer Agents: General 
Description and Mechanisms of Action, Anticancer. Agents Med. Chem. 11 (2011) 921–928. 
doi:10.2174/187152011797927670. 
[87] M.J. McKeage, L. Maharaj, S.J. Berners-Price, Mechanisms of cytotoxicity and antitumor 
activity of gold(I) phosphine complexes: The possible role of mitochondria, Coord. Chem. Rev. 
232 (2002) 127–135. doi:10.1016/S0010-8545(02)00048-6. 
[88] F. Caruso, R. Villa, M. Rossi, C. Pettinari, F. Paduano, M. Pennati, M.G. Daidone, N. Zaffaroni, 
Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species 
chlorotriphenylphosphine-1, 3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines, 
Biochem. Pharmacol. 73 (2007) 773–781. doi:10.1016/j.bcp.2006.11.018. 
137 
 
[89] L. Messori, F. Abbate, G. Marcon, P. Orioli, M. Fontani, E. Mini, T. Mazzei, S. Carotti, T. 
O’Connell, P. Zanello, Gold(III) complexes as potential antitumor agents: Solution chemistry 
and cytotoxic properties of some selected gold(III) compounds, J. Med. Chem. 43 (2000) 3541–
3548. doi:10.1021/jm990492u. 
[90] C.L. Fox, Silver Sulfadiazine - A New Topical Therapy for Pseudomonas in Burns, Arch. Surg. 
96 (1968) 184–188. doi:10.1001/archsurg.1968.01330200022004. 
[91] C.L. Fox, S.M. Modak, Mechanism of silver sulfadiazine action on burn wound infections., 
Antimicrob. Agents Chemother. 5 (1974) 582–588. doi:10.1128/AAC.5.6.582. 
[92] S.M. Modak, C.L. Fox, Binding of silver sulfadiazine to the cellular components of Pseudomonas 
aeruginosa, Biochem. Pharmacol. 22 (1973) 2391–2404. doi:10.1016/0006-2952(73)90341-9. 
[93] D.E. Marx, D.J. Barillo, Silver in medicine: The basic science, Burns. 40 (2014) S9–S18. 
doi:10.1016/j.burns.2014.09.010. 
[94] S.J. Tan, Y.K. Yan, P.P.F. Lee, K.H. Lim, Copper, gold and silver compounds as potential new 
anti-tumor metallodrugs, Future Med. Chem. 2 (2010) 1591–1608. doi:10.4155/fmc.10.234. 
[95] C.N. Banti, S.K. Hadjikakou, Anti-proliferative and anti-tumor activity of silver(I) compounds, 
Metallomics. 5 (2013) 569–596. doi:10.1039/c3mt00046j. 
[96] S. Medici, M. Peana, G. Crisponi, V.M. Nurchi, J.I. Lachowicz, M. Remelli, M.A. Zoroddu, 
Silver coordination compounds: A new horizon in medicine, Coord. Chem. Rev. 327–328 (2016) 
349–359. doi:10.1016/j.ccr.2016.05.015. 
[97] M. He, C. He, Z. Yin, Y. Zou, L. Yin, X. Song, Z. Yuan, W. Zhang, C. Lv, X. Liang, S. Luan, 
L. Li, Recent advances in the medical use of silver complex, Eur. J. Med. Chem. 157 (2018) 62–
80. doi:10.1016/j.ejmech.2018.07.057. 
[98] S. Medici, M. Peana, V.M. Nurchi, M.A. Zoroddu, Medical Uses of Silver: History, Myths, and 




[99] R.B.K. Wakshlak, R. Pedahzur, D. Avnir, Antibacterial activity of silver-killed bacteria: The 
“zombies” effect, Sci. Rep. 5 (2015) 1–5. doi:10.1038/srep09555. 
[100] M. Pellei, V. Gandin, M. Marinelli, C. Marzano, M. Yousufuddin, H.V.R. Dias, C. Santini, 
Synthesis and biological activity of ester- and amide-functionalized imidazolium salts and related 
water-soluble coinage metal N-heterocyclic carbene complexes, Inorg. Chem. 51 (2012) 9873–
9882. doi:10.1021/ic3013188. 
[101] M. He, C. He, Z. Yin, Y. Zou, L. Yin, X. Song, Z. Yuan, W. Zhang, C. Lv, X. Liang, S. Luan, 
L. Li, Recent advances in the medical use of silver complex, Eur. J. Med. Chem. 157 (2018) 62–
80. doi:10.1016/j.ejmech.2018.07.057. 
[102] T. Storr, K.H. Thompson, C. Orvig, Design of targeting ligands in medicinal inorganic chemistry, 
Chem. Soc. Rev. 35 (2006) 534–544. doi:10.1039/b514859f. 
[103] C. Isanbor, D. O ’hagan, Fluorine in medicinal chemistry: A review of anti-cancer agents, J. 
Fluor. Chem. 127 (2006) 303–319. doi:10.1016/j.jfluchem.2006.01.011. 
[104] A. Pałasz, D. Cież, In search of uracil derivatives as bioactive agents. Uracils and fused uracils: 
Synthesis, biological activity and applications, Eur. J. Med. Chem. 97 (2015) 582–611. 
doi:10.1016/j.ejmech.2014.10.008. 
[105] H.J. Lenz, S. Stintzing, F. Loupakis, TAS-102, a novel antitumor agent: A review of the 
mechanism of action, Cancer Treat. Rev. 41 (2015) 777–783. doi:10.1016/j.ctrv.2015.06.001. 
[106] D.B. Longley, D.P. Harkin, P.G. Johnston, 5-Fluorouracil: Mechanisms of Action and Clinical 
Strategies., Nat. Rev. Cancer. 3 (2003) 330–338. doi:10.1038/nrc1074. 
[107] J.P. Bégué, D. Bonnet-Delpon, Recent advances (1995-2005) in fluorinated pharmaceuticals 
based on natural products, J. Fluor. Chem. 127 (2006) 992–1012. 
doi:10.1016/j.jfluchem.2006.05.006. 
[108] M.I. Gel’fman, N.A. Kustova, Complexes of Silver(I) with 5-Fluorouracil, Russ. J. Inorg. Chem. 
15 (1970) 47–49. 
139 
 
[109] M.I. Gel’fman, N.A. Kustova, Complexes of Palladium(II) with 5-Fluoro-uracil, Russ. J. Inorg. 
Chem. 14 (1969) 985–988. 
[110] M.I. Gel’fman, N.A. Kustova, Complexes of Platinum(II) with 5-Fluorouracil, Russ. J. Inorg. 
Chem. 15 (1970) 1602–1604. 
[111] J.H.B. Nunes, P.P. de Paiva, A.L.T.G. Ruiz, J.E. de Carvalho, P.P. Corbi, A platinum(II) complex 
with the antitumor drug 5-fluorouracil: synthesis, spectroscopic characterization and biological 
assays, in: J. Biol. Inorg. Chem. - 18th Int. Conf. Biol. Inorg. Chem., 2017: p. S93. 
doi:10.1007/s00775-017-1475-y. 
[112] J.H. Bormio Nunes, F.R.G. Bergamini, W.R. Lustri, P.P. Paiva, A.L.T.G. Ruiz, J.E. Carvalho, 
P.P. Corbi, Synthesis, characterization and in vitro biological assays of a silver(I) complex with 
5-fluorouracil: a strategy to overcome multidrug resistant tumor cells, J. Fluor. Chem. 195 (2017) 
93–101. doi:10.1016/j.jfluchem.2017.01.016. 
[113] G.W. Anderson, I.F. Halverstadt, W.H. Miller, R.O. Roblin, Studies in Chemotherapy. X. 
Antithyroid Compounds. Synthesis of 5- and 6- Substituted 2-Thiouracils from ß-Oxoesters and 
Thiourea, J. Am. Chem. Soc. 67 (1945) 2197–2200. 
[114] M.S. Masoud, O.H.A. El-Hamid, Z.M. Zaki, 2-thiouracil-based cobalt(II), nickel(II) and 
copper(II) complexes, Transit. Met. Chem. 19 (1994) 21–24. 
[115] Y. Wei-Da, H. Yin-Ping, Copper Complexes of 2-Thiouracil, Polyhedron. 9 (1990) 2747–2750. 
[116] L.G. Golubyatnikova, R.А. Khisamutdinov, S.А. Grabovskii, N.N. Kabal’nova, Y.I. Murinov, 
Complexes of Palladium(II) and Platinum(II) with 6-tert-butyl-2-thiouracil, Russ. J. Gen. Chem. 
87 (2017) 117–121. 
[117] D.M.L. Goodgame, G.A. Leach, Complexes of 2-Thiouracil with Some Divalent Metal ions, 
Inorganica Chim. Acta. 37 (1979) L505–L506. 
[118] J.R. Lusty, J. Peeling, M.A. Abdel-aal, Complexes of 6-Methyl-2-thiouracil with Rhodium, 
Iridium, Platinum and Palladium, Inorganica Chim. Acta. 56 (1981) 21–26. 
140 
 
[119] C. Vetter, G.N. Kaluderovic, R. Paschke, R. Kluge, J. Schmidt, D. Steinborn, Synthesis, 
characterization and in vitro cytotoxicity studies of platinum(IV) complexes with thiouracil 
ligands, Inorganica Chim. Acta. 363 (2010) 2452–2460. doi:10.1016/j.ica.2010.03.079. 
[120] M.N. Shaikh, B.A. Al-Maythalony, M.I.M. Wazeer, A.A. Isab, Complexations of 2-thiouracil 
and 2,4-dithiouracil with Cd(SeCN)2 and Hg(SeCN)2: NMR and anti-bacterial activity studies, 
Spectroscopy. 25 (2011) 187–195. doi:10.3233/SPE-2011-0503. 
[121] Bruker, APEX2, SAINT and SADABS, Bruker AXS Inc., Madison, Wisconsin, USA, 2010. 
[122] G.M. Sheldrick, A short history of SHELX, Acta Crystallogr. A. A64 (2008) 112–122. 
doi:10.1107/S0108767307043930. 
[123] G.M. Sheldrick, SHELXT - Integrated space-group and crystal-structure determination, Acta 
Crystallogr. A. A71 (2015) 3–8. doi:10.1107/S2053273314026370. 
[124] V. Vichai, K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening, Nat. 
Protoc. 1 (2006) 1112–1116. doi:10.1038/nprot.2006.179. 
[125] E.A. Orellana, A.L. Kasinski, Sulforhodamine B (SRB) Assay in Cell Culture to Investigate Cell 
Proliferation, Bio-Protocol. 6 (2016). doi:10.21769/BioProtoc.1984. 
[126] R.H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen, Nat. Rev. Cancer. 
6 (2006) 813–823. doi:10.1038/nrc1951. 
[127] A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. 
Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, Feasibility of a 
High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines, 
J. Natl. Cancer Inst. 83 (1991) 757–766. doi:10.1093/jnci/83.11.757. 
[128] N.A.P. Franken, H.M. Rodermond, J. Stap, J. Haveman, C. van Bree, Clonogenic assay of cells 
in vitro, Nat. Protoc. 1 (2006) 2315–2319. doi:10.1038/nprot.2006.339. 
[129] A.D. Katnani, K.I. Papathomas, D.P. Drolet, A.J. Lees, THERMAL DECOMPOSITION OF 
PALLADIUM-IMIDAZOLE COMPLEXES, J. Therm. Anal. 35 (1989) 147–152. 
141 
 
[130] K. Nomiya, S. Takahashi, R. Noguchi, S. Nemoto, T. Takayama, M. Oda, Synthesis and 
characterization of water-soluble silver(I) complexes with L-histidine (H2his) and (S)-(-)-2-
pyrrolidone-5-carboxylic acid (H2pyrrld) showing a wide spectrum of effective antibacterial and 
antifungal activities. Crystal structures of chiral , Inorg. Chem. 39 (2000) 3301–3311. 
doi:10.1021/ic990526o. 
[131] G. Socrates, Infrared and Raman Characteristic Group Frequencies, 3rd ed., John Wiley & Sons, 
Inc., 2001. 
[132] D.L. Pavia, G.M. Lampman, G.S. Kriz, Introduction to Spectroscopy, Thomson Learning, 2001. 
[133] D.W. Zaharevitz, S.L. Holbeck, C. Bowerman, P.A. Svetlik, COMPARE: A web accessible tool 
for investigating mechanisms of cell growth inhibition, J. Mol. Graph. Model. 20 (2002) 297–
303. doi:10.1016/S1093-3263(01)00126-7. 
[134] T. Priestman, The Theoretical Basis of Cancer Chemotherapy, in: Cancer Chemother. Clin. 
Pract., Springer London, London, 2008: pp. 1–34. doi:10.1007/978-1-84628-991-0_1. 
[135] A.J. Wilson, A.Y. Liu, J. Roland, O.B. Adebayo, S.A. Fletcher, J.C. Slaughter, J. Saskowski, 
M.A. Crispens, H.W. Jones, S. James, O. Fadare, D. Khabele, TR3 modulates platinum resistance 
in ovarian cancer, Cancer Res. 73 (2013) 4758–4769. doi:10.1158/0008-5472.CAN-12-4560. 
[136] P.F. De Oliveira, J.M. Alves, J.L. Damasceno, R. Aparecida, M. Oliveira, H.J. Dias, A.E.M. 
Crotti, D.C. Tavares, Cytotoxicity screening of essential oils in cancer cell lines, Brazilian J. 
Pharmacogn. 25 (2015) 183–188. doi:10.1016/j.bjp.2015.02.009. 
[137] J.S. Dwivedi, U. Agarwala, 2,4-Dithiouracil as Complexing Agent: Part I - Complexes of Co(II), 
Ni(II), Cu(II), Cd(II), Ag(I), Tl(I) & Pb(II), Indian J. Chem. 10 (1972) 652–656. 
[138] B.F. Hoskins, L. Zhenrong, E.R.T. Tiekink, The characterization of 2-





[139] G.M. Stewart, E.R.T. Tiekink, M.A. Buntine, Structural Aspects of the Coordination of 
Triethylphosphinegold(I) to 2-Thiouracil: A Comparison between Theory and Experiment, J. 
Phys. Chem. A. 101 (1997) 5368–5373. 
[140] C. Abbehausen, J.F. Castro, M.B.M. Spera, T.A. Heinrich, C.M. Costa-Neto, W.R. Lustri, A.L.B. 
Formiga, P.P. Corbi, Synthesis, spectroscopic characterization, DFT studies and biological 
assays of a novel gold(I) complex with 2-mercaptothiazoline, Polyhedron. 30 (2011) 2354–2359. 
doi:10.1016/j.poly.2011.06.021. 
[141] C. Abbehausen, C.M. Manzano, P.P. Corbi, N.P. Farrell, Effects of coordination mode of 2-
mercaptothiazoline on reactivity of Au(I) compounds with thiols and sulfur-containing proteins, 
J. Inorg. Biochem. 165 (2016) 136–145. doi:10.1016/j.jinorgbio.2016.05.011. 
[142] C.S.W. Harker, E.R.T. Tielink, M.W. Whitehouse, Studies on the interaction of gold(I) 
phosphines with 2-thiouracil. Related studies with silver(I) phosphines, Inorganica Chim. Acta. 
181 (1991) 23–30. doi:10.1016/S0020-1693(00)85255-X. 
[143] E.R.T. Tiekink, Crystal structure of 2-thiouracil, Zeitschrift Für Krist. 187 (1989) 79–84. 
[144] D.R. Lide, CRC Handbook of Chemistry and Physics, Internet Version 2005, 85th ed, CRC Press, 
Boca Raton, FL, 2005. 
[145] A. Sułkowska, W.W. Sułkowski, K. Nowak, D. Pentak, M. Maciazek-Jurczyk, J. Równicka-
Zubik, Determination of the binding site of chloro(triethylphosphine)gold(I) in serum albumin, 
J. Mol. Struct. 970 (2010) 106–110. doi:10.1016/j.molstruc.2010.02.053. 
[146] A. Adan, G. Alizada, Y. Kiraz, Y. Baran, A. Nalbant, Flow cytometry: basic principles and 
applications, Crit. Rev. Biotechnol. 37 (2017) 163–176. doi:10.3109/07388551.2015.1128876. 
[147] L.C.U. Junqueira, J. Carneiro, Biologia Celular e Molecular, 9th ed., Guanabara Koogan, 2012. 
[148] National Cancer Institute, Cell Lines in the In Vitro Screen, (2015). 








[150] J.C. Chuang, G.T. Sheu, P.C. Wang, F.T. Liao, W.S. Liu, C.F. Huang, M.H. Tseng, M.F. Wu, 
Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short 
sequence at core promoter element, Toxicol. Vitr. 26 (2012) 678–685. 
doi:10.1016/j.tiv.2012.03.004. 
[151] K. Vermeulen, Z.N. Berneman, D.R. Van Bockstaele, Cell cycle and apoptosis, Cell Prolif. 36 
(2003) 165–175. doi:10.1046/j.1365-2184.2003.00267.x. 
[152] M. de C. Filgueiras, A. Morrot, P.M.G. Soares, M.L. Costa, C. Mermelstein, Effects of 5-
Fluorouracil in Nuclear and Cellular Morphology, Proliferation, Cell Cycle, Apoptosis, 
Cytoskeletal and Caveolar Distribution in Primary Cultures of Smooth Muscle Cells, PLoS One. 
8 (2013). doi:10.1371/journal.pone.0063177. 
[153] H. Rafehi, C. Orlowski, G.T. Georgiadis, K. Ververis, A. El-Osta, T.C. Karagiannis, Clonogenic 
Assay: Adherent Cells, J. Vis. Exp. (2011) 15–17. doi:10.3791/2573. 
[154] A. Munshi, M. Hobbs, R.E. Meyn, Clonogenic Cell Survival Assay, in: R.D. Blumenthal (Ed.), 









[155] L. Galluzzi, I. Vitale, S.A. Aaronson, J.M. Abrams, D. Adam, P. Agostinis, E.S. Alnemri, L. 
Altucci, I. Amelio, D.W. Andrews, M. Annicchiarico-Petruzzelli, A. V Antonov, E. Arama, E.H. 
Baehrecke, N.A. Barlev, N.G. Bazan, F. Bernassola, M.J.M. Bertrand, K. Bianchi, M. V 
Blagosklonny, K. Blomgren, C. Borner, P. Boya, C. Brenner, M. Campanella, E. Candi, D. 
Carmona-Gutierrez, F. Cecconi, F.K.-M. Chan, N.S. Chandel, E.H. Cheng, J.E. Chipuk, J.A. 
Cidlowski, A. Ciechanover, G.M. Cohen, M. Conrad, J.R. Cubillos-Ruiz, P.E. Czabotar, V. 
D’Angiolella, T.M. Dawson, V.L. Dawson, V. De Laurenzi, R. De Maria, K.-M. Debatin, R.J. 
DeBerardinis, M. Deshmukh, N. Di Daniele, F. Di Virgilio, V.M. Dixit, S.J. Dixon, C.S. Duckett, 
B.D. Dynlacht, W.S. El-Deiry, J.W. Elrod, G.M. Fimia, S. Fulda, A.J. García-Sáez, A.D. Garg, 
C. Garrido, E. Gavathiotis, P. Golstein, E. Gottlieb, D.R. Green, L.A. Greene, H. Gronemeyer, 
A. Gross, G. Hajnoczky, J.M. Hardwick, I.S. Harris, M.O. Hengartner, C. Hetz, H. Ichijo, M. 
Jäättelä, B. Joseph, P.J. Jost, P.P. Juin, W.J. Kaiser, M. Karin, T. Kaufmann, O. Kepp, A. Kimchi, 
R.N. Kitsis, D.J. Klionsky, R.A. Knight, S. Kumar, S.W. Lee, J.J. Lemasters, B. Levine, A. 
Linkermann, S.A. Lipton, R.A. Lockshin, C. López-Otín, S.W. Lowe, T. Luedde, E. Lugli, M. 
MacFarlane, F. Madeo, M. Malewicz, W. Malorni, G. Manic, J.-C. Marine, S.J. Martin, J.-C. 
Martinou, J.P. Medema, P. Mehlen, P. Meier, S. Melino, E.A. Miao, J.D. Molkentin, U.M. Moll, 
C. Muñoz-Pinedo, S. Nagata, G. Nuñez, A. Oberst, M. Oren, M. Overholtzer, M. Pagano, T. 
Panaretakis, M. Pasparakis, J.M. Penninger, D.M. Pereira, S. Pervaiz, M.E. Peter, M. Piacentini, 
P. Pinton, J.H.M. Prehn, H. Puthalakath, G.A. Rabinovich, M. Rehm, R. Rizzuto, C.M.P. 
Rodrigues, D.C. Rubinsztein, T. Rudel, K.M. Ryan, E. Sayan, L. Scorrano, F. Shao, Y. Shi, J. 
Silke, H.-U. Simon, A. Sistigu, B.R. Stockwell, A. Strasser, G. Szabadkai, S.W.G. Tait, D. Tang, 
N. Tavernarakis, A. Thorburn, Y. Tsujimoto, B. Turk, T. Vanden Berghe, P. Vandenabeele, M.G. 
Vander Heiden, A. Villunger, H.W. Virgin, K.H. Vousden, D. Vucic, E.F. Wagner, H. Walczak, 
D. Wallach, Y. Wang, J.A. Wells, W. Wood, J. Yuan, Z. Zakeri, B. Zhivotovsky, L. Zitvogel, G. 
Melino, G. Kroemer, Molecular mechanisms of cell death: recommendations of the 




[156] G.B. Longato, G.F. Fiorito, D.B. Vendramini-Costa, I.M. de O. Sousa, S.V. Tinti, A.L.T.G. Ruiz, 
S.M.V. de Almeida, R.J.R. Padilha, M.A. Foglio, J.E. de Carvalho, Different cell death responses 
induced by eupomatenoid-5 in MCF-7 and 786-0 tumor cell lines, Toxicol. Vitr. 29 (2015) 1026–
1033. doi:10.1016/j.tiv.2015.04.002. 
[157] P. Ludovico, F. Sansonetty, M. Corte-Real, Assessment of mitochondrial membrane potential in 
yeast cell populations by flow cytometry, Microbiology. 147 (2001) 3335–3343. 
doi:10.1099/00221287-147-12-3335. 
[158] K. Mohana, R. Srivalli, P.K. Lakshmi, Overview of P-glycoprotein inhibitors: a rational outlook, 
Brazilian J. Pharm. Sci. 48 (2012) 353–367. doi:10.1590/S1984-82502012000300002. 
[159] Y. Ji, S. Wei, J. Hou, C. Zhang, P. Xue, J. Wang, X. Chen, X. Guo, F. Yang, Integrated proteomic 
and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal 
glycoprotein alteration in protein abundance and glycosylation, Oncotarget. 8 (2017) 13413–
13427. doi:10.18632/oncotarget.14542. 
[160] Y. Bin Im, I. Ha, K.W. Kang, M.-Y. Lee, H.-K. Han, Macelignan: A New Modulator of P-
Glycoprotein in Multidrug-Resistant Cancer Cells, Nutr. Cancer. 61 (2009) 538–543. 
doi:10.1080/01635580802666273. 
[161] L. Eloy, A.S. Jarrousse, M.L. Teyssot, A. Gautier, L. Morel, C. Jolivalt, T. Cresteil, S. Roland, 
Anticancer Activity of Silver-N-Heterocyclic Carbene Complexes: Caspase-Independent 
Induction of Apoptosis via Mitochondrial Apoptosis-Inducing Factor (AIF), ChemMedChem. 7 
(2012) 805–814. doi:10.1002/cmdc.201200055. 
[162] Z. Engelbrecht, R. Meijboom, M.J. Cronjé, The ability of silver(I) thiocyanate 4-methoxyphenyl 
phosphine to induce apoptotic cell death in esophageal cancer cells is correlated to mitochondrial 
perturbations, BioMetals. 31 (2018) 189–202. doi:10.1007/s10534-017-0051-9. 
[163] J.M. Brown, L.D. Attardi, The role of apoptosis in cancer development and treatment response, 
Nat. Rev. Cancer. 5 (2005) 231–237. doi:10.2174/138161210789941883. 
146 
 
[164] S.L. Fink, B.T. Cookson, Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead 
and Dying Eukaryotic Cells, Infect. Immun. 73 (2005) 1907–1916. doi:10.1128/IAI.73.4.1907–
1916.2005. 
[165] F. Manning, K. Zuzel, Comparison of types of cell death: apoptosis and necrosis, J. Biol. Educ. 
373 (2003) 141–145. doi:10.1080/00219266.2003.9655870. 
[166] Merk Millipore, Guava Nexin Reagent, (2017). 
http://www.merckmillipore.com/BR/pt/product/Guava-Nexin-Reagent-for-Flow-Cytometry---
100-tests,MM_NF-4500-0450. 
[167] R.C. Barcelos, J.C. Pastre, D.B. Vendramini-Costa, V. Caixeta, G.B. Longato, P.A. Monteiro, 
J.E. De Carvalho, R.A. Pilli, Design and synthesis of N-acylated aza-goniothalamin derivatives 
and evaluation of their in vitro and in vivo antitumor activity, ChemMedChem. 9 (2014) 2725–
2743. doi:10.1002/cmdc.201402292. 
[168] A. Filippi, M. Zancani, E. Petrussa, E. Braidot, Caspase-3-like activity and proteasome 
degradation in grapevine suspension cell cultures undergoing silver-induced programmed cell 
death, J. Plant Physiol. 233 (2019) 42–51. doi:10.1016/j.jplph.2018.12.003. 
[169] E.A. Slee, C. Adrain, S.J. Martin, Serial killers: Ordering caspase activation events in apoptosis, 
Cell Death Differ. 6 (1999) 1067–1074. doi:10.1038/sj.cdd.4400601. 
[170] N. Akpan, C.M. Troy, Caspase Inhibitors, Neurosci. 19 (2013) 129–136. 
doi:10.1177/1073858412447875. 
[171] A. Gomes, E. Fernandes, J.L.F.C. Lima, Fluorescence probes used for detection of reactive 
oxygen species, J. Biochem. Biophys. Methods. 65 (2005) 45–80. 
doi:10.1016/j.jbbm.2005.10.003. 
[172] C.P. LeBel, H. Ischiropoulos, S.C. Bondy, Evaluation of the probe 2’,7’-dichlorofluorescin as an 




[173] T.S. Lobana, R. Sharma, G. Bawa, S. Khanna, Bonding and structure trends of 
thiosemicarbazone derivatives of metals-An overview, Coord. Chem. Rev. 253 (2009) 977–
1055. doi:10.1016/j.ccr.2008.07.004. 
[174] J. Shim, N.R. Jyothi, N.A.M. Farook, Biological applications of thiosemicarbazones and their 
metal complexes, Asian J. Chem. 25 (2013) 5838–5840. doi:10.14233/ajchem.2013.OH105. 
[175] R.W. Brockman, J.R. Thomson, M.J. Bell, H.E. Skipper, Observations on the antileukemic 
activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone, Cancer Res. 
16 (1956) 167–170. 
[176] F.A. French, B.L. Freedlander, Carcinostatic Action of Polycarbonyl Compounds and Their 
Derivatives: IV. Glyoxal Bis (thiosemicarbazone) and Derivatives, Cancer Res. 18 (1958) 1290–
1300. 
[177] H.G. Petering, H.H. Buskirk, G.E. Underwood, The Anti-Tumor Activity of 2-Keto-3-
Ethoxybutyraldehyde Bis(Thiosemicarbazone) and Related Compounds., Cancer Res. 24 (1964) 
367–372. 
[178] H.G. Petering, H.H. Buskirk, J.A. Crim, G.J. Van Giessen, The Effect of Essential Metal Ions on 
the Antitumor Activity of Kethoxal Bis(thiosemicarbazone) (KTS), Pharmacologist. 5 (1963) 
271. 
[179] J.A. Crim, H.G. Petering, The Antitumor Activity of Cu(II) KTS, the Copper(II) Chelate of 3-
Ethoxy-2-oxobutyraldehyde Bis(thisemicarbazone), Cancer Res. 27 (1967) 1278–1285. 
[180] E. Mihich, A.I. Mulhern, In vivo Effects of the Zinc Chelate of Kethoxal Bis(thiosemicarbazone) 
(KTS-Zn), Pharmacologist. 7 (1965) 179. 
[181] B.A. Booth, A.C. Sartorelli, Metabolic Activity Effects of Copper in Intact Cells: Comparative 
Activity of Cupric Chrolide and the Cupric Chelate of Kethoxal Bis (thiosemicarbazone), Mol. 




[182] D.T. Minkel, L.A. Saryan, D.H. Petering, Structure-Function Correlations in the Reaction of 
Bis(thiosemicarbazonato) Copper(II) Complexes with Ehrlich Ascites Tumor Cells, Cancer Res. 
38 (1978) 124–129. 
[183] D.S. Kalinowski, C. Stefani, S. Toyokuni, T. Ganz, G.J. Anderson, N. V. Subramaniam, D. 
Trinder, J.K. Olynyk, A. Chua, P.J. Jansson, S. Sahni, D.J.R. Lane, A.M. Merlot, Z. Kovacevic, 
M.L.H. Huang, C.S. Lee, D.R. Richardson, Redox cycling metals: Pedaling their roles in 
metabolism and their use in the development of novel therapeutics, Biochim. Biophys. Acta. 
1863 (2016) 727–748. doi:10.1016/j.bbamcr.2016.01.026. 
[184] E.C. Moore, M.S. Zedeck, K.C. Agrawal, A.C. Sartorelli, Inhibition of Ribonucleoside 
Diphosphate Reductase by 1-Formylisoquinolone Thiosemicarbazone and Related Compounds, 
Biochemistry. 9 (1970) 4492–4498. 
[185] L. Thelander, A. Graslung, Mechanism of Inhibition of Mammalian Ribonucleotide Reductase 
by the Iron Chelate of 1-Formylisoquinoline Thiosemicarbazone, J. Biol. Chem. 258 (1983) 
1063–1066. 
[186] R.H.U. Borges, E. Paniago, H. Beraldo, Equilibrium and kinetic studies of iron(II) and iron(III) 
complexes of some a-(N)-heterocyclic thiosemicarbazones. Reduction of the iron(III) complexes 
of 2-formylpyridine thiosemicarbazone and 2-acetylpyridine thiosemicarbazone by cellular thiol-
like red, J. Inorg. Biochem. 65 (1997) 267–275. doi:10.1016/S0162-0134(96)00142-0. 
[187] B.S.P. H. Beraldo, B.S.P. D. Gambinob, The Wide Pharmacological Versatility of 
Semicarbazones, Thiosemicarbazones and Their Metal Complexes, Mini-Reviews Med. Chem. 
4 (2004) 31–39. doi:10.2174/1389557043487484. 
[188] J. García-Tojal, A. García-Orad, J.L. Serra, J.L. Pizarro, L. Lezama, M.I. Arriortua, T. Rojo, 
Synthesis and spectroscopic properties of copper(II) complexes derived from thiophene-2-
carbaldehyde thiosemicarbazone. Structure and biological activity of [Cu(C6H6N3S2)2], J. 
Inorg. Biochem. 75 (1999) 45–54. doi:10.1016/S0162-0134(99)00031-8. 
149 
 
[189] J. García-Tojal, A. García-Orad,  a a Díaz, J.L. Serra, M.K. Urtiaga, M.I. Arriortua, T. Rojo, 
Biological activity of complexes derived from pyridine-2-carbaldehyde thiosemicarbazone. 
Structure of., J. Inorg. Biochem. 84 (2001) 271–278. doi:10.1016/S0162-0134(01)00184-2. 
[190] R.C. DeConti, B.R. Toftness, K.C. Agrawal, R. Tomchick, J.A.R. Mead, J.R. Bertino, A.C. 
Sartorelli, W.A. Creasey, Clinical and Pharmacological Studies with 5-Hydroxy-2-
formylpyridine Thiosemicarbazone, Cancer Res. 32 (1972) 1455–1462. 
[191] Y. Yu, D.S. Kalinowski, Z. Kovacevic, A.R. Siafakas, P.J. Jansson, C. Stefani, D.B. Lovejoy, 
P.C. Sharpe, P. V. Bernhardt, D.R. Richardson, Thiosemicarbazones from the old to new: Iron 
chelators that are more than just ribonucleotide reductase inhibitors, J. Med. Chem. 52 (2009) 
5271–5294. doi:10.1021/jm900552r. 
[192] K. Pelivan, W. Miklos, S. Van Schoonhoven, G. Koellensperger, L. Gille, W. Berger, P. Heffeter, 
C.R. Kowol, B.K. Keppler, Differences in protein binding and excretion of Triapine and its 
Fe(III) complex, J. Inorg. Biochem. 160 (2016) 61–69. doi:10.1016/j.jinorgbio.2015.10.006. 
[193] J. Yuan, D.B. Lovejoy, D.R. Richardson, Novel di-2-pyridyl–derived iron chelators with marked 
and selective antitumor activity: in vitro and in vivo assessment, Blood. 104 (2004) 1450–1458. 
doi:10.1182/blood-2004-03-0868. 
[194] M. Whitnall, J. Howard, P. Ponka, D.R. Richardson, A class of iron chelators with a wide 
spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics, Proc. Natl. 
Acad. Sci. U. S. A. 103 (2006) 12901–14906. 
http://www.pnas.org/content/103/40/14901.full.pdf. 
[195] C.R. Kowol, R. Trondl, P. Heffeter, V.B. Arion, M.A. Jakupec, A. Roller, M. Galanski, W. 
Berger, B.K. Keppler, Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-
carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation, 




[196] P. Heffeter, C. Pirker, C.R. Kowol, G. Herrman, R. Dornetshuber, W. Miklos, U. Jungwirth, G. 
Koellensperger, B.K. Keppler, W. Berger, Impact of terminal dimethylation on the resistance 
profile of α-N-heterocyclic thiosemicarbazones, Biochem. Pharmacol. 83 (2012) 1623–1633. 
doi:10.1016/j.bcp.2012.03.004. 
[197] C.R. Kowol, W. Miklos, S. Pfaff, S. Hager, S. Kallus, K. Pelivan, M. Kubanik, É.A. Enyedy, W. 
Berger, P. Heffeter, B.K. Keppler, Impact of Stepwise NH2-Methylation of Triapine on the 
Physicochemical Properties, Anticancer Activity, and Resistance Circumvention, J. Med. Chem. 
59 (2016) 6739–6752. doi:10.1021/acs.jmedchem.6b00342. 
[198] Z. Kovacevic, S. Chikhani, D.B. Lovejoy, D.R. Richardson, Novel Thiosemicarbazone Iron 
Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc 
Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer, Mol. 
Pharmacol. 80 (2011) 598–609. doi:10.1124/mol.111.073627. 
[199] Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With 
Advanced Solid Tumors, (2016). 
https://clinicaltrials.gov/ct2/show/NCT02688101?term=DpC&rank=1. 
[200] A Study of COTI-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies 
(COTI2-101), (2015). https://clinicaltrials.gov/ct2/show/NCT02433626?term=COTI-
2&rank=1. 
[201] W.R. Danter, M. Brown, F. Lepifre, Compounds and method for treatment of cancer. Patent 
US8034815B2, US8034815B2, 2011. 
[202] K.Y. Salim, S. Maleki Vareki, W.R. Danter, J. Koropatnick, COTI-2, a novel small molecule 
that is active against multiple human cancer cell lines in vitro and in vivo., Oncotarget. 7 (2016) 
41363–41379. doi:10.18632/oncotarget.9133. 




[204] Bruker SAINT v8.38B, Bruker AXS, (2005) Copyright 2005-2019. 
[205] G.M. Sheldrick, SADABS, (1996) University of Göttingen, Germany. 
[206] O. V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, OLEX2: a complete 
structure solution, refinement and analysis program, J. Appl. Crystallogr. 42 (2009) 339–341. 
doi:10.1107/S0021889808042726. 
[207] C.B. Hübschle, G.M. Sheldrick, B. Dittrich, ShelXle: A Qt graphical user interface for SHELXL, 
J. Appl. Crystallogr. 44 (2011) 1281–1284. doi:10.1107/S0021889811043202. 
[208] G.M. Sheldrick, SHELXS v 2016/4, (2015) University of Göttingen, Germany. 
[209] G.M. Sheldrick, SHELXL v 2016/4, (2015) University of Göttingen, Germany. 
[210] A.L. Spek, Structure validation in chemical crystallography, Acta Crystallogr. Sect. D Biol. 
Crystallogr. 65 (2009) 148–155. doi:10.1107/S090744490804362X. 
[211] T.L. Lemke, T.W. Shek, L.A.L.K.S. Cates, L.A. Cosby, A.C. Sartorelli, Synthesis of 
thiosemicarbazones as potential antitumor agents, J. Med. Chem. 20 (1977) 1351–1354. 
[212] M. Serda, D.S. Kalinowski, N. Rasko, E. Potůčková, A. Mrozek-Wilczkiewicz, R. Musiol, J.G. 
Małecki, M. Sajewicz, A. Ratuszna, A. Muchowicz, J. Gołąb, T. Šimůnek, D.R. Richardson, J. 
Polanski, Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through 
the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships, 
PLoS One. 9 (2014) e110291. doi:10.1371/journal.pone.0110291. 
[213] C.R. Kowol, R. Eichinger, M.A. Jakupec, M. Galanski, V.B. Arion, B.K. Keppler, Effect of metal 
ion complexation and chalcogen donor identity on the antiproliferative activity of 2-






[214] C.R. Kowol, P. Heffeter, W. Miklos, L. Gille, R. Trondl, L. Cappellacci, W. Berger, B.K. 
Keppler, Mechanisms underlying reductant-induced reactive oxygen species formation by 
anticancer copper(II) compounds, J. Biol. Inorg. Chem. 17 (2012) 409–423. doi:10.1007/s00775-
011-0864-x. 
[215] C.R. Kowol, R. Trondl, V.B. Arion, M.A. Jakupec, B.K. Keppler, Fluorescence properties and 
cellular distribution of the investigational anticancer drug Triapine (3-aminopyridine-2-
carboxaldehyde thiosemicarbazone) and its zinc(II) complex, Dalt. Trans. 39 (2010) 704–706. 
doi:10.1039/b919119b. 
[216] M. Joseph, M. Kuriakose, M.R.P. Kurup, E. Suresh, A. Kishore, S.G. Bhat, Structural, 
antimicrobial and spectral studies of copper(II) complexes of 2-benzoylpyridine N(4)-phenyl 
thiosemicarbazone, Polyhedron. 25 (2006) 61–70. doi:10.1016/j.poly.2005.07.006. 
[217] S. Saswati, A. Chakraborty, S.P. Dash, A.K. Panda, R. Acharyya, A. Biswas, S. Mukhopadhyay, 
S.K. Bhutia, A. Crochet, Y.P. Patil, M. Nethaji, R. Dinda, Synthesis, X-ray structure and in vitro 
cytotoxicity studies of Cu(I/II) complexes of thiosemicarbazone: special emphasis on their 
interactions with DNA, Dalt. Trans. 44 (2015) 6140–6157. doi:10.1039/C4DT03764B. 
[218] A.B. Beshir, S.K. Guchhait, J.A. Gascón, G. Fenteany, Synthesis and structure-activity 
relationships of metal-ligand complexes that potently inhibit cell migration, Bioorganic Med. 
Chem. Lett. 18 (2008) 498–504. doi:10.1016/j.bmcl.2007.11.099. 
[219] Y.H. Liu, A. Li, J. Shao, C.Z. Xie, X.Q. Song, W.G. Bao, J.Y. Xu, Four Cu(II) complexes based 
on antitumor chelators: Synthesis, structure, DNA binding/damage, HSA interaction and 
enhanced cytotoxicity, Dalt. Trans. 45 (2016) 8036–8049. doi:10.1039/c6dt00451b. 
[220] S. van Schoonhoven, C.R. Kowol, B.K. Keppler, M. Spitzwieser, C. Pirker, R. Dornetshuber-
Fleiss, P. Heffeter, B. Englinger, M. Cichna-Markl, W. Berger, K. Pelivan, G. Koellensperger, 
W. Miklos, Triapine-mediated ABCB1 induction via PKC induces widespread therapy 




[221] P. Heffeter, V.F.S. Pape, E.A. Enyedy, B.K. Keppler, G. Szakacs, C.R. Kowol, Anticancer 
thiosemicarbazones: chemical properties, interaction with iron metabolism, and resistance 

























PART 1: Metal complexes with uracil derivatives 
 
Figure A1. Molecular structure of tuH2 (C4H4N2OS) with atom numbering. 
 
 













































































Figure A7. Plates with fixed NCI/ADR-RES cells after 12 days of growth from 200 cells previously 


















Figure A8. Plates with fixed NCI/ADR-RES cells after 12 days of growth from 200 cells previously 
treated with 0.75 and 1.5 µg mL-1 of 5fu. Untreated cells are expressed as control. 
 
 
Figure A9. Plates with fixed NCI/ADR-RES cells after 12 days of growth from 200 cells previously 




Figure A10. Plates with fixed NCI-H460 cells after 6 days of growth from 100 cells previously treated 
with 12.0 and 24.0 µg mL-1 of Ph3P-Au-tuH. Untreated cells are expressed as control. 
 
 
Figure A11. Plates with fixed NCI-H460 cells after 6 days of growth from 100 cells previously treated 
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Figure A12. Influence of Ag-5fu, 5fu, and AgNO3 on phosphatidylserine externalization of NCI/ADR-
RES after 8 h of treatment. NCI/ADR-RES cells were treated for 8 h with Ag-5fu (1.5 and 3.0 µg/mL), 
5fu (0.75 and 1.5 µg/mL) or AgNO3 (0.75 and 1.5 µg/mL). Cell subpopulation (%) after Annexin-V and 
7-AAD staining. Statistical analysis: 2way-ANOVA followed by Bonferroni test (*p < 0.05, **p < 0.01 


































































Figure A13. Influence of Ag-5fu, 5fu, and AgNO3 on phosphatidylserine externalization of NCI/ADR-
RES after 14 h of treatment. NCI/ADR-RES cells were treated for 14 h with Ag-5fu (3.0 µg/mL), 5fu 
(1.5 µg/mL) or AgNO3 (1.5 µg/mL). Cell subpopulation (%) after Annexin-V and 7-AAD staining. 



































































































Figure A14. Influence of Ag-5fu, 5fu, and AgNO3 on phosphatidylserine externalization of NCI/ADR-
RES after 24 h of treatment. NCI/ADR-RES cells were treated for 24 h with Ag-5fu (1.5 and 3.0 µg/mL), 
5fu (0.75 and 1.5 µg/mL) or AgNO3 (0.75 and 1.5 µg/mL). Cell subpopulation (%) after Annexin-V and 
7-AAD staining. Statistical analysis: 2way-ANOVA followed by Bonferroni test (***p < 0.001, relative 
to untreated cells). 
 
 
Figure A15. Dot-plot graphs of Nexin assay of Ag-5fu, 5fu and AgNO3 over NCI/ADR-RES cells (18 





































































































































Figure A16. Influence of Ph3P-Au-tuH and Ph3P-Au-Cl on phosphatidylserine externalization of NCI-
H460 after 24 h of treatment. NCI-H460 cells were treated for 24 h with Ph3P-Au-tuH (6.0, 12.0 and 
24.0 µg/mL), or Ph3P-Au-Cl (10.1 and 20.2 µg/mL). Cell subpopulation (%) after Annexin-V and 7-
AAD staining. Statistical analysis: 2way-ANOVA followed by Bonferroni test (*p < 0.05, **p < 0.01 and 
***p < 0.001, relative to untreated cells). 
 
 
Figure A17. Dot-plot graphs of Nexin assay of Ph3P-Au-tuH and Ph3P-Au-Cl over NCI-H460 cells (18 





















Figure A18. Dot-plot graphs of Caspases assay of Ag-5fu, 5fu and AgNO3 over NCI/ADR-RES cells 
(17 h) in comparison to control. 
 
 
Figure A19. Dot-plot graphs of Caspases assay of Ph3P-Au-tuH and Ph3P-Au-Cl over NCI-H460 cells 





















































PART 2: Thiosemicarbazones and their metal complexes 
 



























































Figure A29. COTI-NMe2 numbering for NMR. 
 
 





























Figure A31. 1H-NMR spectrum in DMSO-d6 of COTI-2. 
 




Figure A33. HSQC 1H-13C NMR in DMSO-d6 of COTI-2. 
 




Figure A35. 1H-NMR spectrum in DMSO-d6 of COTI-NH2. 
 




Figure A37. HSQC 1H-13C NMR in DMSO-d6 of COTI-NH2. 
 




Figure A39. 1H-NMR spectrum in DMSO-d6 of COTI-NMe2. 
 




Figure A41. HSQC 1H-13C NMR in DMSO-d6 of COTI-NMe2. 
 





Figure A43. 1H-NMR spectrum in DMSO-d6 of COTI-Nchexyl. 
 




Figure A45. HSQC 1H-13C NMR in DMSO-d6 of COTI-Nchexyl. 
 




Figure A47. 1H-NMR spectrum in D2O of Zn-COTI-2. 
 
 
Figure A48. Concentration-response curves for Triapine, COTI-2, COTI-NH2, COTI-NMe2, COTI-









































































PART 1: Metal complexes with uracil derivatives 
 
Table A1. GI50 values in µmol L
-1 of the in vitro antiproliferative activity of free 5fu, Ag-5fu, Pd-5fu,      
Pt-5fu, K2[PdCl4], K2[PtCl4]. 
Compounds 
 Cell lines*  
MM 
(g mol-1) 
2 M A 7 4 P O H K Cat 
5fu 130.08 6.00 0.47 17.68 1.31 0.65 3.92 0.70 3.23 1.46 0.67 
Ag-5fu 580.73 1.95 <0.43 0.62 0.50 0.79 3.93 0.67 0.59 0.43 0.43 
Pd-5fu 457.12 7.04 0.24 54.69 1.60 0.96 4.48 2.52 5.62 54.69 0.90 
Pt-5fu 602.32 41.51 13.51 41.51 41.51 9.45 41.51 8.28 36.86 41.51 16.60 
AgNO3 169.87 19.84 9.77 18.90 20.96 33.85 17.60 16.95 16.90 2.83 15.89 
K2[PdCl4] 326.43 76.59 76.59 76.59 76.59 76.59 76.59 76.59 76.59 76.59 76.59 
K2[PtCl4] 415.09 17.59 11.42 14.43 12.21 13.80 7.44 13.92 13.71 6.02 8.43 
Cisplatin 300.05 4.27 7.23 8.30 3.73 0.60 8.70 10.70 17.03 8.07 3.80 
*Human tumor cell lines: 2: U251 (glioma); M = MCF-7 (breast); A = NCI/ADR-RES (ovarian 
multidrug resistant); 7 = 786-0 (renal); 4 = NCI-H460 (lung, non-small cells); P = PC-3 (prostate); O = 


























Table A2. TGI values in µmol L-1 of the in vitro antiproliferative activity of dtuH2, [Ag2(dtu)], AgNO3, 
tuH2, Ph3P-Au-tuH, Ph3P-Au-Cl, and doxorubicin. 
Compounds 
 Cell lines*  
MM 
(g mol-1) 
2 M A 7 4 O H K Cat 
dtuH2 144.22 980 1733 1733 1733 1733 1733 1733 1733 1733 
[Ag2(dtu)] 357.94 698 698 698 698 698 698 698 698 698 
AgNO3 169.87 42.39 17.66 198.4 134.2 140.1 35.91 80.06 6.48 226.1 
tuH2 128.15 1951 1951 1951 1951 1951 1951 1951 1951 1951 
Ph3P-Au-tuH 586.4 2.56 8.70 18.76 3.92 45.53 17.74 48.60 0.43 10.40 
Ph3P-Au-Cl 494.7 4.65 9.50 21.22 8.09 505 11.93 505 6.67 29.31 
Doxorubicin 543.52 1.49 1.05 46.00 2.02 46.00 3.31 46.00 2.21 1.07 
*Human tumor cell lines: 2: U251 (glioma); M = MCF-7 (breast); A = NCI-ADR/RES (multidrug 
resistant ovarian); 7 = 786-0 (renal); 4 = NCI-H460 (lung, non-small cells); O = OVCAR-3 (ovarian); 
H = HT29 (colon); K = K562 (leukemia); Non-tumor human line: Cat = HaCat (immortal keratinocyte). 
 
Table A3. Number of counted colonies of NCI/ADR-RES cells after 12 days of growth from 200 cells 
previously treated with Ag-5fu, 5fu and AgNO3. 
Treatment Triplicate 1 Triplicate 2 Triplicate 3 
Control 121 115 113 
Ag-5fu 1.5 µg/mL 5 9 9 
Ag-5fu 3.0 µg/mL 0 0 0 
5fu 0.75 µg/mL 48 60 35 
5fu 1.5 µg/mL 1 1 2 
AgNO3 0.75 µg/mL 47 72 62 







Table A4. Number of counted colonies of NCI/ADR-RES cells after 6 days of growth from 100 cells 
previously treated with Ph3P-Au-tuH and Ph3P-Au-Cl. 
Treatment Triplicate 1 Triplicate 2 Triplicate 3 
Control 137 140 140 
Ph3P-Au-tuH 12 µg/mL 47 45 40 
Ph3P-Au-tuH 24 µg/mL 2 1 2 
Ph3P-Au-Cl 10.1 µg/mL 34 20 20 
Ph3P-Au-Cl 20.2 µg/mL 4 4 1 
 
 
PART 2: Thiosemicarbazones and their metal complexes 
 
Table A5. Experimental parameters for COTI-2 and Cu-COTI-2. 








 Bruker  [K] [mm] [s]  [°] 
COTI-2 
D8 Mo 100 30 5 5110 0.200 
Cu-COTI-2 
D8 Mo 100 30 1 3502 0.500 
 
Table A6. Concentration range for MTT assays. 
Compound Conc. SW480 (µM) Conc. SW480/COTI (µM) Conc. SW480/tria (µM) 
COTI-2 0.01; 0.05; 0.1; 1; 5 0.1; 1; 5; 10; 20 0.01; 0.05; 0.1; 1; 5 
COTI-NH2 0.01; 0.05; 0.1; 1; 5 0.05; 0.1; 1; 5; 10 0.1; 1; 5; 10; 20 
COTI-NMe2 0.005; 0.01; 0.05; 0.1; 1 0.005; 0.01; 0.05; 0.1; 1 0.005; 0.01; 0.05; 0.1; 1 
COTI-Nchexyl 0.01; 0.05; 0.1; 1; 5 0.01; 0.05; 0.1; 1; 5 0.01; 0.05; 0.1; 1; 5 
Fe-COTI-2 0.1; 1; 5; 10; 20 0.1; 1; 5; 10; 20 0.1; 1; 5; 10; 20 
Cu-COTI-2 0.01; 0.05; 0.1; 1; 5 0.01; 0.05; 0.1; 1; 5 0.01; 0.05; 0.1; 1; 5 
Zn-COTI-2 0.01; 0.05; 0.1; 1; 5 0.01; 0.05; 0.1; 1; 5 0.01; 0.05; 0.1; 1; 5 
Triapine 0.01; 0.05; 0.1; 1; 5 0.01; 0.05; 0.1; 1; 5 0.1; 1; 5; 10; 20 
 
 
